<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Reyataz-H-494-IB-101-PI-d25-en-clean compared with
Reyataz-H-494-X-094-PI-en-clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
h5
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
h6
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.75pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePAC, li.EMEAHiddenTitlePAC, div.EMEAHiddenTitlePAC
	{mso-style-name:"EMEA Hidden Title PAC";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	font-family:"Times New Roman",serif;
	color:red;
	display:none;
	font-style:italic;
	text-decoration:none none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	margin:0in;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";}
span.BMSSubscript
	{mso-style-name:"BMS Subscript";
	vertical-align:sub;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.emeabodytext0, li.emeabodytext0, div.emeabodytext0
	{mso-style-name:emeabodytext;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BMSTableText, li.BMSTableText, div.BMSTableText
	{mso-style-name:"BMS Table Text";
	mso-style-link:"BMS Table Text Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.BMSTableTextChar
	{mso-style-name:"BMS Table Text Char";
	mso-style-link:"BMS Table Text";}
span.BMSSuperscript
	{mso-style-name:"BMS Superscript";
	vertical-align:super;}
p.StyleBMSTableText9pt, li.StyleBMSTableText9pt, div.StyleBMSTableText9pt
	{mso-style-name:"Style BMS Table Text + 9 pt";
	mso-style-link:"Style BMS Table Text + 9 pt Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
span.StyleBMSTableText9ptChar
	{mso-style-name:"Style BMS Table Text + 9 pt Char";
	mso-style-link:"Style BMS Table Text + 9 pt";}
p.BMSBodyText, li.BMSBodyText, div.BMSBodyText
	{mso-style-name:"BMS Body Text";
	mso-style-link:"BMS Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.BMSBodyTextChar
	{mso-style-name:"BMS Body Text Char";
	mso-style-link:"BMS Body Text";
	color:black;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.BMSTableHeader, li.BMSTableHeader, div.BMSTableHeader
	{mso-style-name:"BMS Table Header";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.BMSTableTitle, li.BMSTableTitle, div.BMSTableTitle
	{mso-style-name:"BMS Table Title";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.85pt 56.7pt 70.85pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEATitle><span lang=BG>ANNEX I</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEATitle><span lang=BG>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 100&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipient with known effect: 54.79&nbsp;mg
of lactose per capsule.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 150&nbsp;mg of atazanavir
(as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipient with known effect: 82.18&nbsp;mg
of lactose per capsule.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 200&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipient with known effect: 109.57&nbsp;mg
of lactose per capsule.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 300&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipient with known effect: 164.36&nbsp;mg
of lactose per capsule.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For the full list of excipients,
see&nbsp;section&nbsp;6.1.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
form</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hard capsule</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Opaque blue and white capsule printed with
white and blue inks, with &quot;BMS&nbsp;100&nbsp;mg&quot; on one half and with
&quot;3623&quot; on the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Opaque blue and powder blue capsule printed
with white and blue inks, with &quot;BMS&nbsp;150&nbsp;mg&quot; on one half and
with &quot;3624&quot; on the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Opaque blue capsule printed with white ink,
with &quot;BMS&nbsp;200&nbsp;mg&quot; on one half and with &quot;3631&quot; on
the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Opaque red and blue capsule printed with
white ink, with &quot;BMS&nbsp;300&nbsp;mg&quot; on one half and with
&quot;3622&quot; on the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ capsules, co-administered with low
dose ritonavir, are indicated for the treatment of HIV-1 infected adults and
paediatric patients 6&nbsp;years of age and older in combination with other
antiretroviral medicinal products (see&nbsp;section&nbsp;4.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Based on available virological and clinical
data from adult patients, no benefit is expected in patients with strains resistant
to multiple protease inhibitors (&#8805;&nbsp;4&nbsp;PI mutations). </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The choice of REYATAZ in treatment
experienced adult and paediatric patients should be based on individual viral
resistance testing and the patient&#8217;s treatment history
(see&nbsp;sections&nbsp;4.4 and&nbsp;5.1).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and
method of administration</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Therapy should be initiated by a physician
experienced in the management of HIV infection.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>Posology</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Adults</span></i></p>

<p class=EMEABodyText><span lang=BG>The recommended dose of REYATAZ capsules is
300&nbsp;mg once daily taken with ritonavir 100&nbsp;mg once daily and with
food. Ritonavir is used as a booster of atazanavir pharmacokinetics
(see&nbsp;sections 4.5&nbsp;and&nbsp;5.1). (See also section&nbsp;4.4
Withdrawal of ritonavir only under restrictive conditions).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Paediatric patients (6&nbsp;years to
less than 18&nbsp;years of age and weighing at least 15&nbsp;kg)</span></i></p>

<p class=EMEABodyText><span lang=BG>The dose of atazanavir capsules for
paediatric patients is based on body weight as shown in Table&nbsp;1 and should
not exceed the recommended adult dose. REYATAZ capsules must be taken with
ritonavir and have to be taken with food.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:56.7pt;text-indent:-56.7pt;
  page-break-after:avoid'><b><span lang=BG>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose
  for paediatric patients (6&nbsp;years to less than 18&nbsp;years of age and
  weighing at least 15&nbsp;kg) for REYATAZ capsules with ritonavir</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 style='width:2.15in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Body
  Weight (kg)</span></b></p>
  </td>
  <td width=206 style='width:154.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>REYATAZ once daily dose</span></b></p>
  </td>
  <td width=206 style='width:2.15in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>ritonavir once daily dose</span></b><b><sup><span
  lang=BG style='font-size:14.0pt'>a</span></sup></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:2.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>15 to less
  than 35</span></p>
  </td>
  <td width=206 valign=top style='width:154.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>200&nbsp;mg</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>100&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:2.15in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>at least
  35</span></p>
  </td>
  <td width=206 valign=top style='width:154.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>300&nbsp;mg</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>100&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
  style='font-size:9.0pt'>a</span></sup><span lang=BG style='font-size:9.0pt'>
  Ritonavir capsules, tablets or oral solution.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric patients (at least
3&nbsp;months of age and weighing at least 5&nbsp;kg):</span></i><span lang=BG>
REYATAZ oral powder is available for paediatric patients at least 3&nbsp;months
of age and weighing at least 5&nbsp;kg (see Summary of Product Characteristics
for REYATAZ oral powder). Switching to REYATAZ capsules from REYATAZ oral
powder is encouraged as soon as patients are able to consistently swallow
capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>When transitioning between formulations, a
change in dose may be needed. Consult the dosing table for the specific
formulation (see Summary of Product Characteristics for REYATAZ oral powder).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Special populations</span></i></p>

<p class=EMEABodyText><i><span lang=BG>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=BG>No dosage adjustment is needed. REYATAZ
with ritonavir is not recommended in patients undergoing haemodialysis
(see&nbsp;sections&nbsp;4.4 and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=BG>REYATAZ with ritonavir has not been studied
in patients with hepatic impairment. REYATAZ with ritonavir should be used with
caution in patients with mild hepatic impairment. REYATAZ with ritonavir must
not be used in patients with moderate to severe hepatic impairment
(see&nbsp;sections&nbsp;4.3,&nbsp;4.4&nbsp;and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In case of withdrawal of ritonavir from the
initial recommended ritonavir boosted regimen (see&nbsp;section&nbsp;4.4),
unboosted REYATAZ could be maintained in patients with mild hepatic impairment
at a dose of 400&nbsp;mg, and in patients with moderate hepatic impairment with
a reduced dose of 300&nbsp;mg once daily with food (see&nbsp;section&nbsp;5.2).
Unboosted REYATAZ must not be used in patients with severe hepatic impairment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Pregnancy and Postpartum</span></i></p>

<p class=EMEABodyText><span lang=BG>During the second and third trimesters of
pregnancy:</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ 300&nbsp;mg with ritonavir
100&nbsp;mg may not provide sufficient exposure to atazanavir, especially when
the activity of atazanavir or the whole regimen may be compromised due to drug
resistance. Since there are limited data available and due to inter-patient
variability during pregnancy, Therapeutic Drug Monitoring (TDM) may be
considered to ensure adequate exposure.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The risk of a further decrease in
atazanavir exposure is expected when atazanavir is given with medicinal
products known to reduce its exposure (e.g., tenofovir disoproxil or H</span><sub><span
lang=BG>2</span></sub><span lang=BG>-receptor antagonists).</span></p>

<p class=EMEABodyTextIndent style='margin-left:14.2pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>If tenofovir disoproxil or an H<sub>2</sub>-receptor
antagonist is needed, a dose increase to REYATAZ 400&nbsp;mg with ritonavir
100&nbsp;mg with TDM may be considered (see&nbsp;sections&nbsp;4.6
and&nbsp;5.2).</span></p>

<p class=EMEABodyTextIndent style='margin-left:14.2pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>It is not recommended to use REYATAZ with ritonavir
for pregnant patients who are receiving both tenofovir disoproxil and an H<sub>2</sub>-receptor
antagonist.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>(See section&nbsp;4.4 Withdrawal of
ritonavir only under restrictive conditions).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During postpartum:</span></p>

<p class=EMEABodyText><span lang=BG>Following a possible decrease in atazanavir
exposure during the second and third trimester, atazanavir exposures might
increase during the first two months after delivery
(see&nbsp;section&nbsp;5.2). Therefore, postpartum patients should be closely
monitored for adverse reactions.</span></p>

<p class=EMEABodyTextIndent style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>During this time, postpartum patients should follow
the same dose recommendation as for non-pregnant patients, including those for
co-administration of medicinal products known to affect atazanavir exposure
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric patients (less than
3&nbsp;months of age)</span></i></p>

<p class=EMEABodyText><span lang=BG>REYATAZ should not be used in children less
than 3&nbsp;months because of safety concerns especially taking into account
the potential risk of kernicterus.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>Method of administration</span></u><span
lang=BG>:</span></p>

<p class=EMEABodyText><span lang=BG>For oral use. The capsules should be
swallowed whole. </span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hypersensitivity to the active substance or
to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ is contraindicated in patients with
severe hepatic insufficiency
(see&nbsp;sections&nbsp;4.2,&nbsp;4.4&nbsp;and&nbsp;5.2). REYATAZ with
ritonavir is contraindicated in patients with moderate hepatic insufficiency
(see&nbsp;sections&nbsp;4.2,&nbsp;4.4 and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with simvastatin or
lovastatin (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Combination of rifampicin
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Combination of the PDE5 inhibitor
sildenafil when used for the treatment of pulmonary arterial hypertension (PAH)
only (see section&nbsp;4.5). For co-administration of sildenafil for the
treatment of erectile dysfunction see sections&nbsp;4.4 and&nbsp;4.5.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with medicinal products
that are substrates of the&nbsp;CYP3A4 isoform of cytochrome P450 and have
narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin,
astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam,
midazolam administered orally (for caution on parenterally administered
midazolam, see&nbsp;section&nbsp;4.5), and ergot alkaloids, particularly,
ergotamine, dihydroergotamine, ergonovine, methylergonovine)
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with
grazoprevir-containing products, including elbasvir/grazoprevir fixed dose
combination (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><i><span lang=BG>Co-administration with </span></i><span
lang=BG>glecaprevir/pibrentasvir fixed dose combination
(see&nbsp;section&nbsp;4.5)</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>Co-administration with products containing
St.&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>)
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>While effective viral suppression with
antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with ritonavir
at doses greater than 100&nbsp;mg once daily has not been clinically evaluated.
The use of higher ritonavir doses may alter the safety profile of atazanavir
(cardiac effects, hyperbilirubinaemia) and therefore is not recommended. Only
when atazanavir with ritonavir is co-administered with efavirenz, a dose
increase of ritonavir to 200&nbsp;mg once daily could be considered. In this
instance, close clinical monitoring is warranted (see Interaction with other
Medicinal Products below).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Patients
with coexisting conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=EMEABodyText><span lang=BG>Hepatic impairment: Atazanavir is primarily
hepatically metabolised and increased plasma concentrations were observed in
patients with hepatic impairment (see&nbsp;sections&nbsp;4.2 and&nbsp;4.3). The
safety and efficacy of REYATAZ has not been established in patients with
significant underlying liver disorders. Patients with chronic
hepatitis&nbsp;B&nbsp;or&nbsp;C and treated with combination antiretroviral
therapy are at an increased risk for severe and potentially fatal hepatic
adverse reactions. In case of concomitant antiviral therapy for
hepatitis&nbsp;B&nbsp;or&nbsp;C, please refer also to the relevant Summary of
Product Characteristics for these medicinal products
(see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Patients with pre-existing liver
dysfunction, including chronic active hepatitis, have an increased frequency of
liver function abnormalities during combination antiretroviral therapy and
should be monitored according to standard practice. If there is evidence of
worsening liver disease in such patients, interruption or discontinuation of
treatment must be considered.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Renal impairment: No dosage adjustment is
needed in patients with renal impairment. However, REYATAZ is not recommended
in patients undergoing haemodialysis (see&nbsp;sections&nbsp;4.2 and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>QT prolongation: Dose related asymptomatic
prolongations in PR interval with REYATAZ have been observed in clinical
studies. Caution should be used with medicinal products known to induce PR
prolongations. In patients with pre-existing conduction problems (second degree
or higher atrioventricular or complex bundle-branch block), REYATAZ should be
used with caution and only if the benefits exceed the risk
(see&nbsp;section&nbsp;5.1). Particular caution should be used when prescribing
REYATAZ in association with medicinal products which have the potential to
increase the QT interval and/or in patients with pre-existing risk factors
(bradycardia, long congenital QT, electrolyte imbalances
(see&nbsp;sections&nbsp;4.8 and&nbsp;5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Haemophiliac patients: There have been
reports of increased bleeding, including spontaneous skin haematomas and
haemarthroses, in type&nbsp;A&nbsp;and&nbsp;B haemophiliac patients treated
with protease inhibitors. In some patients additional factor&nbsp;VIII was
given. In more than half of the reported cases, treatment with protease inhibitors
was continued or reintroduced if treatment had been discontinued. A causal
relationship has been suggested, although the mechanism of action has not been
elucidated. Haemophiliac patients should therefore be made aware of the
possibility of increased bleeding.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Weight
and metabolic parameters</span></u></p>

<p class=EMEABodyText><span lang=BG>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to the disease control and life style. For lipids, there
is in some cases evidence for a treatment effect, while for weight gain there
is no strong evidence relating this to any particular treatment. For monitoring
of blood lipids and glucose reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In clinical studies, REYATAZ (with or
without ritonavir) has been shown to induce dyslipidaemia to a lesser extent
than comparators. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Hyperbilirubinaemia</span></u></p>

<p class=EMEABodyText><span lang=BG>Reversible elevations in indirect
(unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase
(UGT) have occurred in patients receiving REYATAZ (see&nbsp;section&nbsp;4.8).
Hepatic transaminase elevations that occur with elevated bilirubin in patients
receiving REYATAZ should be evaluated for alternative aetiologies. Alternative
antiretroviral therapy to REYATAZ may be considered if jaundice or scleral
icterus is unacceptable to a patient. Dose reduction of atazanavir is not
recommended because it may result in a loss of therapeutic effect and
development of resistance.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Indinavir is also associated with indirect
(unconjugated) hyperbilirubinaemia due to inhibition of UGT. Combinations of
REYATAZ and indinavir have not been studied and co-administration of these
medicinal products is not recommended (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Withdrawal of ritonavir only under
restrictive conditions</span></u></p>

<p class=EMEABodyText><span lang=BG>The recommended standard treatment is
REYATAZ boosted with ritonavir, ensuring optimal pharmacokinetic parameters and
level of virologic suppression. </span></p>

<p class=EMEABodyText><span lang=BG>The withdrawal of ritonavir from the
boosted regimen of REYATAZ is not recommended, but may be considered in adults
patients at the dose of 400&nbsp;mg once daily with food only under the
following combined restrictive conditions:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>absence of prior virologic failure </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>undetectable viral load during the last
6&nbsp;months under current regimen</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>viral strains not harbouring HIV resistance
associated mutations (RAMs) to current regimen.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ given without ritonavir should not
be considered in patients treated with a backbone regimen containing tenofovir disoproxil
and with other concomitant medications that reduce atazanavir bioavailability
(see section&nbsp;4.5 In case of withdrawal of ritonavir from the recommended
atazanavir boosted regimen) or in case of perceived challenging compliance.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ given without ritonavir should not
be used in pregnant patients given that it could result of suboptimal exposure
of particular concern for the mother infection and vertical transmission. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Cholelithiasis</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Cholelithiasis
has been reported in patients receiving REYATAZ (see&nbsp;section&nbsp;4.8).
Some patients required hospitalization for additional management and some had
complications. If signs or symptoms of cholelithiasis occur, temporary
interruption or discontinuation of treatment may be considered.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Chronic kidney disease</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Chronic
kidney disease in HIV-infected patients treated with atazanavir, with or
without ritonavir, has been reported during postmarketing surveillance. A large
prospective observational study has shown an association between an increased
incidence of chronic kidney disease and cumulative exposure to
atazanavir/ritonavir-containing regimen in HIV-infected patients with an
initially normal eGFR. This association was observed independently of exposure
to tenofovir disoproxil. Regular monitoring of the renal function of patients
should be maintained throughout the treatment duration
(see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Nephrolithiasis</span></u></p>

<p class=EMEABodyText><span lang=BG>Nephrolithiasis has been reported in
patients receiving REYATAZ (see&nbsp;section&nbsp;4.8). Some patients required
hospitalization for additional management and some had complications. In some
cases, nephrolithiasis has been associated with acute renal failure or renal
insufficiency. If signs or symptoms of nephrolithiasis occur, temporary
interruption or discontinuation of treatment may be considered. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Immune
reactivation syndrome</span></u></p>

<p class=EMEABodyText><span lang=BG>In HIV-infected patients with severe immune
deficiency at the time of institution of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
pathogens may arise and cause serious clinical conditions, or aggravation of
symptoms. Typically, such reactions have been observed within the first few
weeks or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections, and <i>Pneumocystis
jirovecii </i>pneumonia. Any inflammatory symptoms should be evaluated and
treatment instituted when necessary. Autoimmune disorders (such as Graves'
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and these events can occurs many months after initiation of treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><u><span lang=BG
style='font-weight:normal'>Osteonecrosis</span></u></p>

<p class=EMEABodyText><span lang=BG>Although the aetiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV-disease and/or long-term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Rash and associated syndromes</span></u></p>

<p class=EMEABodyText><span lang=BG>Rashes are usually mild -to-moderate
maculopapular skin eruptions that occur within the first 3 weeks of starting
therapy with REYATAZ. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Stevens-Johnson syndrome (SJS), erythema
multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic
symptoms (DRESS) syndrome have been reported in patients receiving REYATAZ.
Patients should be advised of the signs and symptoms and monitored closely for
skin reactions. REYATAZ should be discontinued if severe rash develops.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The best results in managing these events
come from early diagnosis and immediate interruption of any suspect medicines.
If the patient has developed SJS or DRESS associated with the use of REYATAZ,
REYATAZ may not be restarted.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Interactions
with other medicinal products</span></u></p>

<p class=EMEABodyText><span lang=BG>The combination of REYATAZ with
atorvastatin is not recommended (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
nevirapine or efavirenz is not recommended (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=BG>If the co-administration of REYATAZ with an
NNRTI is required, an increase in the dose of both REYATAZ and ritonavir to
400&nbsp;mg and 200&nbsp;mg, respectively, in combination with efavirenz could
be considered with close clinical monitoring.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir is metabolised principally by
CYP3A4. Co-administration of REYATAZ and medicinal products that induce CYP3A4
is not recommended (see&nbsp;sections&nbsp;4.3 and&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>PDE5 inhibitors used for the treatment of
erectile dysfunction: particular caution should be used when prescribing
PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of
erectile dysfunction in patients receiving REYATAZ. Co-administration of
REYATAZ with these medicinal products is expected to substantially increase
their concentrations and may result in PDE5-associated adverse reactions such
as hypotension, visual changes and priapism (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of voriconazole and
REYATAZ with ritonavir is not recommended, unless an assessment of the
benefit/risk justifies the use of voriconazole.</span></p>

<p class=EMEABodyText><span style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>In the majority of patients, a reduction in
both voriconazole and atazanavir exposures are expected. In a small number of
patients without a functional CYP2C19 allele, significantly increased
voriconazole exposures are expected (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Concomitant use of REYATAZ/ritonavir and
fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not
recommended unless the potential benefit of treatment outweighs the risk of
systemic corticosteroid effects, including Cushing's syndrome and adrenal
suppression (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Concomitant use of salmeterol and REYATAZ
may result in increased cardiovascular adverse events associated with
salmeterol. Co-administration of salmeterol and REYATAZ is not recommended
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The absorption of atazanavir may be reduced
in situations where gastric pH is increased irrespective of cause.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with proton
pump inhibitors is not recommended (see&nbsp;section&nbsp;4.5). If the
combination of REYATAZ with a proton pump inhibitor is judged unavoidable,
close clinical monitoring is recommended in combination with an increase in the
dose of REYATAZ to 400&nbsp;mg with 100&nbsp;mg of ritonavir; doses of proton
pump inhibitors comparable to omeprazole 20&nbsp;mg should not be exceeded.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with other
hormonal contraceptives or oral contraceptives containing progestogens other
than norgestimate or norethindrone has not been studied, and therefore should
be avoided (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Paediatric population</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Safety</span></i></p>

<p class=EMEABodyText><span lang=BG>Asymptomatic PR interval prolongation was
more frequent in paediatric patients than adults. Asymptomatic first- and
second-degree AV block was reported in paediatric patients (see&nbsp;section&nbsp;4.8).
Caution should be used with medicinal products known to induce PR
prolongations. In paediatric patients with pre-existing conduction problems
(second degree or higher atrioventricular or complex bundle-branch block),
REYATAZ should be used with caution and only if the benefits exceed the risk.
Cardiac monitoring is recommended based on the presence of clinical findings
(e.g., bradycardia).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Efficacy</span></i></p>

<p class=EMEABodyText><span lang=BG>Atazanavir/ritonavir is not effective in
viral strains harbouring multiple mutations of resistance. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Excipients</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Lactose</span></i></p>

<p class=EMEABodyText><span lang=BG>Patients with rare hereditary problems of
galactose intolerance, the Lapp lactase deficiency or glucose-galactose
malabsorption should not take this medicinal product.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>When REYATAZ and ritonavir are
co-administered, the metabolic drug interaction profile for ritonavir may
predominate because ritonavir is a more potent CYP3A4 inhibitor than
atazanavir. The Summary of Product Characteristics for ritonavir must be
consulted before initiation of therapy with REYATAZ and ritonavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir is metabolised in the liver
through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ is contraindicated with
medicinal products that are substrates of CYP3A4 and have a narrow therapeutic
index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and
ergot alkaloids, particularly ergotamine and dihydroergotamine
(see&nbsp;section&nbsp;4.3).<br>
Co-administration of REYATAZ with grazoprevir-containing products, including
elbasvir/grazoprevir fixed dose combination is contraindicated because of the
increase in grazoprevir and elbasvir plasma concentrations and potential for
the increase in risk of ALT elevations associated with increased grazoprevir
concentrations (see&nbsp;section&nbsp;4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed dose combination is contraindicated because of
the potential increase in the risk of ALT elevations due to a significant
increase in glecapreir and pibrentasvir plasma concentrations
(see&nbsp;section&nbsp;4.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><i><span lang=BG style='font-weight:normal'>Other
interactions</span></i></p>

<p class=EMEABodyText><span lang=BG>Interactions between atazanavir and other
medicinal products are listed in the table below (increase is indicated as
&#8220;&#8593;&#8221;, decrease as &#8220;&#8595;&#8221;, no change as
&#8220;&#8596;&#8221;). If available, 90% confidence intervals (CI) are shown
in parentheses. The studies presented in Table&nbsp;2 were conducted in healthy
subjects unless otherwise noted. Of importance, many studies were conducted with
unboosted atazanavir, which is not the recommended regimen of atazanavir
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>If withdrawal of ritonavir is medically
warranted under restrictive conditions (see&nbsp;section&nbsp;4.4), special
attention should be given to atazanavir interactions that may differ in the
absence of ritonavir (see&nbsp;information below&nbsp;Table&nbsp;2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Table&nbsp;2: Interactions between REYATAZ
and other medicinal products</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=659
 style='width:494.5pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:36.85pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.85pt'>
  <p class=EMEABodyText><b><span lang=BG>Medicinal products by therapeutic area</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:36.85pt'>
  <p class=EMEABodyText><b><span lang=BG>Interaction</span></b></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:36.85pt'>
  <p class=EMEABodyText><b><span lang=BG>Recommendations concerning
  co-administration</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.3pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTI-HCV AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Grazoprevir 200 mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;43% (&#8593;30%
  &#8593;57%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;12% (&#8593;1% &#8593;24%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;23% (&#8593;13% &#8593;134%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir AUC: &#8593;958% (&#8593;678%
  &#8593;1339%)</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>: &#8593;524% (&#8593;342% &#8593;781%)</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;1064% (&#8593;696% &#8593;1602%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir concentrations were greatly
  increased when co&#8209;administered with atazanavir/ritonavir.</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ and
  elbasvir/grazoprevir is contraindicated because of a significant increase in
  grazoprevir plasma concentrations and an associated potential increase in the
  risk of ALT elevations (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Elbasvir 50 mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;7% (&#8595;2%
  &#8593;17%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;2% (&#8595;4% &#8593;8%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;15% (&#8593;2% &#8593;29%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Elbasvir AUC: &#8593;376% (&#8593;307%
  &#8593;456%)</span></p>
  <p class=EMEABodyText><span lang=BG>Elbasvir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>: &#8593;315% (&#8593;246% &#8593;397%)</span></p>
  <p class=EMEABodyText><span lang=BG>Elbasvir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;545% (&#8593;451% &#8593;654%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Elbasvir concentrations were increased
  when co&#8209;administered with atazanavir/ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Sofosbuvir 400&nbsp;mg / velpatasvir
  100&nbsp;mg /voxilaprevir 100&nbsp;mg single dose</span></b><span lang=BG>*</span></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Sofosbuvir AUC&nbsp;: &#8593;40%
  (&#8593;25% &#8593;57%)</span></p>
  <p class=EMEABodyText><span lang=BG>Sofosbuvir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>:&#8593;29% (&#8593;9% &#8593;52%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Velpatasvir AUC: &#8593;93% (&#8593;58%
  &#8593;136%)</span></p>
  <p class=EMEABodyText><span lang=BG>Velpatasvir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>: &#8593;29% (&#8593;7% &#8593;56%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Voxilaprevir AUC</span><sub><span
  lang=BG>&nbsp;</span></sub><span lang=BG>: &#8593;331% (&#8593;276%
  &#8593;393%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voxilaprevir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>: &#8593;342% (&#8593;265% &#8593;435%)</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  <p class=MsoNormal><span lang=BG>*Lack of pharmacokinetics interaction bounds
  70-143% </span></p>
  <p class=EMEABodyText><sub>&nbsp;</sub></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>Effect on
  atazanavir and ritonavir exposure has not been studied.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>Expected:</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#8596; Atazanavir
  </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#8596;
  Ritonavir </span></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>The mechanism of
  interaction between REYATAZ/ritonavir and sofosbuvir/velpatasvir/voxilaprevir
  is inhibition of OATP1B, Pgp, and CYP3A.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
  voxilaprevir-containing products is expected to increase the concentration of
  voxilaprevir. Co-administration of REYATAZ with voxilaprevir-containing
  regimens is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Glecaprevir 300&nbsp;mg / pibrentasvir
  120&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily*)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Glecaprevir AUC&nbsp;: &#8593;553%
  (&#8593;424% &#8593;714%)</span></p>
  <p class=EMEABodyText><span lang=BG>Glecaprevir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>&nbsp;: &#8593;306% (&#8593;215% &#8593;423%)</span></p>
  <p class=EMEABodyText><span lang=BG>Glecaprevir C</span><sub><span lang=BG>min
  </span></sub><span lang=BG>: &#8593;1330% (&#8593;885% &#8593;1970%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Pibrentasvir AUC&nbsp;: &#8593;64%
  (&#8593;48% &#8593;82%)</span></p>
  <p class=EMEABodyText><span lang=BG>Pibrentasvir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>: &#8593;29% (&#8593;15% &#8593;45%)</span></p>
  <p class=EMEABodyText><span lang=BG>Pibrentasvir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;129% (&#8593;95% &#8593;168%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>* Effect of atazanavir and ritonavir on
  the first dose of glecaprevir and pibrentasvir is reported.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
  glecaprevir/pibrentasvir is contraindicated because of the potential increase
  in the risk of ALT elevations due to a significant increase in glecaprevir
  and pibrentasvir plasma concentrations (see&nbsp;section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTI-RETROVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Protease inhibitors:</span></i><b><span
  lang=BG> </span></b><span lang=BG>The co-administration of REYATAZ/ritonavir
  and other protease inhibitors has not been studied but would be expected to
  increase exposure to other protease inhibitors. Therefore, such
  co-administration is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Ritonavir 100&nbsp;mg once daily</span></b></p>
  <p class=MsoNormal><span lang=BG>(atazanavir 300&nbsp;mg once daily)</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>Studies conducted in HIV-infected patients.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC: &#8593;250% (&#8593;144%
  &#8593;403%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>: &#8593;120% (&#8593;56% &#8593;211%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;713% (&#8593;359% &#8593;1339%)*</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>* In a combined analysis, atazanavir
  300&nbsp;mg and ritonavir 100&nbsp;mg (n=33) was compared to atazanavir
  400&nbsp;mg without ritonavir (n=28).</span></p>
  <p class=EMEABodyText><span lang=BG>The mechanism of interaction between
  atazanavir and ritonavir is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Ritonavir 100&nbsp;mg once daily is used
  as a booster of atazanavir pharmacokinetics.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Indinavir</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Indinavir is associated with indirect
  unconjugated hyperbilirubinaemia due to inhibition of UGT.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ and
  indinavir is not recommended (see&nbsp;section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Nucleoside/nucleotide reverse
  transcriptase inhibitors (NRTIs)</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Lamivudine 150&nbsp;mg twice daily +
  zidovudine 300&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No significant effect on lamivudine and
  zidovudine concentrations was observed.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Based on these data and because ritonavir
  is not expected to have a significant impact on the pharmacokinetics of
  NRTIs, the co-administration of these medicinal products and REYATAZ is not
  expected to significantly alter the exposure of the co-administered medicinal
  products.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Abacavir</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>The co-administration of abacavir and
  REYATAZ is not expected to significantly alter the exposure of abacavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Didanosine (buffered tablets)
  200&nbsp;mg/stavudine 40&nbsp;mg, both single dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg single dose)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir, simultaneous administration
  with ddI+d4T (fasted)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;87% (&#8595;92%
  &#8595;79%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;89% (&#8595;94% &#8595;82%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;84% (&#8595;90% &#8595;73%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir, dosed 1&nbsp;hr after ddI+d4T
  (fasted)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;3% (&#8595;36%
  &#8593;67%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;12% (&#8595;33% &#8593;18%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8596;3% (&#8595;39% &#8593;73%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir concentrations were greatly
  decreased when co-administered with didanosine (buffered tablets) and
  stavudine. The mechanism of interaction is a reduced solubility of atazanavir
  with increasing pH related to the presence of anti-acid agent in didanosine
  buffered tablets.</span></p>
  <p class=EMEABodyText><span lang=BG>No significant effect on didanosine and
  stavudine concentrations was observed.</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Didanosine should be taken at the fasted
  state 2&nbsp;hours after REYATAZ taken with food. The co-administration of
  stavudine with REYATAZ is not expected to significantly alter the exposure of
  stavudine.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Didanosine (enteric coated capsules)
  400&nbsp;mg single dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Didanosine (with food)</span></p>
  <p class=EMEABodyText><span lang=BG>Didanosine AUC &#8595;34% (&#8595;41%
  &#8595;27%)</span></p>
  <p class=EMEABodyText><span lang=BG>Didanosine C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;38% (&#8595;48% &#8595;26%)</span></p>
  <p class=EMEABodyText><span lang=BG>Didanosine C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;25% (&#8595;8% &#8593;69%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>No significant effect on atazanavir
  concentrations was observed when administered with enteric-coated didanosine,
  but administration with food decreased didanosine concentrations.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Tenofovir disoproxil fumarate
  300&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>300 mg tenofovir disoproxil fumarate is
  equivalent to <br>
  245 mg tenofovir disoproxil.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Studies conducted in HIV-infected
  patients</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;22% (&#8595;35%
  &#8595;6%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;16% (&#8595;30% &#8596;0%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;23% (&#8595;43% &#8593;2%) *</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>* In a combined analysis from several
  clinical studies, atazanavir/ritonavir 300/100&nbsp;mg co-administered with
  tenofovir disoproxil fumarate 300&nbsp;mg (n=39) was compared to
  atazanavir/ritonavir 300/100&nbsp;mg (n=33).</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>The efficacy of REYATAZ/ritonavir in
  combination with tenofovir disoproxil fumarate in treatment-experienced
  patients has been demonstrated in clinical study&nbsp;045 and in treatment
  naive patients in clinical study&nbsp;138 (see&nbsp;sections&nbsp;4.8
  and&nbsp;5.1). The mechanism of interaction between atazanavir and tenofovir
  disoproxil fumarate is unknown.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>When co-administered with tenofovir
  disoproxil fumarate, it is recommended that REYATAZ 300&nbsp;mg be given with
  ritonavir 100&nbsp;mg and tenofovir disoproxil fumarate 300&nbsp;mg (all as a
  single dose with food). </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Tenofovir disoproxil fumarate
  300&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>300 mg tenofovir disoproxil fumarate is
  equivalent to <br>
  245 mg tenofovir disoproxil.</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Tenofovir disoproxil fumarate AUC
  &#8593;37% (&#8593;30% &#8593;45%)</span></p>
  <p class=EMEABodyText><span lang=BG>Tenofovir disoproxil fumarate C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;34% (&#8593;20% &#8593;51%)</span></p>
  <p class=EMEABodyText><span lang=BG>Tenofovir disoproxil fumarate C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;29% (&#8593;21% &#8593;36%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Patients should be closely monitored for
  tenofovir disoproxil fumarate-associated adverse reactions, including renal
  disorders.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Non-nucleoside reverse transcriptase
  inhibitors (NNRTIs)</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Efavirenz 600&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir (pm): all administered with
  food</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;0%(&#8595;9%
  &#8593;10%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;17%(&#8593;8% &#8593;27%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;42%(&#8595;51% &#8595;31%)*</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of efavirenz and
  REYATAZ is not recommended (see&nbsp;section&nbsp;4.4)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Efavirenz 600&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 200&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir (pm): all administered with
  food</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;6% (&#8595;10%
  &#8593;26%) */**</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;9% (&#8595;5% &#8593;26%) */**</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8596;12% (&#8595;16% &#8593;49%) */**</span></p>
  <p class=EMEABodyText><span lang=BG>* When compared to REYATAZ
  300&nbsp;mg/ritonavir 100&nbsp;mg once daily in the evening without
  efavirenz. This decrease in atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>, might negatively impact the efficacy of atazanavir. The mechanism
  of efavirenz/atazanavir interaction is CYP3A4 induction.</span></p>
  <p class=EMEABodyText><span lang=BG>** Based on historical comparison.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Nevirapine 200&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Study conducted in HIV infected patients</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Nevirapine AUC &#8593;26% (&#8593;17%
  &#8593;36%)</span></p>
  <p class=EMEABodyText><span lang=BG>Nevirapine C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;21% (&#8593;11% &#8593;32%)</span></p>
  <p class=EMEABodyText><span lang=BG>Nevirapine C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;35% (&#8593;25% &#8593;47%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;19% (&#8595;35%
  &#8593;2%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;2% (&#8595;15% &#8593;24%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;59% (&#8595;73% &#8595;40%) *</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>* When compared to REYATAZ 300&nbsp;mg
  and ritonavir 100&nbsp;mg without nevirapine. This decrease in atazanavir C</span><sub><span
  lang=BG>min</span></sub><span lang=BG>, might negatively impact the efficacy
  of atazanavir. The mechanism of nevirapine/atazanavir interaction is CYP3A4
  induction.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of nevirapine and
  REYATAZ is not recommended (see&nbsp;section&nbsp;4.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Integrase Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Raltegravir 400&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir/ritonavir)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Raltegravir AUC &#8593;41%</span></p>
  <p class=EMEABodyText><span lang=BG>Raltegravir C</span><sub><span lang=BG>max
  </span></sub><span lang=BG>&#8593;24%</span></p>
  <p class=EMEABodyText><span lang=BG>Raltegravir C</span><sub><span lang=BG>12hr
  </span></sub><span lang=BG>&#8593;77%</span></p>
  <p class=EMEABodyText><span lang=ES>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>The mechanism is UGT1A1 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No dose adjustment required for
  raltegravir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>HCV Protease
  Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Boceprevir 800&nbsp;mg three times
  daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg/ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=Default><span lang=BG style='font-size:11.0pt'>boceprevir AUC
  &#8596;5%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>boceprevir C<sub>max</sub>
  &#8596;7%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>boceprevir C<sub>min</sub>
  &#8596;18%</span></p>
  <p class=Default><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>atazanavir AUC
  &#8595; 35%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>atazanavir C<sub>max</sub>
  &#8595; 25%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>atazanavir C<sub>min</sub>
  &#8595; 49%</span></p>
  <p class=Default><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>ritonavir AUC &#8595;
  36%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>ritonavir C<sub>max</sub>
  &#8595; 27%</span></p>
  <p class=EMEABodyText><span lang=BG>ritonavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595; 45%</span></p>
  <p class=EMEABodyText><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=Default><span lang=BG style='font-size:11.0pt'>Co-administration of
  atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir
  which may be associated with lower efficacy and loss of HIV control. This
  co-administration might be considered on a case by case basis if deemed
  necessary, in patients with suppressed HIV viral loads and with HIV viral
  strain without any suspected resistance to the HIV regimen. Increased
  clinical and laboratory monitoring for HIV suppression is warranted. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>ANTIBIOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Clarithromycin
  500&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>(atazanavir
  400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Clarithromycin
  AUC &#8593;94% (&#8593;75% &#8593;116%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Clarithromycin
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8593;50%
  (&#8593;32% &#8593;71%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Clarithromycin
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8593;160%
  (&#8593;135% &#8593;188%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>14-OH
  clarithromycin</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>14-OH
  clarithromycin AUC &#8595;70% (&#8595;74% &#8595;66%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>14-OH
  clarithromycin C</span><sub><span lang=BG>max</span></sub><span lang=BG>
  &#8595;72% (&#8595;76% &#8595;67%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>14-OH
  clarithromycin C</span><sub><span lang=BG>min</span></sub><span lang=BG>
  &#8595;62% (&#8595;66% &#8595;58%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  AUC &#8593;28% (&#8593;16% &#8593;43%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8596;6%
  (&#8595;7% &#8593;20%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8593;91%
  (&#8593;66% &#8593;121%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>A dose
  reduction of clarithromycin may result in subtherapeutic concentrations of
  14-OH clarithromycin. The mechanism of the clarithromycin/atazanavir
  interaction is CYP3A4 inhibition.</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>No
  recommendation regarding dose reduction can be made; therefore, caution
  should be exercised if REYATAZ is co-administered with clarithromycin.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>ANTIFUNGALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Ketoconazole
  200&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>(atazanavir
  400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>No
  significant effect on atazanavir concentrations was observed.</span></p>
  </td>
  <td width=208 rowspan=3 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Ketoconazole and itraconazole should be
  used cautiously with REYATAZ/ritonavir, high doses of ketoconazole and
  itraconazole (&gt;200&nbsp;mg/day) are not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:46.7pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.7pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Itraconazole</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:46.7pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Itraconazole,
  like ketoconazole, is a potent inhibitor as well as a substrate of CYP3A4.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:86.25pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:86.25pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:86.25pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Based on
  data obtained with other boosted PIs and ketoconazole, where ketoconazole AUC
  showed a 3-fold increase, REYATAZ/ritonavir is expected to increase
  ketoconazole or itraconazole concentrations.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Voriconazole 200&nbsp;mg twice daily </span></b><span
  lang=BG>(atazanavir 300&nbsp;mg/ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Subjects with at least one functional
  CYP2C19 allele.</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Voriconazole AUC &#8595;33% (&#8595;42%
  &#8595;22%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;10% (&#8595;22% &#8595;4%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;39% (&#8595;49% &#8595;28%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;12% (&#8595;18%
  &#8595;5%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;13% (&#8595;20% &#8595;4%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595; 20 % (&#8595;28 % &#8595;10%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Ritonavir AUC &#8595;12% (&#8595;17%
  &#8595;7%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;9% (&#8595;17% &#8596;0%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;25% (&#8595;35% &#8595;14%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>In the majority of patients with at least
  one functional CYP2C19 allele, a reduction in both voriconazole and
  atazanavir exposures are expected. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of voriconazole and
  REYATAZ with ritonavir is not recommended unless an assessment of the benefit/risk
  to the patient justifies the use of voriconazole (see&nbsp;section&nbsp;4.4).
  </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>At the time voriconazole treatment is
  required, a patient's CYP2C19 genotype should be performed if feasible.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Therefore if the combination is
  unavoidable, the following recommendations are made according to the CYP2C19
  status:</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>- in patients with at least one
  functional CYP2C19 allele, close clinical monitoring for a loss of both
  voriconazole (clinical signs) and atazanavir (virologic response) efficacy is
  recommended. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>- in patients without a functional
  CYP2C19 allele, close clinical and laboratory monitoring of
  voriconazole-associated adverse events is recommended.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>If genotyping is not feasible, full
  monitoring of safety and efficacy should be performed.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Voriconazole 50&nbsp;mg twice daily </span></b><span
  lang=BG>(atazanavir 300&nbsp;mg/ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  <p class=EMEABodyText><span lang=BG>Subjects without a functional CYP2C19
  allele.</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Voriconazole AUC &#8593;561% (&#8593;451%
  &#8593;699%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;438% (&#8593;355% &#8593;539%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;765% (&#8593;571% &#8593;1,020%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;20% (&#8595;35%
  &#8595;3%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;19% (&#8595;34% &#8596;0.2%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595; 31 % (&#8595;46 % &#8595;13%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Ritonavir AUC &#8595;11% (&#8595;20%
  &#8595;1%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;11% (&#8595;24% &#8593;4%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;19% (&#8595;35% &#8593;1%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>In a small number of patients without a
  functional CYP2C19 allele, significantly increased voriconazole exposures are
  expected. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Fluconazole 200&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg and ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir and fluconazole concentrations
  were not significantly modified when REYATAZ/ritonavir was co-administered
  with fluconazole.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No dosage adjustments are needed for
  fluconazole and REYATAZ.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>ANTIMYCOBACTERIAL</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Rifabutin 150&nbsp;mg twice weekly</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg and ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Rifabutin AUC &#8593;48% (&#8593;19%
  &#8593;84%) **</span></p>
  <p class=EMEABodyText><span lang=BG>Rifabutin C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;149% (&#8593;103% &#8593;206%) **</span></p>
  <p class=EMEABodyText><span lang=BG>Rifabutin C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;40% (&#8593;5% &#8593;87%) **</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>25-O-desacetyl-rifabutin AUC &#8593;990%
  (&#8593;714% &#8593;1361%) **</span></p>
  <p class=EMEABodyText><span lang=BG>25-O-desacetyl-rifabutin C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;677% (&#8593;513% &#8593;883%)
  **</span></p>
  <p class=EMEABodyText><span lang=BG>25-O-desacetyl-rifabutin C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;1045% (&#8593;715%
  &#8593;1510%) **</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>** When compared to rifabutin 150&nbsp;mg
  once daily alone. Total rifabutin and 25-O-desacetyl-rifabutin AUC
  &#8593;119% (&#8593;78% &#8593;169%).</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>In previous studies, the pharmacokinetics
  of atazanavir was not altered by rifabutin.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>When given with REYATAZ, the recommended
  dose of rifabutin is 150&nbsp;mg 3&nbsp;times per week on set days (for
  example Monday-Wednesday-Friday). Increased monitoring for
  rifabutin-associated adverse reactions including neutropenia and uveitis is
  warranted due to an expected increase in exposure to rifabutin. Further
  dosage reduction of rifabutin to 150&nbsp;mg twice weekly on set days is
  recommended for patients in whom the 150&nbsp;mg dose 3&nbsp;times per week
  is not tolerated. It should be kept in mind that the twice weekly dosage of
  150&nbsp;mg may not provide an optimal exposure to rifabutin thus leading to
  a risk of rifamycin resistance and a treatment failure. No dose adjustment is
  needed for REYATAZ.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Rifampicin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Rifampicin is a strong CYP3A4 inducer and
  has been shown to cause a 72% decrease in atazanavir AUC which can result in
  virological failure and resistance development. During attempts to overcome
  the decreased exposure by increasing the dose of REYATAZ or other protease
  inhibitors with ritonavir, a high frequency of liver reactions was seen.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>The combination of rifampicin and REYATAZ
  is contraindicated (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTIPSYCHOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Quetiapine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Due to CYP3A4 inhibition by REYATAZ,
  concentrations of quetiapine are expected to increase.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of quetiapine with REYATAZ
  is contraindicated as REYATAZ may increase quetiapine-related toxicity.
  Increased plasma concentrations of quetiapine may lead to coma
  (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Lurasidone</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>REYATAZ is expected to increase plasma
  levels of lurasidone due to CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of lurasidone with
  REYATAZ is contra-ndicated as this may increase lurasidone-related toxicity
  (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>ACID
  REDUCING AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>H<sub>2</sub>-Receptor
  antagonists</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Without
  Tenofovir</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>In
  HIV-infected patients with atazanavir/ritonavir at the recommended
  dose&nbsp;300/100&nbsp;mg once daily</span></p>
  </td>
  <td width=208 rowspan=5 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>For
  patients not taking tenofovir,</span></b><span lang=BG> if REYATAZ
  300&nbsp;mg/ritonavir 100&nbsp;mg and H</span><sub><span lang=BG>2</span></sub><span
  lang=BG>-receptor antagonists are co-administered, a dose equivalent to
  famotidine 20&nbsp;mg twice daily should not be exceeded. If a higher dose of
  an H</span><sub><span lang=BG>2</span></sub><span lang=BG>-receptor
  antagonist is required (e.g., famotidine 40&nbsp;mg twice daily or
  equivalent) an increase of the REYATAZ/ritonavir dose from 300/100&nbsp;mg to
  400/100&nbsp;mg can be considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Famotidine
  20&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  AUC &#8595;18% (&#8595;25% &#8593;1%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8595;20%
  (&#8595;32% &#8595;7%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8596;1%
  (&#8595;16% &#8593;18%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Famotidine
  40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  AUC &#8595;23% (&#8595;32% &#8595;14%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8595;23%
  (&#8595;33% &#8595;12%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8595;20%
  (&#8595;31% &#8595;8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>In Healthy
  volunteers with atazanavir/ritonavir at an increased dose
  of&nbsp;400/100&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Famotidine
  40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  AUC &#8596;3% (&#8595;14% &#8593;22%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8596;2%
  (&#8595;13% &#8593;8%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8595;14%
  (&#8595;32% &#8593;8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>With Tenofovir disoproxil fumarate
  300&nbsp;mg once daily (equivalent to 245 mg tenofovir disoproxil)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>In HIV-infected patients with
  atazanavir/ritonavir at the recommended dose of&nbsp;300/100&nbsp;mg once
  daily</span></p>
  </td>
  <td width=208 rowspan=7 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>For patients who are taking tenofovir
  disoproxil fumarate, </span></b><span lang=BG>if REYATAZ/ritonavir with both
  tenofovir disoproxil fumarate and an H</span><sub><span lang=BG>2</span></sub><span
  lang=BG>-receptor antagonist are co-administered, a dose increase of REYATAZ
  to 400&nbsp;mg with 100&nbsp;mg of ritonavir is recommended. A dose equivalent
  to famotidine 40&nbsp;mg twice daily should not be exceeded.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 20&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;21% (&#8595;34%
  &#8595;4%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;21% (&#8595;36% &#8595;4%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;19% (&#8595;37% &#8593;5%) *</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;24% (&#8595;36%
  &#8595;11%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;23% (&#8595;36% &#8595;8%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;25% (&#8595;47% &#8593;7%) *</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>In HIV-infected patients with
  atazanavir/ritonavir at an increased dose of&nbsp;400/100&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 20&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;18% (&#8593;6.5%
  &#8593;30%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;18% (&#8593;6.7% &#8593;31%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;24 % (&#8593;10% &#8593;39%)*</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Famotidine
  40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  AUC &#8596;2.3% (&#8595;13% &#8593;10%)*</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8596;5%
  (&#8595;17% &#8593;8.4%)*</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Atazanavir
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8596;1.3%
  (&#8595;10% &#8593;15)*</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>* When compared to atazanavir 300&nbsp;mg
  once daily with ritonavir 100&nbsp;mg once daily and tenofovir disoproxil
  fumarate 300&nbsp;mg all as a single dose with food. When compared to
  atazanavir 300&nbsp;mg with ritonavir 100&nbsp;mg </span><i><span lang=BG>without
  tenofovir disoproxil fumarate</span></i><span lang=BG>, atazanavir
  concentrations are expected to be additionally decreased by about 20%. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>The mechanism of interaction is decreased
  solubility of atazanavir as intra-gastric pH increases with H</span><sub><span
  lang=BG>2</span></sub><span lang=BG>-blockers.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Proton pump inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Omeprazole 40&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir (am): 2&nbsp;hr after
  omeprazole</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;61% (&#8595;65%
  &#8595;55%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;66% (&#8595;62% &#8595;49%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;65% (&#8595;71% &#8595;59%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
  ritonavir and proton pump inhibitors is not recommended. If the combination
  is judged unavoidable, close clinical monitoring is recommended in
  combination with an increase in the dose of REYATAZ to 400&nbsp;mg with
  100&nbsp;mg of ritonavir; doses of proton pump inhibitors comparable to
  omeprazole 20&nbsp;mg should not be exceeded (see&nbsp;section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Omeprazole 20&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Atazanavir (am): 1&nbsp;hr after omeprazole</span></p>
  <p class=MsoNormal style='margin-right:-5.45pt'><span lang=BG>Atazanavir AUC
  &#8595;30% (&#8595;43% &#8595;14%) *</span></p>
  <p class=MsoNormal style='margin-right:-5.45pt'><span lang=BG>Atazanavir C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8595;31% (&#8595;42% &#8595;17%) *</span></p>
  <p class=MsoNormal style='margin-right:-5.45pt'><span lang=BG>Atazanavir C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8595;31% (&#8595;46% &#8595;12%) *</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>* When compared to atazanavir 300&nbsp;mg
  once daily with ritonavir 100&nbsp;mg once daily.</span></p>
  <p class=EMEABodyText><span lang=BG>The decrease in AUC, C</span><sub><span
  lang=BG>max</span></sub><span lang=BG>, and C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> was not mitigated when an increased dose of REYATAZ/ritonavir
  (400/100&nbsp;mg once daily) was temporally separated from omeprazole by
  12&nbsp;hours. Although not studied, similar results are expected with other
  proton pump inhibitors. This decrease in atazanavir exposure might negatively
  impact the efficacy of atazanavir. The mechanism of interaction is decreased
  solubility of atazanavir as intra-gastric pH increases with proton pump
  inhibitors.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Antacids</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Antacids and medicinal products
  containing buffers</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Reduced plasma concentrations of atazanavir
  may be the consequence of increased gastric pH if antacids, including
  buffered medicinal products, are administered with REYATAZ. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>REYATAZ should be administered 2&nbsp;hours
  before or 1&nbsp;hour after antacids or buffered medicinal products.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>ALPHA
  1-ADRENORECEPTOR ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Alfuzosin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Potential for increased alfuzosin
  concentrations which can result in hypotension. The mechanism of interaction
  is CYP3A4 inhibition by REYATAZ and/or ritonavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of alfuzosin with REYATAZ
  is contraindicated (see&nbsp;section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTICOAGULANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Warfarin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with REYATAZ has the
  potential to increase or decrease warfarin concentrations.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>It is recommended that the International
  Normalised Ratio (INR) be monitored carefully during treatment with REYATAZ,
  especially when commencing therapy.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>ANTIEPILEPTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Carbamazepine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>REYATAZ may increase plasma levels of
  carbamazepine due to CYP3A4 inhibition. </span></p>
  <p class=MsoNormal><span lang=BG>Due to carbamazepine inducing effect, a
  reduction in REYATAZ exposure cannot be ruled out.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Carbamazepine should be used with caution in
  combination with REYATAZ. If necessary, monitor carbamazepine serum
  concentrations and adjust the dose accordingly. Close monitoring of the
  patient's virologic response should be excercised. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Phenytoin, phenobarbital</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Ritonavir may decrease plasma levels of
  phenytoin and/or phenobarbital due to CYP2C9 and CYP2C19 induction.</span></p>
  <p class=MsoNormal><span lang=BG>Due to phenytoin/phenobarbital inducing
  effect, a reduction in REYATAZ exposure cannot be ruled out.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Phenobarbital and phenytoin should be used
  with caution in combination with REYATAZ/ritonavir.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>When REYATAZ/ritonavir is co-administered
  with either phenytoin or phenobarbital, a dose adjustment of phenytoin or
  phenobarbital may be required.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>Close monitoring of patient's virologic
  response should be exercised.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Lamotrigine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of lamotrigine and
  REYATAZ/ritonavir may decrease lamotrigine plasma concentrations due to
  UGT1A4 induction.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Lamotrigine should be used with caution in
  combination with REYATAZ/ritonavir. </span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>If necessary, monitor lamotrigine
  concentrations and adjust the dose accordingly. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTINEOPLASTICS AND IMMUNOSUPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Antineoplastics</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Irinotecan</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Atazanavir inhibits UGT and may interfere
  with the metabolism of irinotecan, resulting in increased irinotecan
  toxicities. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>If REYATAZ is co-administered with
  irinotecan, patients should be closely monitored for adverse events related
  to irinotecan.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Immunosuppressants</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Cyclosporin</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Tacrolimus</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Sirolimus</span></b></p>
  <p class=MsoNormal><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Concentrations of these immunosuppressants
  may be increased when co-administered with REYATAZ due to CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>More frequent therapeutic concentration
  monitoring of these medicinal products is recommended until plasma levels
  have been stabilised.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>CARDIOVASCULAR
  AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Antiarrhythmics</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=BG>Amiodarone,
  </span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=BG>Systemic
  lidocaine, </span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=BG>Quinidine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>Concentrations
  of these antiarrhythmics may be increased when co-administered with REYATAZ.
  The mechanism of amiodarone or systemic lidocaine/atazanavir interaction is
  CYP3A inhibition. Quinidine has a narrow therapeutic window and is
  contraindicated due to potential inhibition of CYP3A by REYATAZ.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>Caution is
  warranted and therapeutic concentration monitoring is recommended when
  available. The concomitant use of quinidine is contraindicated
  (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Calcium channel blockers</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Bepridil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>REYATAZ should not be used in combination
  with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic
  index.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with bepridil is
  contraindicated (see&nbsp;section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Diltiazem 180&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Diltiazem AUC &#8593;125% (&#8593;109%
  &#8593;141%)</span></p>
  <p class=EMEABodyText><span lang=BG>Diltiazem C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;98% (&#8593;78% &#8593;119%)</span></p>
  <p class=EMEABodyText><span lang=BG>Diltiazem C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;142% (&#8593;114% &#8593;173%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Desacetyl-diltiazem AUC &#8593;165%
  (&#8593;145% &#8593;187%)</span></p>
  <p class=EMEABodyText><span lang=BG>Desacetyl-diltiazem C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;172% (&#8593;144% &#8593;203%)</span></p>
  <p class=EMEABodyText><span lang=BG>Desacetyl-diltiazem C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;121% (&#8593;102% &#8593;142%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>No significant effect on atazanavir
  concentrations was observed. There was an increase in the maximum PR interval
  compared to atazanavir alone. Co-administration of diltiazem and
  REYATAZ/ritonavir has not been studied. The mechanism of diltiazem/atazanavir
  interaction is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>An initial dose reduction of diltiazem by
  50% is recommended, with subsequent titration as needed and ECG monitoring.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Verapamil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Serum concentrations of verapamil may be
  increased by REYATAZ due to CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Caution should be exercised when verapamil
  is co-administered with REYATAZ.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>CORTICOSTEROIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Fluticasone
  propionate intranasal 50&nbsp;&micro;g 4&nbsp;times daily for 7&nbsp;days</span></b></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>(ritonavir
  100&nbsp;mg capsules twice daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>The
  fluticasone propionate plasma levels increased significantly, whereas the
  intrinsic cortisol levels decreased by approximately 86% (90% confidence
  interval 82%-89%). Greater effects may be expected when fluticasone
  propionate is inhaled. Systemic corticosteroid effects including
  Cushing&#8217;s syndrome and adrenal suppression have been reported in
  patients receiving ritonavir and inhaled or intranasally administered
  fluticasone propionate; this could also occur with other corticosteroids
  metabolised via the P450 3A pathway, e.g., budesonide. The effects of high
  fluticasone systemic exposure on ritonavir plasma levels are yet unknown. The
  mechanism of interaction is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Co-administration
  of REYATAZ/ritonavir and these glucocorticoids is not recommended unless the
  potential benefit of treatment outweighs the risk of systemic corticosteroid
  effects (see&nbsp;section&nbsp;4.4). A dose reduction of the glucocorticoid
  should be considered with close monitoring of local and systemic effects or a
  switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g.,
  beclomethasone). Moreover, in case of withdrawal of glucocorticoids,
  progressive dose reduction may have to be performed over a longer period.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ERECTILE DYSFUNCTION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>PDE5 Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Sildenafil, tadalafil, vardenafil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Sildenafil, tadalafil and vardenafil are
  metabolised by CYP3A4. Co-administration with REYATAZ may result in increased
  concentrations of the PDE5 inhibitor and an increase in PDE5-associated
  adverse events, including hypotension, visual changes, and priapism. The
  mechanism of this interaction is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Patients should be warned about these possible
  side effects when using PDE5 inhibitors for erectile dysfunction with REYATAZ
  (see section&nbsp;4.4).</span></p>
  <p class=MsoNormal><span lang=BG>Also see PULMONARY ARTERIAL HYPERTENSION in
  this table for further information regarding co-administration of REYATAZ
  with sildenafil.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>HERBAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>St. John&#8217;s wort (Hypericum
  perforatum)</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Concomitant use of St. John's wort with
  REYATAZ may be expected to result in significant reduction in plasma levels
  of atazanavir. This effect may be due to an induction of CYP3A4. There is a
  risk of loss of therapeutic effect and development of resistance
  (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of REYATAZ with products
  containing St. John's wort is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HORMONAL
  CONTRACEPTIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Ethinyloestradiol 25&nbsp;&#956;g +
  norgestimate</span></b></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>(atazanavir
  300&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Ethinyloestradiol
  AUC &#8595;19% (&#8595;25% &#8595;13%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Ethinyloestradiol
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8595;16%
  (&#8595;26% &#8595;5%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Ethinyloestradiol
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8595;37%
  (&#8595;45% &#8595;29%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Norgestimate
  AUC &#8593;85% (&#8593;67% &#8593;105%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Norgestimate
  C</span><sub><span lang=BG>max</span></sub><span lang=BG> &#8593;68%
  (&#8593;51% &#8593;88%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Norgestimate
  C</span><sub><span lang=BG>min</span></sub><span lang=BG> &#8593;102%
  (&#8593;77% &#8593;131%)</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>While the
  concentration of ethinyloestradiol was increased with atazanavir given alone,
  due to both UGT and CYP3A4 inhibition by atazanavir, the net effect of
  atazanavir/ritonavir is a decrease in ethinyloestradiol levels because of the
  inducing effect of ritonavir. </span></p>
  <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>The
  increase in progestin exposure may lead to related side-effects (e.g. insulin
  resistance, dyslipidemia, acne and spotting), thus possibly affecting the
  compliance.</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>If an oral
  contraceptive is administered with REYATAZ/ritonavir, it is recommended that
  the oral contraceptive contain at least 30&nbsp;&#956;g of ethinyloestradiol
  and that the patient be reminded of strict compliance with this contraceptive
  dosing regimen. Co-administration of REYATAZ/ritonavir with other hormonal
  contraceptives or oral contraceptives containing progestogens other than
  norgestimate has not been studied, and therefore should be avoided. An
  alternate reliable method of contraception is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Ethinyloestradiol 35&nbsp;&micro;g + norethindrone<br>
  </span></b><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Ethinyloestradiol AUC &#8593;48%
  (&#8593;31% &#8593;68%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ethinyloestradiol C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;15% (&#8595;1% &#8593;32%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ethinyloestradiol C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;91% (&#8593;57% &#8593;133%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Norethindrone AUC &#8593;110% (&#8593;68%
  &#8593;162%)</span></p>
  <p class=EMEABodyText><span lang=BG>Norethindrone C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;67% (&#8593;42% &#8593;196%)</span></p>
  <p class=EMEABodyText><span lang=BG>Norethindrone C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;262% (&#8593;157% &#8593;409%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>The increase in progestin exposure may
  lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and
  spotting), thus possibly affecting the compliance.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>LIPID LOWERING AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>HMG-CoA reductase inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Simvastatin</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Lovastatin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Simvastatin and lovastatin are highly
  dependent on CYP3A4 for their metabolism and co-administration with REYATAZ
  may result in increased concentrations. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of simvastatin or
  lovastatin with REYATAZ is contraindicated due to an increased risk of
  myopathy including rhabdomyolysis (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Atorvastatin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>The risk of myopathy including
  rhabdomyolysis may also be increased with atorvastatin, which is also
  metabolised by CYP3A4. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of atorvastatin with
  REYATAZ is not recommended. If the use of atorvastatin is considered strictly
  necessary, the lowest possible dose of atorvastatin should be administered
  with careful safety monitoring (see&nbsp;section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Pravastatin</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Fluvastatin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Although not studied, there is a potential
  for an increase in pravastatin or fluvastatin exposure when co-administered
  with protease inhibitors.</span><span lang=BG style='color:blue'> </span><span
  lang=BG>Pravastatin is not metabolised by CYP3A4. Fluvastatin is partially
  metabolised by CYP2C9.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Caution should be exercised.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>INHALED BETA AGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Salmeterol</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with REYATAZ may result in
  increased concentrations of salmeterol and an increase in
  salmeterol-associated adverse events.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>The mechanism of interaction is CYP3A4
  inhibition by atazanavir and/or ritonavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of salmeterol with REYATAZ
  is not recommended (see&nbsp;section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>OPIOIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Buprenorphine, once daily, stable
  maintenance dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Buprenorphine AUC &#8593;67%</span></p>
  <p class=EMEABodyText><span lang=BG>Buprenorphine C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;37% </span></p>
  <p class=EMEABodyText><span lang=BG>Buprenorphine C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;69%</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Norbuprenorphine AUC &#8593;105%</span></p>
  <p class=EMEABodyText><span lang=BG>Norbuprenorphine C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;61%</span></p>
  <p class=EMEABodyText><span lang=BG>Norbuprenorphine C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;101%</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>The mechanism of interaction is CYP3A4
  and UGT1A1 inhibition.</span></p>
  <p class=EMEABodyText><span lang=BG>Concentrations of atazanavir (when given
  with ritonavir) were not significantly affected.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration with REYATAZ with
  ritonavir warrants clinical monitoring for sedation and cognitive effects. A
  dose reduction of buprenorphine may be considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Methadone, stable maintenance dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No significant effect on methadone
  concentrations was observed. Given that low dose ritonavir (100&nbsp;mg twice
  daily) has been shown to have no significant effect on methadone
  concentrations, no interaction is expected if methadone is co-administered with
  REYATAZ, based on these data.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No dosage adjustment is necessary if
  methadone is co-administered with REYATAZ.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>PULMONARY
  ARTERIAL HYPERTENSION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>PDE5
  Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=BG>Sildenafil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>Co-administration
  with REYATAZ may result in increased concentrations of the PDE5 inhibitor and
  an increase in PDE5-inhibitor-associated adverse events. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>The mechanism
  of interaction is CYP3A4 inhibition by atazanavir and/or ritonavir.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>A safe and
  effective dose in combination with REYATAZ has not been established for
  sildenafil when used to treat pulmonary arterial hypertension. Sildenafil,
  when used for the treatment of pulmonary arterial hypertension, is
  contraindicated (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>SEDATIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Benzodiazepines</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Midazolam</span></b></p>
  <p class=EMEABodyText><b><span lang=BG>Triazolam</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Midazolam and triazolam are extensively
  metabolised by CYP3A4. Co-administration with REYATAZ may cause a large
  increase in the concentration of these benzodiazepines. No drug interaction
  study has been performed for the co-administration of REYATAZ with
  benzodiazepines. Based on data for other CYP3A4 inhibitors, plasma
  concentrations of midazolam are expected to be significantly higher when
  midazolam is given orally. Data from concomitant use of parenteral midazolam
  with other protease inhibitors suggest a possible 3-4&nbsp;fold increase in
  midazolam plasma levels.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
  triazolam or orally administered midazolam is contraindicated
  (see&nbsp;section&nbsp;4.3), whereas caution should be used with
  co-administration of REYATAZ and parenteral midazolam. If REYATAZ is
  co-administered with parenteral midazolam, it should be done in an intensive
  care unit (ICU) or similar setting which ensures close clinical monitoring
  and appropriate medical management in case of respiratory depression and/or
  prolonged sedation. Dosage adjustment for midazolam should be considered,
  especially if more than a single dose of midazolam is administered.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>In case of withdrawal of ritonavir from
the recommended atazanavir boosted regimen (see&nbsp;section&nbsp;4.4)</span></i></p>

<p class=EMEABodyText><span lang=BG>The same recommendations for drug drug
interactions would apply except: </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>that co-administration is not recommended with
tenofovir, boceprevir, carbamazepine, phenytoin, phenobarbital, proton pump
inhibitors, and buprenorphine.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>that co-administration with famotidine is not
recommended but if required, atazanavir without ritonavir should be
administered either 2&nbsp;hours after famotidine or 12&nbsp;hours before. No
single dose of famotidine should exceed 20&nbsp;mg, and the total daily dose of
famotidine should not exceed 40&nbsp;mg. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-14.2pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>the need to consider that </span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>co-administration of voriconazole and REYATAZ
without ritonavir may affect atazanavir concentrations</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>co-administration of fluticasone and REYATAZ
without ritonavir may increase fluticasone concentrations relative to
fluticasone given alone</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if an oral contraceptive is administered with
REYATAZ without ritonavir, it is recommended that the oral contraceptive
contain no more than 30&nbsp;&micro;g of ethinyloestradiol </span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>no dose adjustment of lamotrigine is required </span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=BG>Interaction studies have only been
performed in adults.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Pregnancy</span></u></p>

<p class=EMEABodyText><span lang=BG>A moderate amount of data in pregnant women
(between&nbsp;300-1000 pregnancy outcomes) indicate no malformative toxicity of
atazanavir. Animal studies do not indicate reproductive toxicity
(see&nbsp;section&nbsp;5.3). The use of REYATAZ with ritonavir may be
considered during pregnancy only if the potential benefit justifies the
potential risk.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In clinical trial AI424-182
REYATAZ/ritonavir (300/100&nbsp;mg or 400/100&nbsp;mg) in combination with
zidovudine/lamivudine was administered to 41&nbsp;pregnant women during the
second or third trimester. Six of 20&nbsp;(30%)&nbsp;women on REYATAZ/ritonavir
300/100&nbsp;mg and 13&nbsp;of&nbsp;21&nbsp;(62%)&nbsp;women on REYATAZ/ritonavir
400/100&nbsp;mg experienced
grades&nbsp;3&nbsp;to&nbsp;4&nbsp;hyperbilirubinaemia. There were no cases of
lactic acidosis observed in the clinical trial AI424-182.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The study assessed 40&nbsp;infants who
received antiretroviral prophylactic treatment (which did not include REYATAZ)
and were negative for HIV-1 DNA at the time of delivery and/or during the first
6&nbsp;months postpartum. Three of 20&nbsp;infants&nbsp;(15%)&nbsp;born to
women treated with REYATAZ/ritonavir 300/100&nbsp;mg and four of
20&nbsp;infants&nbsp;(20%)&nbsp;born to women treated with REYATAZ/ritonavir
400/100&nbsp;mg experienced grade&nbsp;3-4&nbsp;bilirubin. There was no
evidence of pathologic jaundice and six of 40&nbsp;infants in this study
received phototherapy for a maximum of 4&nbsp;days. There were no reported
cases of kernicterus in neonates.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For dosing recommendations
see&nbsp;section&nbsp;4.2 and for pharmacokinetic data
see&nbsp;section&nbsp;5.2.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>It is not known whether REYATAZ with
ritonavir administered to the mother during pregnancy will exacerbate
physiological hyperbilirubinaemia and lead to kernicterus in neonates and
infants. In the prepartum period, additional monitoring should be considered.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>Breast-feeding</span></u></p>

<p class=EMEABodyText><span lang=BG>Atazanavir has been detected in human milk.
As a general rule, it is recommended that HIV infected women not breast-feed
their infants in order to avoid transmission of HIV.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Fertility</span></u></p>

<p class=EMEABodyText><span lang=BG>In a nonclinical fertility and early
embryonic development study in rats, atazanavir altered oestrus cycling with no
effects on mating or fertility (see&nbsp;section&nbsp;5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on
ability to drive and use machines</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Patients should be informed that dizziness
has been reported during treatment with regimens containing REYATAZ
(see&nbsp;section&nbsp;4.8). </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Summary of the safety profile</span></u></p>

<p class=EMEABodyText><span lang=BG>REYATAZ has been evaluated for safety in
combination therapy with other antiretroviral medicinal products in controlled
clinical trials in 1,806&nbsp;adult&nbsp;patients receiving REYATAZ 400&nbsp;mg
once daily (1,151&nbsp;patients, 52&nbsp;weeks median duration and
152&nbsp;weeks maximum duration) or REYATAZ 300&nbsp;mg with ritonavir
100&nbsp;mg once daily (655&nbsp;patients, 96&nbsp;weeks median duration and
108&nbsp;weeks maximum duration).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Adverse reactions were consistent between
patients who received REYATAZ 400&nbsp;mg once daily and patients who received
REYATAZ 300&nbsp;mg with ritonavir 100&nbsp;mg once daily, except that jaundice
and elevated total bilirubin levels were reported more frequently with REYATAZ
plus ritonavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Among patients who received REYATAZ
400&nbsp;mg once daily or REYATAZ 300&nbsp;mg with ritonavir 100&nbsp;mg once
daily, the only adverse reactions of any severity reported very commonly with
at least a possible relationship to regimens containing REYATAZ and one or more
NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%). Among patients
receiving REYATAZ 300&nbsp;mg with ritonavir 100&nbsp;mg, the frequency of
jaundice was 19%. In the majority of cases, jaundice was reported within a few
days to a few months after the initiation of treatment
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>Chronic kidney disease in HIV-infected
patients treated with atazanavir, with or without ritonavir, has been reported
during postmarketing surveillance. A large prospective observational study has
shown an association between an increased incidence of chronic kidney disease
and cumulative exposure to atazanavir/ritonavir-containing regimen in
HIV-infected patients with an initially normal eGFR. This association was
observed independently of exposure to tenofovir disoproxil. Regular monitoring
of the renal function of patients should be maintained throughout the treatment
duration (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><s><span style='text-decoration:none'>&nbsp;</span></s></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Tabulated
list of adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=BG>Assessment of adverse reactions for REYATAZ
is based on safety data from clinical studies and post-marketing experience.
Frequency is defined using the following convention: very common
(&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon
(&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000 to
&lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=576
 style='margin-left:33.75pt;border-collapse:collapse'>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Immune system disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: hypersensitivity</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Metabolism and nutrition disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: weight decreased, weight gain,
  anorexia, appetite increased</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Psychiatric disorders:</span></i></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: depression, disorientation,
  anxiety, insomnia, sleep disorder, abnormal dream</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Nervous system disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: headache;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: peripheral neuropathy, syncope,
  amnesia, dizziness, somnolence, dysgeusia</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Eye disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: ocular icterus</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Cardiac disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>uncommon:
  torsades de pointes<sup>a</sup></span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>rare: QTc
  prolongation<sup>a</sup>, oedema, palpitation</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Vascular disorders:</span></i></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: hypertension</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Respiratory, thoracic and mediastinal
  disorders:</span></i></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: dyspnoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Gastrointestinal disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: vomiting, diarrhoea, abdominal
  pain, nausea, dyspepsia;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: pancreatitis, gastritis,
  abdominal distension, stomatitis aphthous, flatulence, dry mouth</span></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Hepatobiliary disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: jaundice;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: hepatitis, cholelithiasis<sup>a</sup>,
  cholestasis<sup>a</sup>;</span></p>
  <p class=EMEABodyText><span lang=BG>rare: hepatosplenomegaly, cholecystitis<sup>a</sup></span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Skin and subcutaneous tissue
  disorders:</span></i></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: rash;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: erythemia multiforme<sup>a,b</sup>,
  toxic skin eruptions<sup>a,b</sup>, drug rash with eosinophilia and systemic
  symptoms (DRESS) syndrome<sup>a,b</sup>, angioedema<sup>a</sup>, urticaria,
  alopecia, pruritus; </span></p>
  <p class=EMEABodyText><span lang=BG>rare: Stevens-Johnson syndrome<sup>a,b</sup>,
  vesiculobullous rash, eczema, vasodilatation</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Musculoskeletal and connective tissue
  disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: muscle atrophy, arthralgia,
  myalgia; </span></p>
  <p class=EMEABodyText><span lang=BG>rare: myopathy</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Renal and urinary disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: nephrolithiasis<sup>a</sup>,
  haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney
  disease<sup>a</sup>;</span></p>
  <p class=EMEABodyText><span lang=BG>rare: kidney pain</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Reproductive system and breast
  disorders:</span></i></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: gynaecomastia</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>General disorders and administration
  site conditions:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: fatigue;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: chest pain, malaise, pyrexia,
  asthenia;</span></p>
  <p class=EMEABodyText><span lang=BG>rare: gait disturbance</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
lang=BG style='font-size:9.0pt'> These adverse reactions were identified
through post-marketing surveillance, however, the frequencies were estimated
from a statistical calculation based on the total number of patients exposed to
REYATAZ in randomised controlled and other available clinical trials (n
=&nbsp;2321).</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
lang=BG style='font-size:9.0pt'> See description of selected adverse reactions
for more details.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Description of selected adverse
reactions</span></u></p>

<p class=EMEABodyText><span lang=BG>In HIV-infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. Autoimmune disorders (such as Graves' disease and
autoimmune hepatitis) have also been reported; however, the reported time to
onset is more variable and these events can occur many months after initiation
of treatment (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><i><u><span style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=EMEABodyText><span lang=BG>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long-term exposure to combination antiretroviral therapy (CART). The
frequency of this is unknown (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Metabolic parameters</span></p>

<p class=EMEABodyText><span lang=BG>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><span lang=BG>Rash and associated syndromes</span></p>

<p class=EMEABodyText><span lang=BG>Rashes are usually mild-to-moderate
maculopapular skin eruptions that occur within the first 3&nbsp;weeks of
starting therapy with REYATAZ. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Stevens-Johnson syndrome (SJS), erythema
multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms
(DRESS) syndrome have been reported with the use of REYATAZ
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Laboratory
abnormalities</span></i></p>

<p class=EMEABodyText><span lang=BG>The most frequently reported laboratory
abnormality in patients receiving regimens containing REYATAZ&nbsp;and one or
more NRTIs was elevated total bilirubin reported predominantly as elevated
indirect [unconjugated] bilirubin (87% Grade&nbsp;1,&nbsp;2,&nbsp;3,
or&nbsp;4). Grade&nbsp;3 or&nbsp;4 elevation of total bilirubin was noted in
37% (6% Grade&nbsp;4). Among experienced patients treated with REYATAZ
300&nbsp;mg once daily with 100&nbsp;mg ritonavir once daily for a median
duration of 95&nbsp;weeks, 53% had Grade&nbsp;3-4&nbsp;total bilirubin
elevations. Among naive patients treated with REYATAZ 300&nbsp;mg once daily
with 100&nbsp;mg ritonavir once daily for a median duration of 96&nbsp;weeks,
48% had Grade&nbsp;3-4&nbsp;total bilirubin elevations
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other marked clinical laboratory
abnormalities (Grade&nbsp;3 or&nbsp;4) reported in&nbsp;&#8805;&nbsp;2% of
patients receiving regimens containing REYATAZ&nbsp;and one or more NRTIs
included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum
glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated
aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT)
(3%), and elevated lipase (3%).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Two percent of patients treated with
REYATAZ experienced concurrent Grade&nbsp;3-4&nbsp;ALT/AST and
Grade&nbsp;3-4&nbsp;total bilirubin elevations.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Paediatric population</span></u></p>

<p class=EMEABodyText><span lang=BG>In a clinical study AI424-020, paediatric
patients 3&nbsp;months to less than 18&nbsp;years of age who received either
the oral powder or capsule formulation had a mean duration of treatment with
REYATAZ of 115&nbsp;weeks. The safety profile in this study was overall
comparable to that seen in adults. Both asymptomatic first-degree (23%) and
second-degree (1%) atrioventricular block were reported in paediatric patients.
The most frequently reported laboratory abnormality in paediatric patients
receiving REYATAZ was elevation of total bilirubin (&#8805; 2.6&nbsp;times ULN,
Grade&nbsp;3-4) which occurred in 45% of patients.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In clinical studies AI424-397 and
AI424-451, paediatric patients 3&nbsp;months to less than 11&nbsp;years of age
had a mean duration of treatment with REYATAZ oral powder of 80&nbsp;weeks. No
deaths were reported. The safety profile in these studies was overall
comparable to that seen in previous paediatric and adult studies. The most frequently
reported laboratory abnormalities in paediatric patients receiving REYATAZ oral
powder was elevation of total bilirubin (&#8805;&nbsp;2.6&nbsp;times&nbsp;ULN,
Grade&nbsp;3-4; 16%) and increased amylase (Grade&nbsp;3-4; 33%), generally of
non-pancreatic origin. Elevation in ALT levels were more frequently reported in
paediatric patients in these studies than in adults.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Other special populations</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Patients
co-infected with hepatitis B and/or hepatitis C virus</span></i></p>

<p class=EMEABodyText><span lang=BG>Among 1,151&nbsp;patients receiving
atazanavir 400&nbsp;mg once daily, 177&nbsp;patients were co-infected with
chronic hepatitis&nbsp;B or&nbsp;C, and among 655&nbsp;patients receiving
atazanavir 300&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily,
97&nbsp;patients were co-infected with chronic hepatitis&nbsp;B or&nbsp;C.
Co-infected patients were more likely to have baseline hepatic transaminase
elevations than those without chronic viral hepatitis. No differences in
frequency of bilirubin elevations were observed between these patients and
those without viral hepatitis. The frequency of treatment emergent hepatitis or
transaminase elevations in co-infected patients was comparable between REYATAZ
and comparator regimens (see&nbsp;section&nbsp;4.4). </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Reporting of suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=BG>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span
class=MsoHyperlink><span lang=BG style='color:windowtext;text-decoration:none'>.</span></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Human experience of acute overdose with
REYATAZ is limited. Single doses up to 1,200&nbsp;mg have been taken by healthy
volunteers without symptomatic untoward effects. At high doses that lead to
high drug exposures, jaundice due to indirect (unconjugated)
hyperbilirubinaemia (without associated liver function test changes) or PR
interval prolongations may be observed (see&nbsp;sections&nbsp;4.4
and&nbsp;4.8).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Treatment of overdose with REYATAZ should
consist of general supportive measures, including monitoring of vital signs and
electrocardiogram (ECG), and observations of the patient's clinical status. If
indicated, elimination of unabsorbed atazanavir should be achieved by emesis or
gastric lavage. Administration of activated charcoal may also be used to aid
removal of unabsorbed drug. There is no specific antidote for overdose with
REYATAZ. Since atazanavir is extensively metabolised by the liver and is highly
protein bound, dialysis is unlikely to be beneficial in significant removal of
this medicinal product.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Pharmacotherapeutic group: antivirals for
systemic use, protease inhibitors, ATC code: J05AE08</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Mechanism of action</span></u></p>

<p class=EMEABodyText><span lang=BG>Atazanavir is an azapeptide HIV-1 protease
inhibitor (PI). The compound selectively inhibits the virus-specific processing
of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of
mature virions and infection of other cells.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Antiviral activity in vitro:</span></i><span
lang=BG> atazanavir exhibits anti-HIV-1 (including all clades tested) and
anti-HIV-2 activity in cell culture.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Resistance</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Antiretroviral
treatment naive adult patients</span></i></p>

<p class=EMEABodyText><span lang=BG>In clinical trials of antiretroviral
treatment naive patients treated with unboosted atazanavir, the I50L
substitution, sometimes in combination with an A71V change, is the signature
resistance substitution for atazanavir. Resistance levels to atazanavir ranged
from 3.5- to 29-fold without evidence of phenotypic cross resistance to other
PIs. In clinical trials of antiretroviral treatment naive patients treated with
boosted atazanavir, the I50L substitution did not emerge in any patient without
baseline PI substitutions. The N88S substitution has been rarely observed in
patients with virologic failure on atazanavir (with or without ritonavir).
While it may contribute to decreased susceptibility to atazanavir when it
occurs with other protease substitutions, in clinical studies N88S by itself
does not always lead to phenotypic resistance to atazanavir or have a
consistent impact on clinical efficacy.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Table&nbsp;3. De novo substitutions in
  treatment naive patients failing therapy with atazanavir + ritonavir
  (Study&nbsp;138, 96&nbsp;weeks)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Frequency</span></b></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>de novo PI substitution (n=26)<sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>&gt;20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>none</span></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>10-20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>none</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
  lang=BG style='font-size:9.0pt'> Number of patients with paired genotypes
  classified as virological failures (HIV RNA &#8805;&nbsp;400&nbsp;copies/ml).</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The M184I/V substitution emerged in 5/26
REYATAZ/ritonavir and 7/26 lopinavir/ritonavir virologic failure patients,
respectively.</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Antiretroviral
treatment experienced adult patients</span></i></p>

<p class=EMEABodyText><span lang=BG>In antiretroviral treatment experienced
patients from Studies&nbsp;009,&nbsp;043, and&nbsp;045, 100&nbsp;isolates from
patients designated as virological failures on therapy that included either
atazanavir, atazanavir + ritonavir, or atazanavir + saquinavir were determined
to have developed resistance to atazanavir. Of the 60&nbsp;isolates from
patients treated with either atazanavir or atazanavir + ritonavir,
18&nbsp;(30%) displayed the I50L phenotype previously described in naive
patients.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Table&nbsp;4. De novo substitutions in
  treatment experienced patients failing therapy with atazanavir + ritonavir
  (Study&nbsp;045, 48&nbsp;weeks)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Frequency</span></b></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>de novo PI substitution (n=35)<sup>a,b</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>&gt;20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>M36,
  M46, I54, A71, V82</span></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>10-20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>L10,
  I15, K20, V32, E35, S37, F53, I62, G73, I84, L90</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
  lang=BG style='font-size:9.0pt'> Number of patients with paired genotypes
  classified as virological failures (HIV RNA &#8805;&nbsp;400&nbsp;copies/ml).</span></p>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
  lang=BG style='font-size:9.0pt'> Ten patients had baseline phenotypic
  resistance to atazanavir + ritonavir (fold change [FC]&gt;5.2). FC
  susceptibility in cell culture relative to the wild-type reference was
  assayed using PhenoSense<sup>TM</sup> (Monogram Biosciences, South San
  Francisco, California, USA)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>None of the de novo substitutions
(see&nbsp;Table&nbsp;4) are specific to atazanavir and may reflect re-emergence
of archived resistance on atazanavir + ritonavir in Study&nbsp;045
treatment-experienced population.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The resistance in antiretroviral treatment
experienced patients mainly occurs by accumulation of the major and minor
resistance substitutions described previously to be involved in protease
inhibitor resistance.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Clinical results</span></b></p>

<p class=EMEABodyText><i><span lang=BG>In antiretroviral naive adult patients</span></i></p>

<p class=EMEABodyText><i><span lang=BG>Study&nbsp;138</span></i><span lang=BG>
is an international randomised, open-label, multicenter, prospective trial of
treatment na&iuml;ve patients comparing REYATAZ/ritonavir
(300&nbsp;mg/100&nbsp;mg once daily) to lopinavir/ritonavir
(400&nbsp;mg/100&nbsp;mg twice daily), each in combination with fixed dose
tenofovir disoproxil fumarate/emtricitabine (300&nbsp;mg/200&nbsp;mg tablets
once daily). The REYATAZ/ritonavir arm showed similar (non-inferior) antiviral
efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion
of patients with HIV RNA &lt; 50&nbsp;copies/ml at week&nbsp;48 (Table&nbsp;5).</span></p>

<p class=EMEABodyText><span lang=BG>Analyses of data through 96&nbsp;weeks of
treatment demonstrated durability of antiviral activity (Table&nbsp;5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy
Outcomes in Study&nbsp;138<sup> a</sup></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=619
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=163 valign=bottom style='width:1.7in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Parameter</span></b></p>
  </td>
  <td width=228 colspan=2 valign=top style='width:171.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>REYATAZ/ritonavir<sup>b</sup>
  (300&nbsp;mg/100&nbsp;mg once daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=440</span></b></p>
  </td>
  <td width=228 colspan=2 valign=top style='width:171.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Lopinavir/ritonavir<sup>c</sup>
  (400&nbsp;mg/100&nbsp;mg twice daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=443</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=bottom style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=bottom style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  &lt;50&nbsp;copies/ml, %</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=bottom style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients<sup>d</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>74</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>76</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>68</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Difference
  estimate </span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  [95% CI]<sup>d</sup></span></p>
  </td>
  <td width=456 colspan=4 valign=top style='width:4.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week&nbsp;48: 1.7% [-3.8%, 7.1%]</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week&nbsp;96: 6.1% [0.3%, 12.0%]</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Per
  protocol analysis<sup>e</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>86</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=392<sup>f</sup>)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>91</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=352)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>89</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=372)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>89</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=331)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Difference
  estimate<sup>e</sup> </span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;&nbsp;
  [95% CI]</span></p>
  </td>
  <td width=456 colspan=4 valign=top style='width:4.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week&nbsp;48: -3% [-7.6%, 1.5%]</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week&nbsp;96: 2.2% [-2.3%, 6.7%]</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>HIV RNA
  &lt;50&nbsp;copies/ml, % by Baseline Characteristic<sup>d</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>HIV RNA <br>
  &nbsp;&nbsp;&nbsp; &lt;100,000&nbsp;copies/ml</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>82 (n=217)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>75 (n=217)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>81 (n=218)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>70 (n=218)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  &#8805;100,000&nbsp;copies/ml</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>74 (n=223)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>74 (n=223)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>72 (n=225)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>66 (n=225)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>CD4 count<br>
  &nbsp;&nbsp;&nbsp; &lt;50&nbsp;cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78 (n=58)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78 (n=58)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>63 (n=48)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>58 (n=48)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  50&nbsp;to &lt;100&nbsp;cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>76 (n=45)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>71 (n=45)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>69 (n=29)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>69 (n=29)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  100&nbsp;to &lt;200&nbsp;cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>75 (n=106)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>71 (n=106)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78 (n=134)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>70 (n=134)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  &#8805;&nbsp;200&nbsp;cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>80 (n=222)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>76 (n=222)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>80 (n=228)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>69 (n=228)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  Mean Change from Baseline, log<sub>10</sub> copies/ml</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  All patients</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.09 (n=397)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.21 (n=360)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.13 (n=379)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.19 (n=340)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>CD4
  Mean Change from Baseline, cells/mm<sup>3</sup> </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  All patients</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>203 (n=370)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>268 (n=336)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>219 (n=363)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>290 (n=317)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>CD4 Mean
  Change from Baseline, cells/mm<sup>3</sup> by Baseline Characteristic</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>HIV RNA <br>
  &nbsp;&nbsp; &lt;100,000&nbsp;copies/ml</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>179 (n=183)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>243 (n=163)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>194 (n=183)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>267 (n=152)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  &#8805;100,000&nbsp;copies/ml</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>227 (n=187)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>291 (n=173)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>245 (n=180)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>310 (n=165)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>a</span></sup><span lang=BG style='font-size:9.0pt'>
Mean baseline CD4 cell count was 214&nbsp;cells/mm<sup>3</sup> (range 2 to
810&nbsp;cells/mm<sup>3</sup>) and mean baseline plasma HIV-1 RNA was
4.94&nbsp;log<sub>10</sub>&nbsp;copies/ml (range 2.6 to 5.88&nbsp;log<sub>10</sub>&nbsp;copies/ml)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>b</span></sup><span lang=BG style='font-size:9.0pt'>
REYATAZ/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>c</span></sup><span lang=BG style='font-size:9.0pt'>
Lopinavir/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>d</span></sup><span lang=BG style='font-size:9.0pt'>
Intent-to-treat analysis, with missing values considered as failures.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>e</span></sup><span lang=BG style='font-size:9.0pt'>
Per protocol analysis: Excluding non-completers and patients with major
protocol deviations.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>f</span></sup><span
lang=BG style='font-size:9.0pt'> Number of patients evaluable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Data on
withdrawal of ritonavir from atazanavir boosted regimen
(see&nbsp;also&nbsp;section&nbsp;4.4)</span></i></p>

<p class=EMEABodyText><i><u><span lang=BG>Study&nbsp;136&nbsp;(INDUMA)</span></u></i></p>

<p class=EMEABodyText><span lang=BG>In an open-label, randomised, comparative
study following a 26- to 30-week induction phase with REYATAZ&nbsp;300 mg
+&nbsp;ritonavir 100&nbsp;mg once daily and two NRTIs, unboosted REYATAZ
400&nbsp;mg once daily and two NRTIs administered during a 48-week maintenance
phase (n=87) had similar antiviral efficacy compared with
REYATAZ&nbsp;+&nbsp;ritonavir and two NRTIs (n=85) in HIV infected subjects
with fully suppressed HIV replication, as assessed by the proportion of
subjects with HIV&nbsp;RNA&nbsp;&lt;&nbsp;50&nbsp;copies/ml: 78% of subjects on
unboosted REYATAZ and two NRTIs compared with 75% on
REYATAZ&nbsp;+&nbsp;ritonavir and two NRTIs.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Eleven subjects (13%) in the unboosted
REYATAZ group and 6 (7%) in the REYATAZ&nbsp;+&nbsp;ritonavir group, had
virologic rebound. Four subjects in the unboosted REYATAZ group and 2 in the
REYATAZ + ritonavir group had HIV RNA&nbsp;&gt;&nbsp;500&nbsp;copies/ml during
the maintenance phase. No subject in either group showed emergence of protease
inhibitor resistance. The M184V substitution in reverse transcriptase, which
confers resistance to lamivudine and emtricitabine, was detected in
2&nbsp;subjects in the unboosted REYATAZ and 1&nbsp;subject in the
REYATAZ&nbsp;+&nbsp;ritonavir group.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There were fewer treatment discontinuations
in the unboosted REYATAZ group (1 vs. 4&nbsp;subjects in the
REYATAZ&nbsp;+&nbsp;ritonavir group). There was less hyperbilirubinaemia and
jaundice in the unboosted REYATAZ group compared with the REYATAZ + ritonavir
group (18 and 28&nbsp;subjects, respectively).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>In
antiretroviral experienced adult patients</span></i></p>

<p class=EMEABodyText><i><u><span lang=BG>Study&nbsp;045</span></u></i><span
lang=BG> is a randomised, multicenter trial comparing REYATAZ/ritonavir
(300/100&nbsp;mg once daily) and REYATAZ/saquinavir (400/1,200&nbsp;mg once
daily), to lopinavir + ritonavir (400/100&nbsp;mg fixed dose combination twice
daily), each in combination with tenofovir disoproxil fumarate
(see&nbsp;sections&nbsp;4.5 and&nbsp;4.8) and one NRTI, in patients with
virologic failure on two or more prior regimens containing at least one PI,
NRTI, and NNRTI. For randomised patients, the mean time of prior antiretroviral
exposure was 138&nbsp;weeks for PIs, 281&nbsp;weeks for NRTIs, and
85&nbsp;weeks for NNRTIs. At baseline, 34% of patients were receiving a PI and
60% were receiving an NNRTI. Fifteen of 120 (13%) patients in the REYATAZ +
ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir +
ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84,
and L90. Thirty-two percent of patients in the study had a viral strain with fewer
than two NRTI substitutions.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The primary endpoint was the time-averaged
difference in change from baseline in HIV RNA through 48&nbsp;weeks
(Table&nbsp;6).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy
Outcomes at Week&nbsp;48<sup>a</sup> and at Week&nbsp;96 (Study&nbsp;045)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=626
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=97 colspan=2 style='width:72.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Parameter</span></b></p>
  </td>
  <td width=176 colspan=2 style='width:132.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>ATV/RTV<sup>b</sup> (300&nbsp;mg/ 100&nbsp;mg once
  daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=120</span></b></p>
  </td>
  <td width=176 colspan=2 style='width:132.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>LPV/RTV<sup>c</sup> (400&nbsp;mg/ 100&nbsp;mg twice
  daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=123</span></b></p>
  </td>
  <td width=176 colspan=2 style='width:132.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Time-averaged difference ATV/RTV-LPV/RTV</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>[97.5% CI<sup>d</sup>]</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 style='width:72.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=626 colspan=8 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  Mean Change from Baseline, log<sub>10</sub> copies/ml</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 style='width:72.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-1.93</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=90<sup> e</sup>)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-2.29 (n=64)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-1.87 (n=99)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-2.08 (n=65)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>0.13</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>[-0.12, 0.39]</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>0.14</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>[-0.13, 0.41]</span></p>
  </td>
 </tr>
 <tr>
  <td width=626 colspan=8 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  &lt;50&nbsp;copies/ml, %<sup>f</sup> (responder/evaluable)</span></b></p>
  </td>
 </tr>
 <tr style='height:7.85pt'>
  <td width=97 colspan=2 valign=top style='width:72.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>36 (43/120)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>32 (38/120)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>42 (52/123)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>35 (41/118)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.85pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr style='height:5.6pt'>
  <td width=626 colspan=8 valign=bottom style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.6pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  &lt;50&nbsp;copies/ml by select baseline PI substitutions,<sup>f, g</sup> %
  (responder/evaluable)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=16 valign=top style='width:12.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=81 valign=top style='width:60.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>0-2</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>44 (28/63)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>41 (26/63)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>56 (32/57)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>48 (26/54)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=16 valign=top style='width:12.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>3</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>18 (2/11)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>9 (1/11)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>38 (6/16)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>33 (5/15)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=16 valign=top style='width:12.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&#8805; 4</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>27 (12/45)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>24 (11/45)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>28 (14/50)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>20 (10/49)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=626 colspan=8 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>CD4
  Mean Change from Baseline, cells/mm<sup>3</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 valign=top style='width:72.9pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.5pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>110 (n=83)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>122 (n=60)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>121 (n=94)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>154 (n=60)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>a</span></sup><span lang=BG style='font-size:9.0pt'>
The mean baseline CD4 cell count was 337&nbsp;cells/mm<sup>3</sup> (range: 14
to 1,543&nbsp;cells/mm<sup>3</sup>) and the mean baseline plasma HIV-1 RNA
level was 4.4&nbsp;log<sub>10</sub>&nbsp;copies/ml (range: 2.6 to 5.88&nbsp;log<sub>10</sub>&nbsp;copies/ml).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>b</span></sup><span lang=BG style='font-size:9.0pt'>
ATV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>c</span></sup><span lang=BG style='font-size:9.0pt'>
LPV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>d</span></sup><span lang=BG style='font-size:9.0pt'>
Confidence interval.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>e</span></sup><span lang=BG style='font-size:9.0pt'>
Number of patients evaluable.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>f</span></sup><span lang=BG style='font-size:9.0pt'>
Intent-to-treat analysis, with missing values considered as failures.
Responders on LPV/RTV who completed treatment before Week 96 are excluded from
Week 96 analysis. The proportion of patients with HIV RNA
&lt;&nbsp;400&nbsp;copies/ml were 53% and 43% for ATV/RTV and 54% and 46% for
LPV/RTV at weeks&nbsp;48 and 96 respectively.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>g</span></sup><span lang=BG style='font-size:9.0pt'>
Select substitutions include any change at positions L10, K20, L24, V32, L33,
M36, M46, G48, I50, I54, L63, A71, G73, V82, I84, and L90 (0-2, 3, 4 or more)
at baseline.</span></p>

<p class=EMEABodyText><span lang=BG style='font-size:9.0pt'>NA = not
applicable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Through 48&nbsp;weeks of treatment, the
mean changes from baseline in HIV RNA levels for REYATAZ + ritonavir and
lopinavir + ritonavir were similar (non-inferior). Consistent results were
obtained with the last observation carried forward method of analysis
(time-averaged difference of 0.11, 97.5% confidence interval [-0.15, 0.36]). By
as-treated analysis, excluding missing values, the proportions of patients with
HIV RNA &lt;&nbsp;400 copies/ml (&lt;&nbsp;50&nbsp;copies/ml) in the REYATAZ +
ritonavir arm and the lopinavir + ritonavir arm were 55% (40%) and 56% (46%),
respectively.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Through 96&nbsp;weeks of treatment, mean
HIV RNA changes from baseline for REYATAZ + ritonavir and lopinavir + ritonavir
met criteria for non-inferiority based on observed cases. Consistent results
were obtained with the last observation carried forward method of analysis. By
as-treated analysis, excluding missing values, the proportions of patients with
HIV RNA &lt;400 copies/ml (&lt;50&nbsp;copies/ml) for REYATAZ + ritonavir were
84% (72%) and for lopinavir + ritonavir were&nbsp;82% (72%). It is important to
note that at time of the 96-week analysis, 48 % of patients overall remained on
study.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ + saquinavir was shown to be
inferior to lopinavir + ritonavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=BG>Assessment of the pharmacokinetics, safety,
tolerability, and efficacy of REYATAZ is based on data from the open-label,
multicenter clinical trial AI424-020 conducted in patients from 3&nbsp;months
to 21&nbsp;years of age. Overall in this study, 182&nbsp;paediatric patients
(81&nbsp;antiretroviral-naive and 101&nbsp;antiretroviral-experienced) received
once daily REYATAZ (capsule or powder formulation), with or without ritonavir,
in combination with two NRTIs.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The clinical data derived from this study
are inadequate to support the use of atazanavir (with or without ritonavir) in
children below 6&nbsp;years of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Efficacy data observed in the
41&nbsp;paediatric patients aged 6&nbsp;years to less than 18&nbsp;years that
received REYATAZ capsules with ritonavir are presented in Table&nbsp;7. For
treatment-naive paediatric patients, the mean baseline CD4 cell count was
344&nbsp;cells/mm<sup>3</sup> (range: 2 to 800&nbsp;cells/ mm<sup>3</sup>) and
mean baseline plasma HIV-1 RNA was 4.67&nbsp;log<sub>10</sub> copies/ml (range:
3.70 to 5.00&nbsp;log<sub>10</sub> copies/ml). For treatment-experienced
paediatric patients, the mean baseline CD4 cell count was 522&nbsp;cells/mm<sup>3</sup>
(range: 100 to 1157&nbsp;cells/ mm<sup>3</sup>) and mean baseline plasma HIV-1
RNA was 4.09&nbsp;log<sub>10</sub> copies/ml (range: 3.28 to 5.00&nbsp;log<sub>10</sub>
copies/ml).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-56.7pt'><b><span
lang=BG>Table&nbsp;7: &nbsp;&nbsp;&nbsp;&nbsp; Efficacy Outcomes (paediatric
patients 6&nbsp;years to less than 18&nbsp;years of age) at Week&nbsp;48 (Study
AI424-020)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=568
 style='width:426.15pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=256 style='width:192.15pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Parameter</span></b></p>
  </td>
  <td width=154 valign=bottom style='width:115.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Treatment-Naive<br>
  REYATAZ Capsules/ritonavir (300&nbsp;mg/100&nbsp;mg once daily) n=16</span></b></p>
  </td>
  <td width=158 valign=bottom style='width:118.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Treatment-Experienced REYATAZ Capsules/ritonavir
  (300&nbsp;mg/100&nbsp;mg once daily) n=25</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>HIV RNA &lt;50&nbsp;copies/ml, % <sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>All patients</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>81
  (13/16)</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>24
  (6/25)</span></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>HIV RNA &lt;400&nbsp;copies/ml, % <sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>All patients</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>88
  (14/16)</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>32
  (8/25)</span></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>CD4 Mean Change from Baseline,
  cells/mm<sup>3</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>All patients</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>293
  (n=14</span><sup><span lang=BG>b</span></sup><span lang=BG>)</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>229
  (n=14</span><sup><span lang=BG>b</span></sup><span lang=BG>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>HIV RNA &lt;50 copies/ml by select
  baseline PI substitutions,<sup>c </sup>% (responder/evaluable</span></b><b><sup><span
  lang=BG>d</span></sup><span lang=BG>)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>0-2</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>NA</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>27
  (4/15)</span></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>3</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>NA</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>-</span></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#8805; 4</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>NA</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>0
  (0/3)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
lang=BG style='font-size:9.0pt'> Intent-to-treat analysis, with missing values
considered as failures.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
lang=BG style='font-size:9.0pt'> Number of patients evaluable.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>c </span></sup><span
lang=BG style='font-size:9.0pt'>PI major L24I, D30N, V32I, L33F, M46IL, I47AV,
G48V, I50LV, F53LY,I54ALMSTV, L76V, V82AFLST, I84V, N88DS, L90M; PI minor:
L10CFIRV, V11I, E35G, K43T, Q58E, A71ILTV, G73ACST, T74P, N83D, L89V.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>d</span></sup><span
lang=BG style='font-size:9.0pt'> Includes patients with baseline resistance
data.</span></p>

<p class=EMEABodyText><span lang=BG style='font-size:9.0pt'>NA = not
applicable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='layout-grid-mode:line'>The
pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and
in HIV-infected patients; significant differences were observed between the two
groups. </span><span lang=BG>The pharmacokinetics of atazanavir exhibit a
non-linear disposition.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Absorption:</span></i><span lang=BG> in
HIV-infected patients (n=33, combined studies), multiple dosing of REYATAZ
300&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily with food produced
a geometric mean (CV%) for atazanavir, C<sub>max</sub> of
4466&nbsp;(42%)&nbsp;ng/ml, with time to C<sub>max</sub> of approximately
2.5&nbsp;hours. The geometric mean (CV%) for atazanavir C<sub>min</sub> and AUC
was 654&nbsp;(76%)&nbsp;ng/ml and 44185&nbsp;(51%)&nbsp;ng&#8226;h/ml,
respectively. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In HIV-infected patients (n=13), multiple
dosing of REYATAZ 400&nbsp;mg (without ritonavir) once&nbsp;daily with food
produced a geometric mean (CV%) for atazanavir C<sub>max</sub> of
2298&nbsp;(71)&nbsp;ng/ml, with time to C<sub>max</sub> of approximately
2.0&nbsp;hours. The geometric mean (CV%) for atazanavir C<sub>min</sub> and AUC
were 120&nbsp;(109)&nbsp;ng/ml and 14874&nbsp;(91)&nbsp;ng&#8226;h/ml,
respectively.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Food effect:</span></u><span lang=BG>
co-administration of REYATAZ and ritonavir with food optimises the
bioavailability of atazanavir. Co-administration of a single 300&nbsp;mg dose
of REYATAZ and 100&nbsp;mg dose of ritonavir with a light meal resulted in a
33% increase in the AUC and a 40% increase in both the C<sub>max</sub> and the
24&nbsp;hour concentration of atazanavir relative to the fasting state.
Co-administration with a high-fat meal did not affect the AUC of atazanavir
relative to fasting conditions and the C<sub>max</sub> was within 11% of
fasting values. The 24&nbsp;hour concentration following a high fat meal was
increased by approximately 33% due to delayed absorption; the median T<sub>max</sub>
increased from 2.0 to 5.0&nbsp;hours. Administration of REYATAZ with ritonavir
with either a light or a high-fat meal decreased the coefficient of variation
of AUC and C<sub>max</sub> by approximately 25% compared to the fasting state.
To enhance bioavailability and minimise variability, REYATAZ is to be taken
with food.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Distribution:</span></i><span lang=BG>
atazanavir was approximately 86% bound to human serum proteins over a
concentration range of 100 to 10,000&nbsp;ng/ml. Atazanavir binds to both
alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%,
respectively, at 1,000&nbsp;ng/ml). In a multiple-dose study in HIV-infected
patients dosed with 400&nbsp;mg of atazanavir once daily with a light meal for
12&nbsp;weeks, atazanavir was detected in the cerebrospinal fluid and semen. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Metabolism:</span></i><b><span lang=BG> </span></b><span
lang=BG>studies in humans and <i>in vitro</i> studies using human liver
microsomes have demonstrated that atazanavir is principally metabolised by
CYP3A4 isozyme to oxygenated metabolites.<u> </u>Metabolites are then excreted
in the bile as either free or glucuronidated metabolites. Additional minor
metabolic pathways consist of N-dealkylation and hydrolysis. Two minor
metabolites of atazanavir in plasma have been characterised. Neither metabolite
demonstrated <i>in vitro</i> antiviral activity.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Elimination:</span></i><span lang=BG>
following a single 400&nbsp;mg dose of <sup>14</sup>C-atazanavir, 79% and 13%
of the total radioactivity was recovered in the faeces and urine, respectively.
Unchanged drug accounted for approximately 20% and 7% of the administered dose
in the faeces and urine, respectively. Mean urinary excretion of unchanged drug
was 7% following 2&nbsp;weeks of dosing at 800&nbsp;mg once daily. In
HIV-infected adult patients (n=33, combined studies) the mean half-life within
a dosing interval for atazanavir was 12&nbsp;hours at steady state following a
dose of 300&nbsp;mg daily with ritonavir 100&nbsp;mg once daily with a light
meal.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Special
populations</span></u></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Renal impairment</span></i><span
lang=BG>: in healthy subjects, the renal elimination of unchanged atazanavir
was approximately 7% of the administered dose. There are no pharmacokinetic
data available for REYATAZ with ritonavir in patients with renal insufficiency.
REYATAZ (without ritonavir) has been studied in adult patients with severe
renal impairment (n=20), including those on haemodialysis, at multiple doses of
400&nbsp;mg once daily. Although this study presented some limitations (i.e.,
unbound drug concentrations not studied), results suggested that the atazanavir
pharmacokinetic parameters were decreased by 30% to 50% in patients undergoing
haemodialysis compared to patients with normal renal function. The mechanism of
this decrease is unknown. (See sections&nbsp;4.2 and&nbsp;4.4.)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Hepatic impairment</span></i><span
lang=BG>: atazanavir is metabolised and eliminated primarily by the liver.
REYATAZ (without ritonavir) has been studied in adult subjects with
moderate-to-severe hepatic impairment (14&nbsp;Child-Pugh Class&nbsp;B and
2&nbsp;Child-Pugh Class&nbsp;C subjects) after a single 400&nbsp;mg dose. The
mean AUC<sub>(0-&#8734;)</sub> was 42% greater in subjects with impaired
hepatic function than in healthy subjects. The mean half-life of atazanavir in
hepatically impaired subjects was 12.1&nbsp;hours compared to 6.4&nbsp;hours in
healthy subjects. The effects of hepatic impairment on the pharmacokinetics of
atazanavir after a 300&nbsp;mg dose with ritonavir have not been studied.
Concentrations of atazanavir with or without ritonavir are expected to be
increased in patients with moderately or severely impaired hepatic function
(see&nbsp;sections&nbsp;4.2,&nbsp;4.3, and&nbsp;4.4).</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><i><span lang=BG>Age/Gender:</span></i><span lang=BG> a
study of the pharmacokinetics of atazanavir was performed in 59&nbsp;healthy
male and female subjects (29&nbsp;young, 30&nbsp;elderly). There were no
clinically important pharmacokinetic differences based on age or gender.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Race:</span></i><span lang=BG> a
population pharmacokinetic analysis of samples from Phase II clinical trials
indicated no effect of race on the pharmacokinetics of atazanavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Pregnancy:</span></i></p>

<p class=EMEABodyText><span lang=BG>The pharmacokinetic data from HIV-infected
pregnant women receiving REYATAZ capsules with ritonavir are presented in
Table&nbsp;8.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steady-State
Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in
the Fed State</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=595
 style='width:446.55pt;margin-left:5.4pt;border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid;height:20.75pt'>
   <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
   height:20.75pt'>
   <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
   </td>
   <td width=403 colspan=3 style='width:302.55pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:20.75pt'>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=BG>atazanavir 300&nbsp;mg with ritonavir 100&nbsp;mg</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:27.75pt'>
   <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
   none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Pharmacokinetic
   Parameter</span></b></p>
   </td>
   <td width=134 style='width:100.85pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=BG>2nd Trimester</span></b></p>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><span lang=BG>(n=9)</span></p>
   </td>
   <td width=134 style='width:100.85pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=BG>3rd Trimester</span></b></p>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><span lang=BG>(n=20)</span></p>
   </td>
   <td width=134 style='width:100.85pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=BG>postpartum<sup>a</sup></span></b></p>
   <p class=EMEABodyText align=center style='text-align:center;page-break-after:
   avoid'><span lang=BG>(n=36)</span></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>C<sub>max</sub>
  ng/mL</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geometric
  mean (CV%)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>3729.09</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(39)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>3291.46</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(48)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>5649.10</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(31)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>AUC
  ng&#8226;h/mL</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geometric
  mean (CV%)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>34399.1</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(37)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>34251.5</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(43)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>60532.7</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(33)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>C<sub>min</sub>
  ng/mL</span><sup><span lang=BG style='font-size:14.0pt'>b</span></sup></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geometric
  mean (CV%)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>663.78</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(36)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>668.48</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(50)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>1420.64</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(47)</span></p>
  </td>
 </tr>
 <tr>
  <td width=595 colspan=4 valign=top style='width:446.55pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a </span></sup><span
  lang=BG style='font-size:9.0pt'>Atazanavir peak concentrations and AUCs were
  found to be approximately 26-40% higher during the postpartum period
  (4-12&nbsp;weeks) than those observed historically in HIV infected,
  non-pregnant patients. Atazanavir plasma trough concentrations were
  approximately 2-fold higher during the postpartum period when compared to
  those observed historically in HIV infected non-pregnant patients.</span></p>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b </span></sup><span
  lang=BG style='font-size:9.0pt'>C<sub>min</sub> is concentration
  24&nbsp;hours post-dose.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=BG>There is a trend toward a higher clearance
in younger children when normalised for body weight. As a result, greater peak
to trough ratios are observed, however at recommended doses, geometric mean
atazanavir exposures (C<sub>min</sub>, C<sub>max</sub> and AUC) in paediatric
patients are expected to be similar to those observed in adults. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In repeat-dose toxicity studies, conducted
in mice, rats, and dogs, atazanavir-related findings were generally confined to
the liver and included generally minimal to mild increases in serum bilirubin
and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female
mice only, hepatic single-cell necrosis. Systemic exposures of atazanavir in
mice (males), rats, and dogs at doses associated with hepatic changes were at
least equal to that observed in humans given 400&nbsp;mg once daily. In female
mice, atazanavir exposure at a dose that produced single-cell necrosis was
12&nbsp;times the exposure in humans given 400&nbsp;mg once daily. Serum
cholesterol and glucose were minimally to mildly increased in rats but not in
mice or dogs.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During <i>in vitro</i> studies, cloned
human cardiac potassium channel (hERG), was inhibited by 15% at a concentration
(30&nbsp;&#956;M) of atazanavir corresponding to 30&nbsp;fold the free drug
concentration at C<sub>max</sub> in humans. Similar concentrations of
atazanavir increased by 13% the action potential duration (APD<sub>90</sub>) in
rabbit Purkinje fibres study. Electrocardiographic changes (sinus bradycardia,
prolongation of PR interval, prolongation of QT interval, and prolongation of
QRS complex) were observed only in an initial 2&nbsp;week oral toxicity study
performed in dogs. Subsequent 9&nbsp;month oral toxicity studies in dogs showed
no drug-related electrocardiographic changes. The clinical relevance of these
non-clinical data is unknown. Potential cardiac effects of this product in
humans cannot be ruled out (see&nbsp;sections&nbsp;4.4 and&nbsp;4.8). The
potential for PR prolongation should be considered in cases of overdose
(see&nbsp;section&nbsp;4.9).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In a fertility and early embryonic
development study in rats, atazanavir altered oestrus cycling with no effects
on mating or fertility. No teratogenic effects were observed in rats or rabbits
at maternally toxic doses. In pregnant rabbits, gross lesions of the stomach
and intestines were observed in dead or moribund does at maternal doses 2 and
4&nbsp;times the highest dose administered in the definitive embryo-development
study. In the pre- and postnatal development assessment in rats, atazanavir
produced a transient reduction in body weight in the offspring at a maternally
toxic dose. Systemic exposure to atazanavir at doses that resulted in maternal
toxicity was at least equal to or slightly greater than that observed in humans
given 400&nbsp;mg once daily.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir was negative in an Ames
reverse-mutation assay but did induce chromosomal aberrations <i>in vitro</i>
in both the absence and presence of metabolic activation. In <i>in vivo</i>
studies in rats, atazanavir did not induce micronuclei in bone marrow, DNA
damage in duodenum (comet assay), or unscheduled DNA repair in liver at plasma
and tissue concentrations exceeding those that were clastogenic <i>in vitro</i>.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In long-term carcinogenicity studies of
atazanavir in mice and rats, an increased incidence of benign hepatic adenomas
was seen in female mice only. The increased incidence of benign hepatic
adenomas in female mice was likely secondary to cytotoxic liver changes
manifested by single-cell necrosis and is considered to have no relevance for
humans at intended therapeutic exposures. There were no tumorigenic findings in
male mice or in rats.</span></p>

<p class=EMEABodyText style='text-align:justify'>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir increased opacity of bovine
corneas in an <i>in vitro</i> ocular irritation study, indicating it may be an
ocular irritant upon direct contact with the eye.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of
excipients</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
contents: crospovidone, lactose monohydrate and magnesium stearate</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
shells: gelatine, indigocarmin (E132) and titanium dioxide (E171)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Blue ink containing: shellac, propylene
glycol, ammonium hydroxide and indigocarmin (E132)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>White ink containing: shellac, titanium
dioxide (E171), ammonium hydroxide, propylene glycol and simethicone</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
contents: crospovidone, lactose monohydrate and magnesium stearate</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
shells: gelatine, indigocarmin (E132) and titanium dioxide (E171)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Blue ink containing: shellac, propylene
glycol, ammonium hydroxide and indigocarmin (E132)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>White ink containing: shellac, titanium
dioxide (E171), ammonium hydroxide, propylene glycol and simethicone</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
contents: crospovidone, lactose monohydrate and magnesium stearate</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
shells: gelatine, indigocarmin (E132) and titanium dioxide (E171)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>White ink containing: shellac, titanium
dioxide (E171), ammonium hydroxide, propylene glycol and simethicone</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
contents: crospovidone, lactose monohydrate and magnesium stearate</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Capsule
shells: gelatine, red iron oxide, black iron oxide, yellow iron oxide,
indigocarmin (E132) and titanium dioxide (E171)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>White ink containing: shellac, titanium
dioxide (E171), ammonium hydroxide, propylene glycol and simethicone</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not applicable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>2&nbsp;years</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and
contents of container</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each carton contains one high-density
polyethylene (HDPE) bottle closed with child-resistant polypropylene closure.
Each bottle contains 60&nbsp;hard capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each carton contains 60&nbsp;x 1 capsules;
10&nbsp;blister cards of 6 x 1 capsules each in Alu/Alu perforated unit dose blisters.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each carton contains one high-density
polyethylene (HDPE) bottle closed with child-resistant polypropylene closure.
Each bottle contains 60&nbsp;hard capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each carton contains 60&nbsp;x 1 capsules;
10&nbsp;blister cards of 6 x 1 capsules each in Alu/Alu perforated unit dose
blisters.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each carton contains one high-density
polyethylene (HDPE) bottle or three high-density polyethylene (HDPE) bottles
closed with child-resistant polypropylene closure. Each bottle contains
60&nbsp;hard capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each carton contains 60&nbsp;x 1 capsules;
10&nbsp;blister cards of 6 x 1 capsules each in Alu/Alu perforated unit dose
blisters.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></u></p>

<p class=EMEABodyText><span lang=BG>Each carton contains one high-density
polyethylene (HDPE) bottle or three high-density polyethylene (HDPE) bottles
closed with child-resistant polypropylene closure. Each bottle contains
30&nbsp;hard capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each carton contains 30&nbsp;x 1 capsules;
5&nbsp;blister cards of 6 x 1 capsules each in Alu/Alu perforated unit dose
blisters.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EU/1/03/267/001-006; 008-011</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Date of first authorisation: 02 March 2004<br>
Date of latest renewal: 02 March 2009</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
REVISION OF THE TEXT</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>{MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;50&nbsp;mg oral powder</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each sachet of 1.5&nbsp;g oral powder
contains 50&nbsp;mg of atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipient with known effect: 63&nbsp;mg of
aspartame; 1305.15&nbsp;mg of sucrose per sachet (1.5&nbsp;g oral powder).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For the full list of excipients,
see&nbsp;section&nbsp;6.1.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
form</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Oral powder</span></p>

<p class=EMEABodyText><span lang=BG>Off white to pale yellow powder.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ oral powder, co-administered with
low dose ritonavir, is indicated in combination with other antiretroviral
medicinal products for the treatment of HIV-1&nbsp;infected paediatric patients
at least 3&nbsp;months of age and weighing at least 5&nbsp;kg (see
section&nbsp;4.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Based on available virological and clinical
data from adult patients, no benefit is expected in patients with strains
resistant to multiple protease inhibitors (&#8805;&nbsp;4&nbsp;PI mutations).
The choice of REYATAZ in treatment experienced adult and paediatric patients
should be based on individual viral resistance testing and the patient&#8217;s
treatment history (see&nbsp;sections&nbsp;4.4 and&nbsp;5.1).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and
method of administration</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Therapy should be initiated by a physician
experienced in the management of HIV infection.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Posology</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric patients (at least
3&nbsp;months of age and weighing at least 5&nbsp;kg)</span></i></p>

<p class=EMEABodyText><span lang=BG>The doses of atazanavir oral powder and
ritonavir for paediatric patients are based on body weight as shown in
Table&nbsp;1. REYATAZ oral powder must be taken with ritonavir and has to be
taken with food.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Table&nbsp;1: Dose of REYATAZ oral powder
  with ritonavir for paediatric patients<sup>a</sup> (at least 3&nbsp;months of
  age and weighing at least 5&nbsp;kg) </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 style='width:2.15in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Body weight (kg)</span></b></p>
  </td>
  <td width=206 style='width:2.15in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>REYATAZ once daily dose </span></b></p>
  </td>
  <td width=206 style='width:154.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>ritonavir once daily dose</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>at least 5 to less than 15</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>200&nbsp;mg (4&nbsp;sachets<sup>b</sup>)</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>80&nbsp;mg<sup>c</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>at least 15 to less than 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>250&nbsp;mg (5&nbsp;sachets<sup>b</sup>)</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>80&nbsp;mg<sup>c</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>at least 35 </span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>300&nbsp;mg (6&nbsp;sachets<sup>b</sup>)</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>100&nbsp;mg<sup>d</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
  lang=BG style='font-size:9.0pt'> The same recommendations regarding the
  timing and maximum doses of concomitant proton pump inhibitors and H<sub>2</sub>-receptor
  antagonists in adults also apply to paediatric patients (see section&nbsp;4.5).</span></p>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
  lang=BG style='font-size:9.0pt'> Each sachet contains 50&nbsp;mg of
  atazanavir.</span><span lang=BG style='font-size:10.0pt'> </span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>c</span></sup><span
lang=BG style='font-size:9.0pt'> Ritonavir oral solution.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>d </span></sup><span
lang=BG style='font-size:9.0pt'>Ritonavir oral solution or capsule/tablet.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ capsules are available for
paediatric patients at least 6&nbsp;years of age who weigh at least 15&nbsp;kg
and who are able to swallow capsules (see Summary of Product Characteristics
for REYATAZ capsules). Switching from REYATAZ oral powder to REYATAZ capsules
is encouraged as soon as patients are able to consistently swallow capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>When transitioning between formulations, a
change in dose may be needed. Consult the dosing table for the specific
formulation (see Summary of Product Characteristics for REYATAZ capsules).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Special populations</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=BG>No dosage adjustment is needed. REYATAZ
with ritonavir is not recommended in patients undergoing haemodialysis
(see&nbsp;sections&nbsp;4.4 and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=BG>REYATAZ with ritonavir has not been studied
in patients with hepatic impairment. REYATAZ with ritonavir should be used with
caution in patients with mild hepatic impairment. REYATAZ must not be used in
patients with moderate to severe hepatic impairment
(see&nbsp;sections&nbsp;4.3,&nbsp;4.4, and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Pregnancy and Postpartum</span></i></p>

<p class=EMEABodyText><span lang=BG>During the second and third trimesters of
pregnancy:</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ 300&nbsp;mg with ritonavir
100&nbsp;mg may not provide sufficient exposure to atazanavir, especially when
the activity of atazanavir or the whole regimen may be compromised due to drug
resistance. Since there are limited data available and due to inter-patient
variability during pregnancy, Therapeutic Drug Monitoring (TDM) may be
considered to ensure adequate exposure.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The risk of a further decrease in
atazanavir exposure is expected when atazanavir is given with medicinal
products known to reduce its exposure (e.g., tenofovir disoproxil or H<sub>2</sub>-receptor
antagonists).</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>If tenofovir disoproxil or an H<sub>2</sub>-receptor
antagonist is needed, a dose increase to REYATAZ 400&nbsp;mg with ritonavir
100&nbsp;mg with TDM may be considered (see sections&nbsp;4.6 and&nbsp;5.2).</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>It is not recommended to use REYATAZ with ritonavir
for pregnant patients who are receiving both tenofovir disoproxil and an H<sub>2</sub>-receptor
antagonist.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During postpartum:</span></p>

<p class=EMEABodyText><span lang=BG>Following a possible decrease in atazanavir
exposure during the second and third trimester, atazanavir exposures might
increase during the first two months after delivery (see section&nbsp;5.2).
Therefore, postpartum patients should be closely monitored for adverse
reactions.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>During this time, postpartum patients should follow
the same dose recommendation as for non-pregnant patients, including those for
co-administration of medicinal products known to affect atazanavir exposure
(see section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Paediatric patients (less than
3&nbsp;months of age)</span></i></p>

<p class=EMEABodyText><span lang=BG>REYATAZ has not been studied in children
less than 3&nbsp;months of age and is not recommended because of the potential
risk of kernicterus.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>Method of administration</span></u></p>

<p class=EMEABodyText><span lang=BG>For oral use. </span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ oral powder should be taken/given
with food (e.g. applesauce or yogurt) or drinks (e.g. milk, infant formula or
water) for infants who can drink from a cup. For young infants (less than
6&nbsp;months) who cannot eat solid food or drink from a cup, REYATAZ oral
powder should be mixed with infant formula and given using an oral syringe,
which can be obtained from a pharmacist. Administration of REYATAZ and infant
formula using an infant bottle is not recommended because the full dose may not
be delivered.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For details on preparation and
administration of the REYATAZ oral powder and Instructions for Use, see
section&nbsp;6.6.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hypersensitivity to the active substance or
to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Patients with moderate to severe hepatic
insufficiency (see&nbsp;sections&nbsp;4.2 and&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with simvastatin or
lovastatin (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Combination of rifampicin with concomitant
low-dose ritonavir (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of the PDE5 inhibitor
sildenafil when used for the treatment of pulmonary arterial hypertension (PAH)
only (see section&nbsp;4.5). For co-administration of sildenafil for the
treatment of erectile dysfunction see sections&nbsp;4.4 and 4.5.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with medicinal products
that are substrates of the&nbsp;CYP3A4 isoform of cytochrome P450 and have
narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole,
terfenadine, cisapride, pimozide, quinidine, lurasidone, bepridil, triazolam,
midazolam administered orally (for caution on parenterally administered
midazolam, see&nbsp;section&nbsp;4.5), and ergot alkaloids, particularly,
ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>Co-administration with
grazoprevir-containing products, including elbasvir/grazoprevir fixed dose
combination (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with
glecaprevir/pibrentasvir fixed dose combination (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration with products containing
St.&nbsp;John&#8217;s&nbsp;wort (<i>Hypericum perforatum</i>)
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>While effective viral suppression with
antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with ritonavir
at doses greater than 100&nbsp;mg once daily has not been clinically evaluated.
The use of higher ritonavir doses may alter the safety profile of atazanavir
(cardiac effects, hyperbilirubinaemia) and therefore is not recommended. Only
when atazanavir with ritonavir is co-administered with efavirenz, a dose
increase of ritonavir to 200&nbsp;mg once daily could be considered. In this
instance, close clinical monitoring is warranted (see Interaction with other
Medicinal Products below).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Patients
with coexisting conditions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=BG>Atazanavir is primarily hepatically metabolised
and increased plasma concentrations were observed in patients with hepatic
impairment (see&nbsp;sections&nbsp;4.2 and&nbsp;4.3). The safety and efficacy
of REYATAZ has not been established in patients with significant underlying
liver disorders. Patients with chronic hepatitis B or C and treated with
combination antiretroviral therapy are at an increased risk for severe and
potentially fatal hepatic adverse reactions. In case of concomitant antiviral
therapy for hepatitis B or C, please refer also to the relevant Summary of
Product Characteristics for these medicinal products
(see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Patients with pre-existing liver
dysfunction, including chronic active hepatitis, have an increased frequency of
liver function abnormalities during combination antiretroviral therapy and
should be monitored according to standard practice. If there is evidence of
worsening liver disease in such patients, interruption or discontinuation of
treatment must be considered.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Renal impairment </span></i></p>

<p class=EMEABodyText><span lang=BG>No dosage adjustment is needed in patients
with renal impairment. However, REYATAZ with ritonavir is not recommended in
patients undergoing haemodialysis (see&nbsp;sections&nbsp;4.2 and&nbsp;5.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>QT prolongation</span></i></p>

<p class=EMEABodyText><span lang=BG>Dose related asymptomatic prolongations in
PR interval with REYATAZ have been observed in clinical studies. Caution should
be used with medicinal products known to induce PR prolongations. In patients
with pre-existing conduction problems (second degree or higher atrioventricular
or complex bundle-branch block), REYATAZ should be used with caution and only
if the benefits exceed the risk (see&nbsp;section&nbsp;5.1). Particular caution
should be used when prescribing REYATAZ in association with medicinal products
which have the potential to increase the QT interval and/or in patients with
pre-existing risk factors (bradycardia, long congenital QT, electrolyte
imbalances (see&nbsp;sections&nbsp;4.8 and&nbsp;5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Haemophiliac patients</span></i></p>

<p class=EMEABodyText><span lang=BG>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthroses, in
type&nbsp;A and B haemophiliac patients treated with protease inhibitors. In
some patients additional factor&nbsp;VIII was given. In more than half of the
reported cases, treatment with protease inhibitors was continued or
reintroduced if treatment had been discontinued. A causal relationship has been
suggested, although the mechanism of action has not been elucidated.
Haemophiliac patients should therefore be made aware of the possibility of
increased bleeding.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Weight
and metabolic parameters</span></u></p>

<p class=EMEABodyText><span lang=BG>An increase in weight and in levels of blood
lipids and glucose may occur during antiretroviral therapy. Such changes may in
part be linked to the disease control and life style. For lipids, there is in
some cases evidence for a treatment effect, while for weight gain there is no
strong evidence relating this to any particular treatment. For monitoring of
blood lipids and glucose reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In clinical studies, REYATAZ (with or
without ritonavir) has been shown to induce dyslipidaemia to a lesser extent
than comparators. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Hyperbilirubinaemia</span></u></p>

<p class=EMEABodyText><span lang=BG>Reversible elevations in indirect
(unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase
(UGT) have occurred in patients receiving REYATAZ (see&nbsp;section&nbsp;4.8).
Hepatic transaminase elevations that occur with elevated bilirubin in patients
receiving REYATAZ should be evaluated for alternative aetiologies. Alternative
antiretroviral therapy to REYATAZ may be considered if jaundice or scleral
icterus is unacceptable to a patient. Dose reduction of atazanavir is not
recommended because it may result in a loss of therapeutic effect and
development of resistance.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Indinavir is also associated with indirect
(unconjugated) hyperbilirubinaemia due to inhibition of UGT. Combinations of
REYATAZ and indinavir have not been studied and co-administration of these
medicinal products is not recommended (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Cholelithiasis</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Cholelithiasis
has been reported in patients receiving REYATAZ (see&nbsp;section&nbsp;4.8).
Some patients required hospitalization for additional management and some had
complications. If signs or symptoms of cholelithiasis occur, temporary
interruption or discontinuation of treatment may be considered.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>Chronic kidney disease</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Chronic
kidney disease in HIV-infected patients treated with atazanavir, with or
without ritonavir, has been reported during postmarketing surveillance. A large
prospective observational study has shown an association between an increased
incidence of chronic kidney disease and cumulative exposure to&nbsp;
atazanavir/ritonavir-containing regimen in HIV-infected patients with an
initially normal eGFR. This association was observed independently of exposure
to tenofovir disoproxil. Regular monitoring of the renal function of patients
should be maintained throughout the treatment duration
(see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Nephrolithiasis</span></u></p>

<p class=EMEABodyText><span lang=BG>Nephrolithiasis has been reported in
patients receiving REYATAZ (see&nbsp;section&nbsp;4.8). Some patients required
hospitalization for additional management and some had complications. In some
cases, nephrolithiasis has been associated with acute renal failure or renal
insufficiency. If signs or symptoms of nephrolithiasis occur, temporary
interruption or discontinuation of treatment may be considered. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Immune
reactivation syndrome</span></u></p>

<p class=EMEABodyText><span lang=BG>In HIV-infected patients with severe immune
deficiency at the time of institution of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
pathogens may arise and cause serious clinical conditions, or aggravation of
symptoms. Typically, such reactions have been observed within the first few
weeks or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections, and <i>Pneumocystis
jirovecii </i>pneumonia. Any inflammatory symptoms should be evaluated and
treatment instituted when necessary. Autoimmune disorders (such as Graves'
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and these events can occurs many months after initiation of treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2 style='margin-left:0in;text-indent:0in'><u><span lang=BG
style='font-weight:normal'>Osteonecrosis</span></u></p>

<p class=EMEABodyText><span lang=BG>Although the aetiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV-disease and/or long-term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Rash and associated syndromes</span></u></p>

<p class=EMEABodyText><span lang=BG>Rashes are usually mild -to-moderate
maculopapular skin eruptions that occur within the first 3 weeks of starting
therapy with REYATAZ. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Stevens-Johnson syndrome (SJS), erythema
multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic
symptoms (DRESS) syndrome have been reported in patients receiving REYATAZ.
Patients should be advised of the signs and symptoms and monitored closely for
skin reactions. REYATAZ should be discontinued if severe rash develops.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The best results in managing these events
come from early diagnosis and immediate interruption of any suspect medicines.
If the patient has developed SJS or DRESS associated with the use of REYATAZ,
REYATAZ may not be restarted.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Interactions
with other medicinal products</span></u></p>

<p class=EMEABodyText><span lang=BG>The combination of REYATAZ with
atorvastatin is not recommended (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
nevirapine or efavirenz is not recommended (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=BG>If the co-administration of REYATAZ with an
NNRTI is required, an increase in the dose of both REYATAZ and ritonavir to
400&nbsp;mg and 200&nbsp;mg, respectively, in combination with efavirenz could
be considered with close clinical monitoring.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir is metabolised principally by
CYP3A4. Co-administration of REYATAZ with ritonavir and medicinal products that
induce CYP3A4 is not recommended (see&nbsp;sections&nbsp;4.3 and&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>PDE5 inhibitors used for the treatment of
erectile dysfunction: particular caution should be used when prescribing
PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of
erectile dysfunction in patients receiving REYATAZ with concomitant low-dose
ritonavir. Co-administration of REYATAZ with these medicinal products is
expected to substantially increase their concentrations and may result in
PDE5-associated adverse reactions such as hypotension, visual changes and
priapism (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of voriconazole and
REYATAZ with ritonavir is not recommended, unless an assessment of the
benefit/risk justifies the use of voriconazole.</span></p>

<p class=EMEABodyText><span style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>In the majority of patients, a reduction in
both voriconazole and atazanavir exposures are expected. In a small number of
patients without a functional CYP2C19 allele, significantly increased
voriconazole exposures are expected (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Concomitant use of REYATAZ/ritonavir and
fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not
recommended unless the potential benefit of treatment outweighs the risk of
systemic corticosteroid effects, including Cushing's syndrome and adrenal
suppression (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Concomitant use of salmeterol and
REYATAZ/ritonavir may result in increased cardiovascular adverse events
associated with salmeterol. Co-administration of salmeterol and REYATAZ is not
recommended (see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The absorption of atazanavir may be reduced
in situations where gastric pH is increased irrespective of cause.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with proton
pump inhibitors is not recommended (see&nbsp;section&nbsp;4.5). If the
combination of REYATAZ with a proton pump inhibitor is judged unavoidable,
close clinical monitoring is recommended in combination with an increase in the
dose of REYATAZ to 400&nbsp;mg with 100&nbsp;mg of ritonavir; doses of proton
pump inhibitors comparable to omeprazole 20&nbsp;mg should not be exceeded.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ/ritonavir with
other hormonal contraceptives or oral contraceptives containing progestogens
other than norgestimate has not been studied, and therefore should be avoided
(see&nbsp;section&nbsp;4.5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Paediatric population</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Safety</span></i></p>

<p class=EMEABodyText><span lang=BG>Asymptomatic PR interval prolongation was
more frequent in paediatric patients than adults. Asymptomatic first- and
second-degree AV block was reported in paediatric patients
(see&nbsp;section&nbsp;4.8). Caution should be used with medicinal products
known to induce PR prolongations. In paediatric patients with pre-existing
conduction problems (second degree or higher atrioventricular or complex
bundle-branch block), REYATAZ should be used with caution and only if the
benefits exceed the risk. Cardiac monitoring is recommended based on the
presence of clinical findings (e.g., bradycardia).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Efficacy</span></i></p>

<p class=EMEABodyText><span lang=BG>Atazanavir/ritonavir is not effective in
viral strains harbouring multiple mutations of resistance. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Excipients</span></u></p>

<p class=EMEABodyText><i><span lang=BG>Phenylketonuria</span></i></p>

<p class=EMEABodyText><span lang=BG>REYATAZ oral powder contains aspartame as a
sweetening agent. Aspartame provides a source of phenylalanine and, therefore,
may not be suitable for persons with phenylketonuria.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Diabetic population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span class=EMEABodyTextChar><span
lang=BG>REYATAZ oral powder contains 1305.15&nbsp;mg of sucrose per sachet. For
the recommended paediatric dosage, REYATAZ oral powder contains 3915.45&nbsp;mg
sucrose per 150&nbsp;mg atazanavir, 5220.60&nbsp;mg sucrose per 200&nbsp;mg
atazanavir, 6525.75&nbsp;mg sucrose per 250&nbsp;mg atazanavir, and 7830.90&nbsp;mg
sucrose per 300&nbsp;mg atazanavir. This should be taken into account in
patients with diabetes mellitus. Patients with rare hereditary problems of
fructose intolerance, glucose galactose malabsorption or sucrase isomaltase
insufficiency should not take this medicine.</span></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>When REYATAZ and ritonavir are
co-administered, the metabolic drug interaction profile for ritonavir may
predominate because ritonavir is a more potent CYP3A4 inhibitor than
atazanavir. The Summary of Product Characteristics for ritonavir must be
consulted before initiation of therapy with REYATAZ and ritonavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir is metabolised in the liver
through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ with ritonavir is
contraindicated with medicinal products that are substrates of CYP3A4 and have
a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole,
terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally
administered midazolam, and ergot alkaloids, particularly ergotamine and
dihydroergotamine (see&nbsp;section&nbsp;4.3). Co-administration of REYATAZ
with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose
combination is contraindicated because of the increase in grazoprevir and
elbasvir plasma concentrations and potential for the increase in risk of ALT
elevations associated with increased grazoprevir concentrations
(see&nbsp;section&nbsp;4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed dose combination is contraindicated because of
the potential increase in the risk of ALT elevations due to a significant
increase in glecapreir and pibrentasvir plasma concentrations
(see&nbsp;section&nbsp;4.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><i><span lang=BG style='font-weight:normal'>Other
interactions</span></i></p>

<p class=EMEABodyText><span lang=BG>Interactions between atazanavir/ritonavir
and protease inhibitors, antiretroviral agents other than protease inhibitors,
and other non-antiretroviral medicinal products are listed in the table below
(increase is indicated as &#8220;&#8593;&#8221;, decrease as
&#8220;&#8595;&#8221;, no change as &#8220;&#8596;&#8221;). If available, 90%
confidence intervals (CI) are shown in parentheses. The studies presented in
Table&nbsp;2 were conducted in healthy subjects unless otherwise noted. Of
importance, many studies were conducted with unboosted atazanavir, which is not
the approved regimen of atazanavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Table&nbsp;2: Interactions between REYATAZ
and other medicinal products</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=659
 style='width:494.5pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:36.7pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.7pt'>
  <p class=EMEABodyText><b><span lang=BG>Medicinal products by therapeutic area</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:36.7pt'>
  <p class=EMEABodyText><b><span lang=BG>Interaction</span></b></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:36.7pt'>
  <p class=EMEABodyText><b><span lang=BG>Recommendations concerning
  co-administration</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.55pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTI-HCV AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:192.25pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:192.25pt'>
  <p class=EMEABodyText><b><span lang=BG>Grazoprevir 200 mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:192.25pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;43% (&#8593;30%
  &#8593;57%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;12% (&#8593;1% &#8593;24%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;23% (&#8593;13% &#8593;134%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir AUC: &#8593;958% (&#8593;678%
  &#8593;1339%)</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>: &#8593;524% (&#8593;342% &#8593;781%)</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;1064% (&#8593;696% &#8593;1602%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Grazoprevir concentrations were greatly
  increased when co&#8209;administered with atazanavir/ritonavir.</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:192.25pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ and
  elbasvir/grazoprevir is contraindicated because of a significant increase in
  grazoprevir plasma concentrations and an associated potential increase in the
  risk of ALT elevations (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:155.5pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><b><span lang=BG>Elbasvir 50 mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;7% (&#8595;2%
  &#8593;17%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;2% (&#8595;4% &#8593;8%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;15% (&#8593;2% &#8593;29%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Elbasvir AUC: &#8593;376% (&#8593;307%
  &#8593;456%)</span></p>
  <p class=EMEABodyText><span lang=BG>Elbasvir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>: &#8593;315% (&#8593;246% &#8593;397%)</span></p>
  <p class=EMEABodyText><span lang=BG>Elbasvir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;545% (&#8593;451% &#8593;654%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Elbasvir concentrations were increased
  when co&#8209;administered with atazanavir/ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:155.5pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><b><span lang=BG>Sofosbuvir 400&nbsp;mg / velpatasvir
  100&nbsp;mg / voxilaprevir 100&nbsp;mg single dose</span></b><span lang=BG>*</span></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><span lang=BG>Sofosbuvir AUC&nbsp;: &#8593;40%
  (&#8593;25% &#8593;57%)</span></p>
  <p class=EMEABodyText><span lang=BG>Sofosbuvir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>:&#8593;29% (&#8593;9% &#8593;52%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Velpatasvir AUC: &#8593;93% (&#8593;58%
  &#8593;136%)</span></p>
  <p class=EMEABodyText><span lang=BG>Velpatasvir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>: &#8593;29% (&#8593;7% &#8593;56%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Voxilaprevir AUC</span><sub><span
  lang=BG>&nbsp;</span></sub><span lang=BG>: &#8593;331% (&#8593;276%
  &#8593;393%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voxilaprevir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>: &#8593;342% (&#8593;265% &#8593;435%)</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  <p class=MsoNormal><span lang=BG>*Lack of pharmacokinetics interaction bounds
  70-143%</span></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>Effect on
  atazanavir and ritonavir exposure has not been studied.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>Expected:</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#8596;
  Atazanavir </span></p>
  <p class=EMEABodyText><span lang=BG>&#8596; Ritonavir </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>The mechanism of
  interaction between REYATAZ/ritonavir and sofosbuvir/velpatasvir/voxilaprevir
  is inhibition of OATP1B, Pgp, and CYP3A.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with
  voxilaprevir-containing products is expected to increase the concentration of
  voxilaprevir. Co-administration of REYATAZ with voxilaprevir-containing
  regimens is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:155.5pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><b><span lang=BG>Glecaprevir 300&nbsp;mg / pibrentasvir
  120&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg / ritonavir
  100&nbsp;mg once daily*)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><span lang=BG>Glecaprevir AUC&nbsp;: &#8593;553%
  (&#8593;424% &#8593;714%)</span></p>
  <p class=EMEABodyText><span lang=BG>Glecaprevir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>&nbsp;: &#8593;306% (&#8593;215% &#8593;423%)</span></p>
  <p class=EMEABodyText><span lang=BG>Glecaprevir C</span><sub><span lang=BG>min
  </span></sub><span lang=BG>: &#8593;1330% (&#8593;885% &#8593;1970%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Pibrentasvir AUC&nbsp;: &#8593;64%
  (&#8593;48% &#8593;82%)</span></p>
  <p class=EMEABodyText><span lang=BG>Pibrentasvir C</span><sub><span lang=BG>max&nbsp;</span></sub><span
  lang=BG>: &#8593;29% (&#8593;15% &#8593;45%)</span></p>
  <p class=EMEABodyText><span lang=BG>Pibrentasvir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;129% (&#8593;95% &#8593;168%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>* Effect of atazanavir and ritonavir on
  the first dose of glecaprevir and pibrentasvir is reported.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:155.5pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ with glecaprevir/pibrentasvir
  is contraindicated because of the potential increase in the risk of ALT
  elevations due to a significant increase in glecaprevir and pibrentasvir
  plasma concentrations (see&nbsp;section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTI-RETROVIRALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Protease inhibitors:</span></i><b><span
  lang=BG> </span></b><span lang=BG>The co-administration of REYATAZ/ritonavir
  and other protease inhibitors has not been studied but would be expected to
  increase exposure to other protease inhibitors. Therefore, such
  co-administration is not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Ritonavir 100&nbsp;mg once daily</span></b></p>
  <p class=MsoNormal><span lang=BG>(atazanavir 300&nbsp;mg once daily)</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>Studies conducted in HIV-infected patients.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC: &#8593;250% (&#8593;144%
  &#8593;403%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>: &#8593;120% (&#8593;56% &#8593;211%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>: &#8593;713% (&#8593;359% &#8593;1339%)*</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>* In a combined analysis, atazanavir
  300&nbsp;mg and ritonavir 100&nbsp;mg (n=33) was compared to atazanavir
  400&nbsp;mg without ritonavir (n=28).</span></p>
  <p class=EMEABodyText><span lang=BG>The mechanism of interaction between
  atazanavir and ritonavir is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Ritonavir 100&nbsp;mg once daily is used
  as a booster of atazanavir pharmacokinetics.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Indinavir</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Indinavir is associated with indirect
  unconjugated hyperbilirubinaemia due to inhibition of UGT.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ/ritonavir
  and indinavir is not recommended (see&nbsp;section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Nucleoside/nucleotide reverse
  transcriptase inhibitors (NRTIs)</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Lamivudine 150&nbsp;mg twice daily +
  zidovudine 300&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No significant effect on lamivudine and
  zidovudine concentrations was observed.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Based on these data and because ritonavir
  is not expected to have a significant impact on the pharmacokinetics of
  NRTIs, the co-administration of REYATAZ/ritonavir with these medicinal
  products is not expected to significantly alter the exposure of the
  co-administered medicinal products.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Abacavir</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>The co-administration of REYATAZ/
  ritonavir with abacavir is not expected to significantly alter the exposure
  of abacavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Didanosine (buffered tablets)
  200&nbsp;mg/stavudine 40&nbsp;mg, both single dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg single dose)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir, simultaneous administration
  with ddI+d4T (fasted)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;87% (&#8595;92%
  &#8595;79%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;89% (&#8595;94% &#8595;82%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;84% (&#8595;90% &#8595;73%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir, dosed 1&nbsp;hr after ddI+d4T
  (fasted)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;3% (&#8595;36%
  &#8593;67%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;12% (&#8595;33% &#8593;18%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8596;3% (&#8595;39% &#8593;73%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir concentrations were greatly
  decreased when co-administered with didanosine (buffered tablets) and
  stavudine. The mechanism of interaction is a reduced solubility of atazanavir
  with increasing pH related to the presence of anti-acid agent in didanosine
  buffered tablets.</span></p>
  <p class=EMEABodyText><span lang=BG>No significant effect on didanosine and
  stavudine concentrations was observed.</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Didanosine should be taken at the fasted
  state 2&nbsp;hours after REYATAZ/ritonavir taken with food. The
  co-administration of REYATAZ/ritonavir with stavudine is not expected to
  significantly alter the exposure of stavudine.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Didanosine (enteric coated capsules)
  400&nbsp;mg single dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Didanosine (with food)</span></p>
  <p class=EMEABodyText><span lang=BG>Didanosine AUC &#8595;34% (&#8595;41%
  &#8595;27%)</span></p>
  <p class=EMEABodyText><span lang=BG>Didanosine C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;38% (&#8595;48% &#8595;26%)</span></p>
  <p class=EMEABodyText><span lang=BG>Didanosine C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;25% (&#8595;8% &#8593;69%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>No significant effect on atazanavir
  concentrations was observed when administered with enteric-coated didanosine,
  but administration with food decreased didanosine concentrations.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Tenofovir disoproxil fumarate
  300&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>300 mg tenofovir disoproxil fumarate is
  equivalent to <br>
  245 mg tenofovir disoproxil.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Studies conducted in HIV-infected
  patients</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;22% (&#8595;35%
  &#8595;6%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;16% (&#8595;30% &#8596;0%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;23% (&#8595;43% &#8593;2%) *</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>* In a combined analysis from several
  clinical studies, atazanavir/ritonavir 300/100&nbsp;mg co-administered with
  tenofovir disoproxil fumarate 300&nbsp;mg (n=39) was compared to
  atazanavir/ritonavir 300/100&nbsp;mg (n=33).</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>The efficacy of REYATAZ/ritonavir in
  combination with tenofovir disoproxil fumarate in treatment-experienced
  patients has been demonstrated in clinical study&nbsp;045 and in treatment
  naive patients in clinical study&nbsp;138 (see sections&nbsp;4.8
  and&nbsp;5.1). The mechanism of interaction between atazanavir and tenofovir
  disoproxil fumarate is unknown.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Tenofovir disoproxil fumarate
  300&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>300 mg tenofovir disoproxil fumarate is
  equivalent to <br>
  245 mg tenofovir disoproxil.</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Tenofovir disoproxil fumarate AUC
  &#8593;37% (&#8593;30% &#8593;45%)</span></p>
  <p class=EMEABodyText><span lang=BG>Tenofovir disoproxil fumarate C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;34% (&#8593;20% &#8593;51%)</span></p>
  <p class=EMEABodyText><span lang=BG>Tenofovir disoproxil fumarate C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;29% (&#8593;21% &#8593;36%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Patients should be closely monitored for
  tenofovir disoproxil-associated adverse reactions, including renal disorders.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Non-nucleoside reverse transcriptase
  inhibitors (NNRTIs)</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Efavirenz 600&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir (pm): all administered with
  food</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;0%(&#8595;9%
  &#8593;10%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;17%(&#8593;8% &#8593;27%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;42%(&#8595;51% &#8595;31%)*</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of efavirenz with
  REYATAZ/ritonavir is not recommended (see section&nbsp;4.4)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Efavirenz 600&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 200&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir (pm): all administered with
  food</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;6% (&#8595;10%
  &#8593;26%) */**</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;9% (&#8595;5% &#8593;26%) */**</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8596;12% (&#8595;16% &#8593;49%) */**</span></p>
  <p class=EMEABodyText><span lang=BG>* When compared to REYATAZ
  300&nbsp;mg/ritonavir 100&nbsp;mg once daily in the evening without
  efavirenz. This decrease in atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG>, might negatively impact the efficacy of atazanavir. The mechanism
  of efavirenz/atazanavir interaction is CYP3A4 induction.</span></p>
  <p class=EMEABodyText><span lang=BG>** Based on historical comparison.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Nevirapine 200&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Study conducted in HIV infected patients</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Nevirapine AUC &#8593;26% (&#8593;17%
  &#8593;36%)</span></p>
  <p class=EMEABodyText><span lang=BG>Nevirapine C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;21% (&#8593;11% &#8593;32%)</span></p>
  <p class=EMEABodyText><span lang=BG>Nevirapine C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;35% (&#8593;25% &#8593;47%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;19% (&#8595;35%
  &#8593;2%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;2% (&#8595;15% &#8593;24%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;59% (&#8595;73% &#8595;40%) *</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>* When compared to REYATAZ 300&nbsp;mg
  and ritonavir 100&nbsp;mg without nevirapine. This decrease in atazanavir C</span><sub><span
  lang=BG>min</span></sub><span lang=BG>, might negatively impact the efficacy
  of atazanavir. The mechanism of nevirapine/atazanavir interaction is CYP3A4
  induction.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of nevirapine with
  REYATAZ/ritonavir is not recommended (see section&nbsp;4.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Integrase Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Raltegravir 400&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir/ritonavir)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Raltegravir AUC&#8593; 41%</span></p>
  <p class=EMEABodyText><span lang=BG>Raltegravir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG>&#8593; 24%</span></p>
  <p class=EMEABodyText><span lang=BG>Raltegravir C</span><sub><span lang=BG>12hr</span></sub><span
  lang=BG>&#8593; 77%</span></p>
  <p class=EMEABodyText><span lang=ES>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>The mechanism is UGT1A1 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No dose adjustment required for
  raltegravir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>HCV Protease Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Boceprevir 800&nbsp;mg three times
  daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg/ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=Default><span lang=BG style='font-size:11.0pt'>boceprevir AUC
  &#8596;5%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>boceprevir C<sub>max</sub>
  &#8596;7%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>boceprevir C<sub>min</sub>
  &#8596;18%</span></p>
  <p class=Default><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>atazanavir AUC
  &#8595; 35%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>atazanavir C<sub>max</sub>
  &#8595; 25%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>atazanavir C<sub>min</sub>
  &#8595; 49%</span></p>
  <p class=Default><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>ritonavir AUC &#8595;
  36%</span></p>
  <p class=Default><span lang=BG style='font-size:11.0pt'>ritonavir C<sub>max</sub>
  &#8595; 27%</span></p>
  <p class=EMEABodyText><span lang=BG>ritonavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595; 45%</span></p>
  <p class=EMEABodyText><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=Default><span lang=BG style='font-size:11.0pt'>Co-administration of
  atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir
  which may be associated with lower efficacy and loss of HIV control. This
  co-administration might be considered on a case by case basis if deemed
  necessary, in patients with suppressed HIV viral loads and with HIV viral
  strain without any suspected resistance to the HIV regimen. Increased
  clinical and laboratory monitoring for HIV suppression is warranted. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTIBIOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Clarithromycin 500&nbsp;mg twice daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Clarithromycin AUC &#8593;94% (&#8593;75%
  &#8593;116%)</span></p>
  <p class=EMEABodyText><span lang=BG>Clarithromycin C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;50% (&#8593;32% &#8593;71%)</span></p>
  <p class=EMEABodyText><span lang=BG>Clarithromycin C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;160% (&#8593;135% &#8593;188%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>14-OH clarithromycin</span></p>
  <p class=EMEABodyText><span lang=BG>14-OH clarithromycin AUC &#8595;70%
  (&#8595;74% &#8595;66%)</span></p>
  <p class=EMEABodyText><span lang=BG>14-OH clarithromycin C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8595;72% (&#8595;76% &#8595;67%)</span></p>
  <p class=EMEABodyText><span lang=BG>14-OH clarithromycin C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8595;62% (&#8595;66% &#8595;58%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;28% (&#8593;16%
  &#8593;43%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;6% (&#8595;7% &#8593;20%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;91% (&#8593;66% &#8593;121%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>A dose reduction of clarithromycin may
  result in subtherapeutic concentrations of 14-OH clarithromycin. The
  mechanism of the clarithromycin/atazanavir interaction is CYP3A4 inhibition.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No recommendation regarding dose
  reduction can be made; therefore, caution should be exercised if
  REYATAZ/ritonavir is co-administered with clarithromycin.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTIFUNGALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Ketoconazole 200&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No significant effect on atazanavir
  concentrations was observed.</span></p>
  </td>
  <td width=208 rowspan=3 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Ketoconazole and itraconazole should be
  used cautiously with REYATAZ/ritonavir. High doses of ketoconazole and
  itraconazole (&gt;200&nbsp;mg/day) are not recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:46.7pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.7pt'>
  <p class=EMEABodyText><b><span lang=BG>Itraconazole</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:46.7pt'>
  <p class=EMEABodyText><span lang=BG>Itraconazole, like ketoconazole, is a
  potent inhibitor as well as a substrate of CYP3A4.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:86.25pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:86.25pt'>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:86.25pt'>
  <p class=EMEABodyText><span lang=BG>Based on data obtained with other boosted
  PIs and ketoconazole, where ketoconazole AUC showed a 3-fold increase,
  REYATAZ/ritonavir is expected to increase ketoconazole or itraconazole
  concentrations.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Voriconazole 200&nbsp;mg twice daily </span></b><span
  lang=BG>(atazanavir 300&nbsp;mg/ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Subjects with at least one functional
  CYP2C19 allele.</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Voriconazole AUC &#8595;33% (&#8595;42%
  &#8595;22%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;10% (&#8595;22% &#8595;4%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;39% (&#8595;49% &#8595;28%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;12% (&#8595;18%
  &#8595;5%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;13% (&#8595;20% &#8595;4%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595; 20 % (&#8595;28 % &#8595;10%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Ritonavir AUC &#8595;12% (&#8595;17%
  &#8595;7%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;9% (&#8595;17% &#8596;0%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;25% (&#8595;35% &#8595;14%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>In the majority of patients with at least
  one functional CYP2C19 allele, a reduction in both voriconazole and
  atazanavir exposures are expected. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of voriconazole and
  REYATAZ/ritonavir is not recommended unless an assessment of the benefit/risk
  to the patient justifies the use of voriconazole (see section&nbsp;4.4). </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>At the time voriconazole treatment is
  required, a patient's CYP2C19 genotype should be performed if feasible.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Therefore if the combination is
  unavoidable, the following recommendations are made according to the CYP2C19
  status:</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>- in patients with at least one
  functional CYP2C19 allele, close clinical monitoring for a loss of both
  voriconazole (clinical signs) and atazanavir (virologic response) efficacy is
  recommended. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>- in patients without a functional
  CYP2C19 allele, close clinical and laboratory monitoring of
  voriconazole-associated adverse events is recommended</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>If genotyping is not feasible, full
  monitoring of safety and efficacy should be performed.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Voriconazole 50&nbsp;mg twice daily </span></b><span
  lang=BG>(atazanavir 300&nbsp;mg/ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  <p class=EMEABodyText><span lang=BG>Subjects without a functional CYP2C19
  allele.</span></p>
  <p class=EMEABodyText><b>&nbsp;</b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Voriconazole AUC &#8593;561% (&#8593;451%
  &#8593;699%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;438% (&#8593;355% &#8593;539%)</span></p>
  <p class=EMEABodyText><span lang=BG>Voriconazole C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;765% (&#8593;571% &#8593;1,020%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;20% (&#8595;35%
  &#8595;3%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;19% (&#8595;34% &#8596;0.2%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595; 31 % (&#8595;46 % &#8595;13%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>Ritonavir AUC &#8595;11% (&#8595;20%
  &#8595;1%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;11% (&#8595;24% &#8593;4%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ritonavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;19% (&#8595;35% &#8593;1%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>In a small number of patients without a
  functional CYP2C19 allele, significantly increased voriconazole exposures are
  expected. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Fluconazole 200&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg and ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir and fluconazole concentrations
  were not significantly modified when REYATAZ/ritonavir was co-administered
  with fluconazole.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No dosage adjustments are needed for
  REYATAZ/ritonavir and fluconazole.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTIMYCOBACTERIAL</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Rifabutin 150&nbsp;mg twice weekly</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg and ritonavir
  100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Rifabutin AUC &#8593;48% (&#8593;19%
  &#8593;84%) **</span></p>
  <p class=EMEABodyText><span lang=BG>Rifabutin C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;149% (&#8593;103% &#8593;206%) **</span></p>
  <p class=EMEABodyText><span lang=BG>Rifabutin C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;40% (&#8593;5% &#8593;87%) **</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>25-O-desacetyl-rifabutin AUC &#8593;990%
  (&#8593;714% &#8593;1361%) **</span></p>
  <p class=EMEABodyText><span lang=BG>25-O-desacetyl-rifabutin C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;677% (&#8593;513% &#8593;883%)
  **</span></p>
  <p class=EMEABodyText><span lang=BG>25-O-desacetyl-rifabutin C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;1045% (&#8593;715%
  &#8593;1510%) **</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>** When compared to rifabutin 150&nbsp;mg
  once daily alone. Total rifabutin and 25-O-desacetyl-rifabutin AUC
  &#8593;119% (&#8593;78% &#8593;169%).</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>In previous studies, the pharmacokinetics
  of atazanavir was not altered by rifabutin.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>When given with REYATAZ/ritonavir, the
  recommended dose of rifabutin is 150&nbsp;mg 3&nbsp;times per week on set
  days (for example Monday-Wednesday-Friday). Increased monitoring for
  rifabutin-associated adverse reactions including neutropenia and uveitis is
  warranted due to an expected increase in exposure to rifabutin. Further dosage
  reduction of rifabutin to 150&nbsp;mg twice weekly on set days is recommended
  for patients in whom the 150&nbsp;mg dose 3&nbsp;times per week is not
  tolerated. It should be kept in mind that the twice weekly dosage of
  150&nbsp;mg may not provide an optimal exposure to rifabutin thus leading to
  a risk of rifamycin resistance and a treatment failure. No dose adjustment is
  needed for REYATAZ/ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Rifampicin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Rifampicin is a strong CYP3A4 inducer and
  has been shown to cause a 72% decrease in atazanavir AUC which can result in
  virological failure and resistance development. During attempts to overcome
  the decreased exposure by increasing the dose of REYATAZ or other protease
  inhibitors with ritonavir, a high frequency of liver reactions was seen.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>The combination of rifampicin and REYATAZ
  with concomitant low-dose ritonavir is contraindicated (see
  section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTIPSYCHOTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Quetiapine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Due to CYP3A4 inhibition by REYATAZ,
  concentrations of quetiapine are expected to increase.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ/ritonavir
  with quetiapine is contraindicated as may increase quetiapine-related
  toxicity. Increased plasma concentrations of quetiapine may lead to coma
  (see&nbsp;section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Lurasidone</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>REYATAZ is expected to increase plasma
  levels of lurasidone due to CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of lurasidone with
  REYATAZ is contraindicated as this may incrrease lurasidone-related toxicity
  (see&nbsp;section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ACID REDUCING AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>H<sub>2</sub>-Receptor antagonists</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=EMEABodyText><b><span lang=BG>Without Tenofovir</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=EMEABodyText><span lang=BG>In HIV-infected patients with atazanavir/ritonavir
  at the recommended dose&nbsp;300/100&nbsp;mg once daily</span></p>
  </td>
  <td width=208 rowspan=5 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=EMEABodyText><b><span lang=BG>For patients not taking tenofovir,</span></b><span
  lang=BG> if REYATAZ 300&nbsp;mg/ritonavir 100&nbsp;mg and H</span><sub><span
  lang=BG>2</span></sub><span lang=BG>-receptor antagonists are
  co-administered, a dose equivalent to famotidine 20&nbsp;mg twice daily
  should not be exceeded. If a higher dose of an H</span><sub><span lang=BG>2</span></sub><span
  lang=BG>-receptor antagonist is required (eg, famotidine 40&nbsp;mg twice
  daily or equivalent) an increase of the REYATAZ/ritonavir dose from
  300/100&nbsp;mg to 400/100&nbsp;mg can be considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 20&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;18% (&#8595;25%
  &#8593;1%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;20% (&#8595;32% &#8595;7%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8596;1% (&#8595;16% &#8593;18%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;23% (&#8595;32%
  &#8595;14%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;23% (&#8595;33% &#8595;12%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;20% (&#8595;31% &#8595;8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>In Healthy volunteers with atazanavir/ritonavir
  at an increased dose of&nbsp;400/100&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;3% (&#8595;14%
  &#8593;22%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;2% (&#8595;13% &#8593;8%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;14% (&#8595;32% &#8593;8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>With Tenofovir disoproxil fumarate
  300&nbsp;mg once daily (equivalent to 245 mg tenofovir disoproxil)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>In HIV-infected patients with
  atazanavir/ritonavir at the recommended dose of&nbsp;300/100&nbsp;mg once
  daily</span></p>
  </td>
  <td width=208 rowspan=7 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>For patients who are taking tenofovir
  disoproxil fumarate, </span></b><span lang=BG>if REYATAZ/ritonavir with both
  tenofovir disoproxil and an H</span><sub><span lang=BG>2</span></sub><span
  lang=BG>-receptor antagonist are co-administered,a dose increase of REYATAZ
  to 400&nbsp;mg with 100&nbsp;mg of ritonavir is recommended. A dose
  equivalent to famotidine 40&nbsp;mg twice daily should not be exceeded.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 20&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;21% (&#8595;34%
  &#8595;4%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;21% (&#8595;36% &#8595;4%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;19% (&#8595;37% &#8593;5%) *</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;24% (&#8595;36% &#8595;11%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;23% (&#8595;36% &#8595;8%) *</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;25% (&#8595;47% &#8593;7%) *</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=451 colspan=2 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>In HIV-infected patients with
  atazanavir/ritonavir at an increased dose of&nbsp;400/100&nbsp;mg once daily</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 20&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8593;18% (&#8593;6.5%
  &#8593;30%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;18% (&#8593;6.7% &#8593;31%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;24 % (&#8593;10% &#8593;39%)*</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Famotidine 40&nbsp;mg twice daily</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8596;2.3% (&#8595;13%
  &#8593;10%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8596;5% (&#8595;17% &#8593;8.4%)*</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8596;1.3% (&#8595;10% &#8593;15)*</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>* When compared to atazanavir 300&nbsp;mg
  once daily with ritonavir 100&nbsp;mg once daily and tenofovir disoproxil
  fumarate 300&nbsp;mg all as a single dose with food. When compared to
  atazanavir 300&nbsp;mg with ritonavir 100&nbsp;mg </span><i><span lang=BG>without
  tenofovir</span></i><span lang=BG>, atazanavir concentrations are expected to
  be additionally decreased by about 20%. </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>The mechanism of interaction is decreased
  solubility of atazanavir as intra-gastric pH increases with H</span><sub><span
  lang=BG>2</span></sub><span lang=BG>-blockers.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Proton pump inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Omeprazole 40&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Atazanavir (am): 2 hr after omeprazole</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir AUC &#8595;61% (&#8595;65%
  &#8595;55%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8595;66% (&#8595;62% &#8595;49%)</span></p>
  <p class=EMEABodyText><span lang=BG>Atazanavir C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8595;65% (&#8595;71% &#8595;59%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=208 rowspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ/ritonavir
  with proton pump inhibitors is not recommended. If the combination of
  REYATAZ/ritonavir with a proton pump inhibitor is judged unavoidable, close
  clinical monitoring is recommended in combination with an increase in the
  dose of REYATAZ to 400&nbsp;mg with 100&nbsp;mg of ritonavir; doses of proton
  pump inhibitors comparable to omeprazole 20&nbsp;mg should not be exceeded
  (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Omeprazole 20&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Atazanavir (am): 1 hr after omeprazole</span></p>
  <p class=MsoNormal style='margin-right:-5.45pt'><span lang=BG>Atazanavir AUC
  &#8595;30% (&#8595;43% &#8595;14%) *</span></p>
  <p class=MsoNormal style='margin-right:-5.45pt'><span lang=BG>Atazanavir C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8595;31% (&#8595;42% &#8595;17%) *</span></p>
  <p class=MsoNormal style='margin-right:-5.45pt'><span lang=BG>Atazanavir C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8595;31% (&#8595;46% &#8595;12%) *</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>* When compared to atazanavir 300&nbsp;mg
  once daily with ritonavir 100&nbsp;mg once daily.</span></p>
  <p class=EMEABodyText><span lang=BG>The decrease in AUC, C</span><sub><span
  lang=BG>max</span></sub><span lang=BG>, and C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> was not mitigated when an increased dose of REYATAZ/ritonavir
  (400/100&nbsp;mg once daily) was temporally separated from omeprazole by
  12&nbsp;hours. Although not studied, similar results are expected with other
  proton pump inhibitors. This decrease in atazanavir exposure might negatively
  impact the efficacy of atazanavir. The mechanism of interaction is decreased
  solubility of atazanavir as intra-gastric pH increases with proton pump
  inhibitors.</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Antacids</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Antacids and medicinal products
  containing buffers</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Reduced plasma concentrations of atazanavir
  may be the consequence of increased gastric pH if antacids, including
  buffered medicinal products, are administered with REYATAZ/ritonavir. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>REYATAZ/ritonavir should be administered
  2&nbsp;hours before or 1 hour after antacids or buffered medicinal products.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ALPHA 1-ADRENORECEPTOR ANTAGONIST</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Alfuzosin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Potential for increased alfuzosin
  concentrations which can result in hypotension. The mechanism of interaction
  is CYP3A4 inhibition by atazanavir/ritonavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of REYATAZ/ritonavir with
  alfuzosin is contraindicated (see section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTICOAGULANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Warfarin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with REYATAZ/ritonavir has
  the potential to produce a decrease or, less often, an increase in INR
  (International Normalised Ratio). </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>It is recommended that the INR be monitored
  carefully during treatment with REYATAZ/ritonavir, especially when commencing
  therapy.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>ANTIEPILEPTICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Carbamazepine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>REYATAZ/ritonavir may increase plasma levels
  of carbamazepine due to CYP3A4 inhibition. </span></p>
  <p class=MsoNormal><span lang=BG>Due to carbamazepine inducing effect, a
  reduction in REYATAZ/ritonavir exposure cannot be ruled out.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Carbamazepine should be used with caution in
  combination with REYATAZ/ritonavir. If necessary, monitor carbamazepine serum
  concentrations and adjust the dose accordingly. Close monitoring of the
  patient's virologic response should be excercised. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Phenytoin, phenobarbital</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Ritonavir may decrease plasma levels of
  phenytoin and/or phenobarbital due to CYP2C9 and CYP2C19 induction.</span></p>
  <p class=MsoNormal><span lang=BG>Due to phenitoine/phenobarbital inducing
  effect, a reduction in REYATAZ/ritonavir exposure cannot be ruled out</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Phenobarbital and phenytoin should be used
  with caution in combination with REYATAZ/ritonavir.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>When REYATAZ/ritonavir is co-administered
  with either phenytoin or phenobarbital, a dose adjustment of phenytoin or
  phenobarbital may be required.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>Close monitoring of patient's virologic
  response should be exercised. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Lamotrigine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of lamotrigine and
  REYATAZ/ritonavir may decrease lamotrigine plasma concentrations due to
  UGT1A4 induction.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Lamotrigine should be used with caution in
  combination with REYATAZ/ritonavir. </span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>If necessary, monitor lamotrigine
  concentrations and adjust the dose accordingly. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ANTINEOPLASTICS AND IMMUNOSUPRESSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Antineoplastics</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Irinotecan</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Atazanavir inhibits UGT and may interfere
  with the metabolism of irinotecan, resulting in increased irinotecan
  toxicities. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>If REYATAZ/ritonavir is co-administered with
  irinotecan, patients should be closely monitored for adverse events related
  to irinotecan.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Immunosuppressants</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Cyclosporin</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Tacrolimus</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Sirolimus</span></b></p>
  <p class=MsoNormal><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Concentrations of these immunosuppressants
  may be increased when co-administered with REYATAZ/ritonavir due to CYP3A4
  inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>More frequent therapeutic concentration
  monitoring of these medicinal products is recommended until plasma levels
  have been stabilised.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>CARDIOVASCULAR AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Antiarrhythmics</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Amiodarone, </span></b></p>
  <p class=MsoNormal><b><span lang=BG>Systemic lidocaine, </span></b></p>
  <p class=MsoNormal><b><span lang=BG>Quinidine</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Concentrations of these antiarrhythmics may
  be increased when co-administered with REYATAZ/ritonavir. The mechanism of
  amiodarone or systemic lidocaine/atazanavir interaction is CYP3A inhibition.
  Quinidine has a narrow therapeutic window and is contraindicated due to
  potential inhibition of CYP3A by REYATAZ/ritonavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Caution is warranted and therapeutic
  concentration monitoring is recommended when available. The concomitant use
  of quinidine is contraindicated (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Calcium channel blockers</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Bepridil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>REYATAZ/ritonavir should not be used in
  combination with medicinal products that are substrates of CYP3A4 and have a
  narrow therapeutic index.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with bepridil is
  contraindicated (see section&nbsp;4.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Diltiazem 180&nbsp;mg once daily</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Diltiazem AUC &#8593;125% (&#8593;109%
  &#8593;141%)</span></p>
  <p class=EMEABodyText><span lang=BG>Diltiazem C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;98% (&#8593;78% &#8593;119%)</span></p>
  <p class=EMEABodyText><span lang=BG>Diltiazem C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;142% (&#8593;114% &#8593;173%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Desacetyl-diltiazem AUC &#8593;165%
  (&#8593;145% &#8593;187%)</span></p>
  <p class=EMEABodyText><span lang=BG>Desacetyl-diltiazem C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;172% (&#8593;144% &#8593;203%)</span></p>
  <p class=EMEABodyText><span lang=BG>Desacetyl-diltiazem C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;121% (&#8593;102% &#8593;142%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>No significant effect on atazanavir concentrations
  was observed. There was an increase in the maximum PR interval compared to
  atazanavir alone. Co-administration of diltiazem and REYATAZ/ritonavir has
  not been studied. The mechanism of diltiazem/atazanavir interaction is CYP3A4
  inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>An initial dose reduction of diltiazem by
  50% is recommended, with subsequent titration as needed and ECG monitoring.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Verapamil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Serum concentrations of verapamil may be
  increased by REYATAZ/ritonavir due to CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Caution should be exercised when verapamil
  is co-administered with REYATAZ/ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>CORTICOSTEROIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Fluticasone propionate intranasal
  50&nbsp;&micro;g 4&nbsp;times daily for 7&nbsp;days</span></b></p>
  <p class=EMEABodyText><span lang=BG>(ritonavir 100&nbsp;mg capsules twice
  daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>The fluticasone propionate plasma levels
  increased significantly, whereas the intrinsic cortisol levels decreased by
  approximately 86% (90% confidence interval 82%-89%). Greater effects may be
  expected when fluticasone propionate is inhaled. Systemic corticosteroid
  effects including Cushing&#8217;s syndrome and adrenal suppression have been
  reported in patients receiving ritonavir and inhaled or intranasally
  administered fluticasone propionate; this could also occur with other
  corticosteroids metabolised via the P450 3A pathway, e.g., budesonide. The
  effects of high fluticasone systemic exposure on ritonavir plasma levels are
  yet unknown. The mechanism of interaction is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration of REYATAZ/ritonavir
  and these glucocorticoids is not recommended unless the potential benefit of
  treatment outweighs the risk of systemic corticosteroid effects (see
  section&nbsp;4.4). A dose reduction of the glucocorticoid should be
  considered with close monitoring of local and systemic effects or a switch to
  a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone).
  Moreover, in case of withdrawal of glucocorticoids, progressive dose
  reduction may have to be performed over a longer period.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>ERECTILE DYSFUNCTION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>PDE5 Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Sildenafil, tadalafil, vardenafil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Sildenafil, tadalafil, and vardenafil are
  metabolised by CYP3A4. Co-administration with REYATAZ/ritonavir may result in
  increased concentrations of the PDE5 inhibitor and an increase in
  PDE5-associated adverse events, including hypotension, visual changes, and
  priapism. The mechanism of this interaction is CYP3A4 inhibition.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Patients should be warned about these
  possible side effects when using PDE5 inhibitors for erectile dysfunction
  with REYATAZ/ritonavir (see section&nbsp;4.4).</span></p>
  <p class=MsoNormal><span lang=BG>Also see PULMONARY ATERIAL HYPERTENSION in
  this table for further information regarding co-administration of
  REYATAZ/ritonavir with sildenafil.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>HERBAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>St. John&#8217;s wort (Hypericum
  perforatum)</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Concomitant use of St. John's wort with
  REYATAZ/ritonavir may be expected to result in significant reduction in
  plasma levels of atazanavir. This effect may be due to an induction of
  CYP3A4. There is a risk of loss of therapeutic effect and development of
  resistance (see section&nbsp;4.3).</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of REYATAZ/ritonavir with
  products containing St. John's wort is contraindicated.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>HORMONAL CONTRACEPTIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Ethinyloestradiol 25&nbsp;&#956;g +
  norgestimate</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Ethinyloestradiol AUC &#8595;19%
  (&#8595;25% &#8595;13%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ethinyloestradiol C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8595;16% (&#8595;26% &#8595;5%)</span></p>
  <p class=EMEABodyText><span lang=BG>Ethinyloestradiol C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8595;37% (&#8595;45% &#8595;29%)</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Norgestimate AUC &#8593;85% (&#8593;67%
  &#8593;105%)</span></p>
  <p class=EMEABodyText><span lang=BG>Norgestimate C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;68% (&#8593;51% &#8593;88%)</span></p>
  <p class=EMEABodyText><span lang=BG>Norgestimate C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;102% (&#8593;77% &#8593;131%)</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>While the concentration of
  ethinyloestradiol was increased with atazanavir given alone, due to both UGT
  and CYP3A4 inhibition by atazanavir, the net effect of atazanavir/ritonavir
  is a decrease in ethinyloestradiol levels because of the inducing effect of ritonavir.
  </span></p>
  <p class=EMEABodyText>&nbsp;</p>
  <p class=EMEABodyText><span lang=BG>The increase in progestin exposure may
  lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and
  spotting), thus possibly affecting the compliance.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>If an oral contraceptive is administered
  with REYATAZ/ritonavir, it is recommended that the oral contraceptive contain
  at least 30&nbsp;&#956;g of ethinyloestradiol and that the patient be
  reminded of strict compliance with this contraceptive dosing regimen.
  Co-administration of REYATAZ/ritonavir with other hormonal contraceptives or
  oral contraceptives containing progestogens other than norgestimate has not
  been studied, and therefore should be avoided. An alternate reliable method
  of contraception is recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>LIPID LOWERING AGENTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>HMG-CoA reductase inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Simvastatin</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Lovastatin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Simvastatin and lovastatin are highly
  dependent on CYP3A4 for their metabolism and co-administration with
  REYATAZ/ritonavir may result in increased concentrations. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of simvastatin or
  lovastatin with REYATAZ is contraindicated due to an increased risk of
  myopathy including rhabdomyolysis (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Atorvastatin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>The risk of myopathy including
  rhabdomyolysis may also be increased with atorvastatin, which is also
  metabolised by CYP3A4. </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of atorvastatin with
  REYATAZ is not recommended. If the use of atorvastatin is considered strictly
  necessary, the lowest possible dose of atorvastatin should be administered
  with careful safety monitoring (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Pravastatin</span></b></p>
  <p class=MsoNormal><b><span lang=BG>Fluvastatin</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Although not studied, there is a potential
  for an increase in pravastatin or fluvastatin exposure when co-administered with
  protease inhibitors.</span><span lang=BG style='color:blue'> </span><span
  lang=BG>Pravastatin is not metabolised by CYP3A4. Fluvastatin is partially
  metabolised by CYP2C9.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Caution should be exercised.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>INHALED BETA AGONISTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Salmeterol</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with REYATAZ/ritonavir may
  result in increased concentrations of salmeterol and an increase in
  salmeterol-associated adverse events.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>The mechanism of interaction is CYP3A4
  inhibition by atazanavir/ritonavir.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration of salmeterol with
  REYATAZ/ritonavir is not recommended (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>OPIOIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Buprenorphine, once daily, stable
  maintenance dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 300&nbsp;mg once daily with
  ritonavir 100&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Buprenorphine AUC &#8593;67%</span></p>
  <p class=EMEABodyText><span lang=BG>Buprenorphine C</span><sub><span lang=BG>max</span></sub><span
  lang=BG> &#8593;37% </span></p>
  <p class=EMEABodyText><span lang=BG>Buprenorphine C</span><sub><span lang=BG>min</span></sub><span
  lang=BG> &#8593;69%</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>Norbuprenorphine AUC &#8593;105%</span></p>
  <p class=EMEABodyText><span lang=BG>Norbuprenorphine C</span><sub><span
  lang=BG>max</span></sub><span lang=BG> &#8593;61%</span></p>
  <p class=EMEABodyText><span lang=BG>Norbuprenorphine C</span><sub><span
  lang=BG>min</span></sub><span lang=BG> &#8593;101%</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=BG>The mechanism of interaction is CYP3A4
  and UGT1A1 inhibition.</span></p>
  <p class=EMEABodyText><span lang=BG>Concentrations of atazanavir were not
  significantly affected.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Co-administration warrants<br>
  clinical monitoring for sedation and cognitive effects. A dose reduction of buprenorphine
  may be considered.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Methadone, stable maintenance dose</span></b></p>
  <p class=EMEABodyText><span lang=BG>(atazanavir 400&nbsp;mg once daily)</span></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No significant effect on methadone
  concentrations was observed. Given that low dose ritonavir (100&nbsp;mg twice
  daily) has been shown to have no significant effect on methadone
  concentrations, no interaction is expected if methadone is co-administered
  with REYATAZ and ritonavir, based on these data.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>No dosage adjustment is necessary if
  methadone is co-administered with REYATAZ and ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>PULMONARY ARTERIAL HYPERTENSION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>PDE5 Inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><b><span lang=BG>Sildenafil</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>Co-administration with REYATAZ/ritonavir may
  result in increased concentrations of the PDE5 inhibitor and an increase in
  PDE5-inhibitor-associated adverse events. </span></p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span lang=BG>The mechanism of interaction is CYP3A4 inhibition
  by atazanavir/ritonavir.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal><span lang=BG>A safe and effective dose in combination
  with REYATAZ/ritonavir has not been established for sildenafil when used to
  treat pulmonary arterial hypertension. Sildenafil, when used for the
  treatment of pulmonary arterial hypertension, is contraindicated (see
  section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>SEDATIVES</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=659 colspan=3 valign=top style='width:494.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><i><span lang=BG>Benzodiazepines</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.0pt'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><b><span lang=BG>Midazolam</span></b></p>
  <p class=EMEABodyText><b><span lang=BG>Triazolam</span></b></p>
  </td>
  <td width=245 valign=top style='width:183.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>Midazolam and triazolam are extensively
  metabolised by CYP3A4. Co-administration with REYATAZ/ritonavir may cause a
  large increase in the concentration of these benzodiazepines. No drug
  interaction study has been performed for the co-administration of
  REYATAZ/ritonavir with benzodiazepines. Based on data for other CYP3A4
  inhibitors, plasma concentrations of midazolam are expected to be significantly
  higher when midazolam is given orally. Data from concomitant use of
  parenteral midazolam with other protease inhibitors suggest a possible 3-4
  fold increase in midazolam plasma levels.</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=EMEABodyText><span lang=BG>REYATAZ/ritonavir should not be
  co-administered with triazolam or orally administered midazolam (see
  section&nbsp;4.3), whereas caution should be used with co-administration of
  REYATAZ/ritonavir and parenteral midazolam. If REYATAZ is co-administered
  with parenteral midazolam, it should be done in an intensive care unit (ICU)
  or similar setting which ensures close clinical monitoring and appropriate
  medical management in case of respiratory depression and/or prolonged
  sedation. Dosage adjustment for midazolam should be considered, especially if
  more than a single dose of midazolam is administered.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Paediatric population</span></i></p>

<p class=EMEABodyText><span lang=BG>Interaction studies have only been
performed in adults.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Pregnancy</span></u></p>

<p class=EMEABodyText><span lang=BG>A moderate amount of data in pregnant women
(between 300-1000 pregnancy outcomes) indicate no malformative toxicity of
atazanavir. Animal studies do not indicate reproductive toxicity (see
section&nbsp;5.3). The use of REYATAZ may be considered during pregnancy only
if the potential benefit justifies the potential risk.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In clinical trial AI424-182 REYATAZ/ritonavir
(300/100&nbsp;mg or 400/100&nbsp;mg) in combination with zidovudine/lamivudine
was administered to 41&nbsp;pregnant women during the second or third
trimester. Six of 20 (30%) women on REYATAZ/ritonavir 300/100&nbsp;mg and 13 of
21 (62%) women on REYATAZ/ritonavir 400/100&nbsp;mg experienced grades 3 to
4&nbsp;hyperbilirubinaemia. There were no cases of lactic acidosis observed in
the clinical trial AI424-182.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The study assessed 40&nbsp;infants who
received antiretroviral prophylactic treatment (which did not include REYATAZ)
and were negative for HIV-1 DNA at the time of delivery and/or during the first
6&nbsp;months postpartum. Three of 20&nbsp;infants (15%) born to women treated
with REYATAZ/ritonavir 300/100&nbsp;mg and four of 20&nbsp;infants (20%) born
to women treated with REYATAZ/ritonavir 400/100&nbsp;mg experienced grade
3-4&nbsp;bilirubin. There was no evidence of pathologic jaundice and six of
40&nbsp;infants in this study received phototherapy for a maximum of
4&nbsp;days. There were no reported cases of kernicterus in neonates.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For dosing recommendations see
section&nbsp;4.2 and for pharmacokinetic data see section&nbsp;5.2.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>It is not known whether REYATAZ
administered to the mother during pregnancy will exacerbate physiological
hyperbilirubinaemia and lead to kernicterus in neonates and infants. In the
prepartum period, additional monitoring should be considered.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText><u><span lang=BG>Breast-feeding</span></u></p>

<p class=EMEABodyText><span lang=BG>Atazanavir has been detected in human milk.
As a general rule, it is recommended that HIV infected women not breast-feed
their infants in order to avoid transmission of HIV.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Fertility</span></u></p>

<p class=EMEABodyText><span lang=BG>In a non-clinical fertility and early
embryonic development study in rats, atazanavir altered oestrus cycling with no
effects on mating or fertility (see&nbsp;section&nbsp;5.3).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on
ability to drive and use machines</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Patients should be informed that dizziness
has been reported during treatment with regimens containing REYATAZ
(see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Summary of the safety profile</span></u></p>

<p class=EMEABodyText><span lang=BG>REYATAZ has been evaluated for safety in
combination therapy with other antiretroviral medicinal products in controlled
clinical trials in 1,806&nbsp;adult&nbsp;patients receiving REYATAZ 400&nbsp;mg
once daily (1,151&nbsp;patients, 52&nbsp;weeks median duration and
152&nbsp;weeks maximum duration) or REYATAZ 300&nbsp;mg with ritonavir
100&nbsp;mg once daily (655&nbsp;patients, 96&nbsp;weeks median duration and
108&nbsp;weeks maximum duration).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Adverse reactions were consistent between
patients who received REYATAZ 400&nbsp;mg once daily and patients who received
REYATAZ 300&nbsp;mg with ritonavir 100&nbsp;mg once daily, except that jaundice
and elevated total bilirubin levels were reported more frequently with REYATAZ
plus ritonavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Among patients who received REYATAZ
400&nbsp;mg once daily or REYATAZ 300&nbsp;mg with ritonavir 100&nbsp;mg once
daily, the only adverse reactions of any severity reported very commonly with
at least a possible relationship to regimens containing REYATAZ and one or more
NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%). Among patients
receiving REYATAZ 300&nbsp;mg with ritonavir 100&nbsp;mg, the frequency of
jaundice was 19%. In the majority of cases, jaundice was reported within a few
days to a few months after the initiation of treatment
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>Chronic kidney disease in HIV-infected
patients treated with atazanavir, with or without ritonavir, has been reported
during postmarketing surveillance.&nbsp; A large prospective observational
study has shown an association between an increased incidence of chronic kidney
disease and cumulative exposure to atazanavir/ritonavir-containing regimen in
HIV-infected patients with an initially normal eGFR. This association was
observed independently of exposure to tenofovir disoproxil. Regular monitoring
of the renal function of patients should be maintained throughout the treatment
duration (see&nbsp;section&nbsp;4.4). </span></p>

<p class=EMEABodyText><s><span style='text-decoration:none'>&nbsp;</span></s></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Tabulated
list of adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=BG>Assessment of adverse reactions for REYATAZ
is based on safety data from clinical studies and post-marketing experience.
Frequency is defined using the following convention: very common
(&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon
(&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000 to
&lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=576
 style='margin-left:33.75pt;border-collapse:collapse'>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Immune system disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: hypersensitivity</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Metabolism and nutrition disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: weight decreased, weight gain,
  anorexia, appetite increased</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Psychiatric disorders:</span></i></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: depression, disorientation,
  anxiety, insomnia, sleep disorder, abnormal dream</span></p>
  <p class=EMEABodyText>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Nervous system disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: headache;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: peripheral neuropathy, syncope,
  amnesia, dizziness, somnolence, dysgeusia</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Eye disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: ocular icterus</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Cardiac disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>uncommon:
  torsades de pointes<sup>a</sup></span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>rare: QTc
  prolongation<sup>a</sup>, oedema, palpitation</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Vascular disorders:</span></i></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: hypertension</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Respiratory, thoracic and mediastinal
  disorders:</span></i></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: dyspnoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Gastrointestinal disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: vomiting, diarrhoea, abdominal
  pain, nausea, dyspepsia;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: pancreatitis, gastritis,
  abdominal distension, stomatitis aphthous, flatulence, dry mouth</span></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Hepatobiliary disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: jaundice;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: hepatitis, cholelithiasis<sup>a</sup>,
  cholestasis<sup>a</sup>;</span></p>
  <p class=EMEABodyText><span lang=BG>rare: hepatosplenomegaly, cholecystitis<sup>a</sup></span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Skin and subcutaneous tissue
  disorders:</span></i></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: rash;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: erythemia multiforme<sup>a,b</sup>,
  toxic skin eruptions<sup>a,b</sup>, drug rash with eosinophilia and systemic
  symptoms (DRESS) syndrome<sup>a,b</sup>, angioedema<sup>a</sup>, urticaria,
  alopecia, pruritus; </span></p>
  <p class=EMEABodyText><span lang=BG>rare: Stevens-Johnson syndrome<sup>a,b</sup>,
  vesiculobullous rash, eczema, vasodilatation</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Musculoskeletal and connective tissue
  disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: muscle atrophy, arthralgia,
  myalgia; </span></p>
  <p class=EMEABodyText><span lang=BG>rare: myopathy</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Renal and urinary disorders:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: nephrolithiasis<sup>a</sup>,
  haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney
  disease<span class=EMEASuperscript>a</span>;</span></p>
  <p class=EMEABodyText><span lang=BG>rare: kidney pain</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>Reproductive system and breast
  disorders:</span></i></p>
  <p class=EMEABodyText><i>&nbsp;</i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>uncommon: gynaecomastia</span></p>
  <p class=EMEABodyText><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=220 valign=top style='width:165.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><i><span lang=BG>General disorders and administration
  site conditions:</span></i></p>
  </td>
  <td width=356 valign=top style='width:267.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>common: fatigue;</span></p>
  <p class=EMEABodyText><span lang=BG>uncommon: chest pain, malaise, pyrexia,
  asthenia;</span></p>
  <p class=EMEABodyText><span lang=BG>rare: gait disturbance</span></p>
  <p class=EMEABodyText><i><span lang=BG>&nbsp;</span></i></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
lang=BG style='font-size:9.0pt'> These adverse reactions were identified
through post-marketing surveillance, however, the frequencies were estimated
from a statistical calculation based on the total number of patients exposed to
REYATAZ in randomised controlled and other available clinical trials (n
=&nbsp;2321).</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
lang=BG style='font-size:9.0pt'> See description of selected adverse reactions
for more details.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Description of selected adverse
reactions</span></u></p>

<p class=EMEABodyText><span lang=BG>In HIV-infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. Autoimmune disorders (such as Graves' disease and
autoimmune hepatitis) have also been reported; however, the reported time to
onset is more variable and these events can occur many months after initiation
of treatment (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><i><u><span style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=EMEABodyText><span lang=BG>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long-term exposure to combination antiretroviral therapy (CART). The
frequency of this is unknown (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Metabolic parameters</span></p>

<p class=EMEABodyText><span lang=BG>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText><i><u><span style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=EMEABodyText><span lang=BG>Rash and associated syndromes</span></p>

<p class=EMEABodyText><span lang=BG>Rashes are usually mild-to-moderate
maculopapular skin eruptions that occur within the first 3&nbsp;weeks of
starting therapy with REYATAZ. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Stevens-Johnson syndrome (SJS), erythema
multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic
symptoms (DRESS) syndrome have been reported with the use of REYATAZ
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Laboratory
abnormalities</span></i></p>

<p class=EMEABodyText><span lang=BG>The most frequently reported laboratory
abnormality in patients receiving regimens containing REYATAZ&nbsp;and one or
more NRTIs was elevated total bilirubin reported predominantly as elevated
indirect [unconjugated] bilirubin (87% Grade&nbsp;1,&nbsp;2,&nbsp;3,
or&nbsp;4). Grade&nbsp;3 or&nbsp;4 elevation of total bilirubin was noted in
37% (6% Grade&nbsp;4). Among experienced patients treated with REYATAZ 300&nbsp;mg
once daily with 100&nbsp;mg ritonavir once daily for a median duration of 95
weeks, 53% had Grade&nbsp;3-4&nbsp;total bilirubin elevations. Among naive
patients treated with REYATAZ 300&nbsp;mg once daily with 100&nbsp;mg ritonavir
once daily for a median duration of 96&nbsp;weeks, 48% had Grade 3-4 total
bilirubin elevations (see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other marked clinical laboratory
abnormalities (Grade&nbsp;3 or&nbsp;4) reported in&nbsp;&#8805;&nbsp;2% of
patients receiving regimens containing REYATAZ&nbsp;and one or more NRTIs
included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum
glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated
aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT)
(3%), and elevated lipase (3%).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Two percent of patients treated with
REYATAZ experienced concurrent Grade&nbsp;3-4 ALT/AST and Grade&nbsp;3-4 total
bilirubin elevations.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Paediatric population</span></u></p>

<p class=EMEABodyText><span lang=BG>In a clinical study&nbsp;AI424-020,
paediatric patients 3&nbsp;months to less than 18&nbsp;years of age who
received either the oral powder or capsule formulation had a mean duration of
treatment with REYATAZ of 115&nbsp;weeks. The safety profile in this study was
overall comparable to that seen in adults. Both asymptomatic first-degree (23%)
and second-degree (1%) atrioventricular block were reported in paediatric patients.
The most frequently reported laboratory abnormalities in paediatric patients
receiving REYATAZ was elevation of total bilirubin (&#8805; 2.6&nbsp;times ULN,
Grade&nbsp;3-4) which occurred in 45% of patients.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In clinical studies AI424-397 and
AI424-451, paediatric patients 3&nbsp;months to less than 11&nbsp;years of age
had a mean duration of treatment with REYATAZ oral powder of 80&nbsp;weeks. No
deaths were reported. The safety profile in these studies was overall
comparable to that seen in previous paediatric and adult studies. The most
frequently reported laboratory abnormalities in paediatric patients receiving
REYATAZ oral powder was elevation of total bilirubin (&#8805; 2.6&nbsp;times
ULN, Grade&nbsp;3-4; 16%) and increased amylase (Grade&nbsp;3-4; 33%),
generally of non-pancreatic origin. Elevation in ALT levels were more
frequently reported in paediatric patients in these studies than in adults.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Other special populations</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Patients
co-infected with hepatitis B and/or hepatitis C virus</span></i></p>

<p class=EMEABodyText><span lang=BG>Among 1,151&nbsp;patients receiving
atazanavir 400&nbsp;mg once daily, 177&nbsp;patients were co-infected with
chronic hepatitis B or C, and among 655&nbsp;patients receiving atazanavir
300&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily, 97&nbsp;patients
were co-infected with chronic hepatitis B or C. Co-infected patients were more
likely to have baseline hepatic transaminase elevations than those without
chronic viral hepatitis. No differences in frequency of bilirubin elevations
were observed between these patients and those without viral hepatitis. The
frequency of treatment emergent hepatitis or transaminase elevations in
co-infected patients was comparable between REYATAZ and comparator regimens
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Reporting of suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=BG>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='background:lightgrey'>.</span></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Human experience of acute overdose with
REYATAZ is limited. Single doses up to 1,200&nbsp;mg have been taken by healthy
volunteers without symptomatic untoward effects. At high doses that lead to
high drug exposures, jaundice due to indirect (unconjugated)
hyperbilirubinaemia (without associated liver function test changes) or PR interval
prolongations may be observed (see&nbsp;sections&nbsp;4.4 and&nbsp;4.8).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Treatment of overdose with REYATAZ should
consist of general supportive measures, including monitoring of vital signs and
electrocardiogram (ECG), and observations of the patient's clinical status. If
indicated, elimination of unabsorbed atazanavir should be achieved by emesis or
gastric lavage. Administration of activated charcoal may also be used to aid
removal of unabsorbed drug. There is no specific antidote for overdose with
REYATAZ. Since atazanavir is extensively metabolised by the liver and is highly
protein bound, dialysis is unlikely to be beneficial in significant removal of
this medicinal product.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Pharmacotherapeutic group: antivirals for
systemic use, protease inhibitors, ATC code: J05AE08</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Mechanism of action</span></i></p>

<p class=EMEABodyText><span lang=BG>Atazanavir is an azapeptide HIV-1 protease
inhibitor (PI). The compound selectively inhibits the virus-specific processing
of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of
mature virions and infection of other cells.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Antiviral activity in vitro:</span></i><span
lang=BG> atazanavir exhibits anti-HIV-1 (including all clades tested) and
anti-HIV-2 activity in cell culture.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Resistance</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Antiretroviral
treatment naive adult patients</span></i></p>

<p class=EMEABodyText><span lang=BG>In clinical trials of antiretroviral
treatment naive patients treated with unboosted atazanavir, the I50L
substitution, sometimes in combination with an A71V change, is the signature
resistance substitution for atazanavir. Resistance levels to atazanavir ranged
from 3.5- to 29-fold without evidence of phenotypic cross resistance to other
PIs. In clinical trials of antiretroviral treatment naive patients treated with
boosted atazanavir, the I50L substitution did not emerge in any patient without
baseline PI substitutions. The N88S substitution has been rarely observed in
patients with virologic failure on atazanavir (with or without ritonavir).
While it may contribute to decreased susceptibility to atazanavir when it
occurs with other protease substitutions, in clinical studies N88S by itself
does not always lead to phenotypic resistance to atazanavir or have a
consistent impact on clinical efficacy.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Table&nbsp;3. De novo substitutions in
  treatment naive patients failing therapy with atazanavir + ritonavir (Study
  138, 96 weeks)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Frequency</span></b></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>de novo PI substitution (n=26)<sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>&gt;20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>none</span></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>10-20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>none</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
  lang=BG style='font-size:9.0pt'> Number of patients with paired genotypes
  classified as virological failures (HIV RNA &#8805;&nbsp;400&nbsp;copies/ml).</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The M184I/V substitution emerged in 5/26
REYATAZ/ritonavir and 7/26 lopinavir/ritonavir virologic failure patients,
respectively.</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>Antiretroviral
treatment experienced adult patients</span></i></p>

<p class=EMEABodyText><span lang=BG>In antiretroviral treatment experienced
patients from Studies&nbsp;009,&nbsp;043, and&nbsp;045, 100&nbsp;isolates from
patients designated as virological failures on therapy that included either
atazanavir, atazanavir + ritonavir, or atazanavir + saquinavir were determined
to have developed resistance to atazanavir. Of the 60&nbsp;isolates from
patients treated with either atazanavir or atazanavir + ritonavir, 18 (30%)
displayed the I50L phenotype previously described in naive patients.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Table&nbsp;4. De novo substitutions in
  treatment experienced patients failing therapy with atazanavir + ritonavir
  (Study&nbsp;045, 48&nbsp;weeks)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Frequency</span></b></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>de novo PI substitution (n=35)<sup>a,b</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>&gt;20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>M36,
  M46, I54, A71, V82</span></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>10-20%</span></p>
  </td>
  <td width=502 valign=top style='width:376.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>L10,
  I15, K20, V32, E35, S37, F53, I62, G73, I84, L90</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
  lang=BG style='font-size:9.0pt'> Number of patients with paired genotypes
  classified as virological failures (HIV RNA &#8805;&nbsp;400&nbsp;copies/ml).</span></p>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
  lang=BG style='font-size:9.0pt'> Ten patients had baseline phenotypic
  resistance to atazanavir + ritonavir (fold change [FC]&gt;5.2). FC
  susceptibility in cell culture relative to the wild-type reference was
  assayed using PhenoSense<sup>TM</sup> (Monogram Biosciences, South San
  Francisco, California, USA)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>None of the de novo substitutions (see
Table&nbsp;4) are specific to atazanavir and may reflect re-emergence of
archived resistance on atazanavir + ritonavir in Study&nbsp;045
treatment-experienced population.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The resistance in antiretroviral treatment
experienced patients mainly occurs by accumulation of the major and minor
resistance substitutions described previously to be involved in protease
inhibitor resistance.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Clinical results</span></b></p>

<p class=EMEABodyText><i><span lang=BG>In antiretroviral naive adult patients</span></i></p>

<p class=EMEABodyText><i><u><span lang=BG>Study&nbsp;138</span></u></i><span
lang=BG> is an international randomised, open-label, multicenter, prospective
trial of 883&nbsp;antiretroviral treatment naive patients comparing
REYATAZ/ritonavir (300&nbsp;mg/100&nbsp;mg once daily) to lopinavir/ritonavir
(400&nbsp;mg/100&nbsp;mg twice daily), each in combination with fixed dose
tenofovir disoproxil fumarate/emtricitabine (300&nbsp;mg/200&nbsp;mg tablets
once daily). The REYATAZ/ritonavir arm showed similar (non-inferior) antiviral
efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion
of patients with HIV&nbsp;RNA&nbsp;&lt; 50&nbsp;copies/ml at week&nbsp;48
(Table&nbsp;5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Analyses of data through 96&nbsp;weeks of
treatment demonstrated durability of antiviral activity (Table&nbsp;5).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The mean baseline CD4&nbsp;cell count was
214&nbsp;cells/mm<sup>3</sup> (range: 2 to 810&nbsp;cells/mm<sup>3</sup>) and
mean baseline plasma HIV-1 RNA was 4.94&nbsp;log<sub>10</sub>&nbsp;copies/ml
(range: 2.6 to 5.88&nbsp;log<sub>10</sub>&nbsp;copies/ml). The
REYATAZ/ritonavir arm has similar (non-inferior) antiviral efficacy compared to
the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV
RNA&nbsp;&lt;&nbsp;50&nbsp;copies/ml at week&nbsp;48: 78% of patients on
REYATAZ/ritonavir compared to 76% on lopinavir/ritonavir (difference estimate
of ATV/RTV-LPV/RTV: 1.7% [95% CI, -3.8%, 7.1%] according to the Confirmed
Virologic Response (CVR) Non-Completer&nbsp;=&nbsp;Failure (NC&nbsp;=&nbsp;F)
definition of response.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In a per protocol analysis which excluded
non-completers (i.e. patients who discontinued before the week&nbsp;48
HIV&nbsp;RNA assessment) and patients with major protocol deviations, the
proportion of patients with HIV&nbsp;RNA&nbsp;&lt;&nbsp;50&nbsp;copies/ml at
week&nbsp;48 was 86% (338/392) for REYATAZ/ritonavir and 89% (332/372) for
lopinavir/ritonavir (difference estimate of ATV/RTV-LPV/RTV: -3% [95% CI,
-7.6%, 1.5%].</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy
Outcomes in Study&nbsp;138<sup> a</sup></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=619
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=163 valign=bottom style='width:1.7in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Parameter</span></b></p>
  </td>
  <td width=228 colspan=2 valign=top style='width:171.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>REYATAZ/ritonavir<sup>b</sup>
  (300&nbsp;mg/100&nbsp;mg once daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=440</span></b></p>
  </td>
  <td width=228 colspan=2 valign=top style='width:171.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Lopinavir/ritonavir<sup>c</sup>
  (400&nbsp;mg/100&nbsp;mg twice daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=443</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=bottom style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week 48</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week 96</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week 48</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week 96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=bottom style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  &lt;50 copies/ml, %</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=bottom style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients<sup>d</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>74</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>76</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>68</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Difference
  estimate </span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  [95% CI]<sup>d</sup></span></p>
  </td>
  <td width=456 colspan=4 valign=top style='width:4.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week 48: 1.7% [-3.8%, 7.1%]</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week 96: 6.1% [0.3%, 12.0%]</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Per
  protocol analysis<sup>e</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>86</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=392<sup>f</sup>)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>91</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=352)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>89</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=372)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>89</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=331)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>Difference
  estimate<sup>e</sup> </span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;&nbsp;
  [95% CI]</span></p>
  </td>
  <td width=456 colspan=4 valign=top style='width:4.75in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week 48: -3% [-7.6%, 1.5%]</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>Week 96: 2.2% [-2.3%, 6.7%]</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>HIV RNA
  &lt;50 copies/ml, % by Baseline Characteristic<sup>d</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>HIV RNA <br>
  &nbsp;&nbsp;&nbsp; &lt;100,000 copies/ml</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>82 (n=217)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>75 (n=217)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>81 (n=218)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>70 (n=218)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  &#8805;100,000 copies/ml</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>74 (n=223)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>74 (n=223)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>72 (n=225)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>66 (n=225)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>CD4 count<br>
  &nbsp;&nbsp;&nbsp; &lt;50 cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78 (n=58)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78 (n=58)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>63 (n=48)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>58 (n=48)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  50 to &lt;100 cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>76 (n=45)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>71 (n=45)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>69 (n=29)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>69 (n=29)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;&nbsp;
  100 to &lt;200 cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>75 (n=106)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>71 (n=106)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>78 (n=134)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>70 (n=134)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  &#8805; 200 cells/mm<sup>3</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>80 (n=222)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>76 (n=222)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>80 (n=228)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>69 (n=228)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  Mean Change from Baseline, log<sub>10</sub> copies/ml</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  All patients</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.09 (n=397)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.21 (n=360)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.13 (n=379)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-3.19 (n=340)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>CD4
  Mean Change from Baseline, cells/mm<sup>3</sup> </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  All patients</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>203 (n=370)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>268 (n=336)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>219 (n=363)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>290 (n=317)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:6.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>CD4 Mean
  Change from Baseline, cells/mm<sup>3</sup> by Baseline Characteristic</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>HIV RNA <br>
  &nbsp;&nbsp; &lt;100,000 copies/ml</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>179 (n=183)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>243 (n=163)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>194 (n=183)</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>267 (n=152)</span></p>
  </td>
 </tr>
 <tr>
  <td width=163 valign=top style='width:1.7in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;&nbsp;
  &#8805;100,000 copies/ml</span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>227 (n=187)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>291 (n=173)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>245 (n=180)</span></p>
  </td>
  <td width=114 valign=bottom style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>310 (n=165)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>a</span></sup><span lang=BG style='font-size:9.0pt'>
Mean baseline CD4 cell count was 214&nbsp;cells/mm<sup>3</sup> (range 2 to
810&nbsp;cells/mm<sup>3</sup>) and mean baseline plasma HIV-1 RNA was
4.94&nbsp;log<sub>10</sub>&nbsp;copies/ml (range 2.6 to 5.88&nbsp;log<sub>10</sub>&nbsp;copies/ml)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>b</span></sup><span lang=BG style='font-size:9.0pt'>
REYATAZ/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>c</span></sup><span lang=BG style='font-size:9.0pt'>
Lopinavir/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>d</span></sup><span lang=BG style='font-size:9.0pt'>
Intent-to-treat analysis, with missing values considered as failures.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>e</span></sup><span lang=BG style='font-size:9.0pt'>
Per protocol analysis: Excluding non-completers and patients with major
protocol deviations.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>f</span></sup><span
lang=BG style='font-size:9.0pt'> Number of patients evaluable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=BG>In
antiretroviral experienced adult patients</span></i></p>

<p class=EMEABodyText><i><u><span lang=BG>Study&nbsp;045</span></u></i><span
lang=BG> is a randomised, multicenter trial comparing REYATAZ/ritonavir
(300/100&nbsp;mg once daily) and REYATAZ/saquinavir (400/1,200&nbsp;mg once
daily), to lopinavir + ritonavir (400/100&nbsp;mg fixed dose combination twice
daily), each in combination with tenofovi disoproxil fumarate
(see&nbsp;sections&nbsp;4.5 and&nbsp;4.8) and one NRTI, in patients with
virologic failure on two or more prior regimens containing at least one PI, NRTI,
and NNRTI. For randomised patients, the mean time of prior antiretroviral
exposure was 138&nbsp;weeks for PIs, 281&nbsp;weeks for NRTIs, and
85&nbsp;weeks for NNRTIs. At baseline, 34% of patients were receiving a PI and
60% were receiving an NNRTI. Fifteen of 120 (13%) patients in the REYATAZ +
ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir +
ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84,
and L90. Thirty-two percent of patients in the study had a viral strain with
fewer than two NRTI substitutions.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The primary endpoint was the time-averaged
difference in change from baseline in HIV RNA through 48&nbsp;weeks
(Table&nbsp;6).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy
Outcomes at Week&nbsp;48<sup>a</sup> and at Week&nbsp;96 (Study&nbsp;045)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=626
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=97 colspan=2 style='width:72.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Parameter</span></b></p>
  </td>
  <td width=176 colspan=2 style='width:132.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>ATV/RTV<sup>b</sup> (300&nbsp;mg/ 100&nbsp;mg once
  daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=120</span></b></p>
  </td>
  <td width=176 colspan=2 style='width:132.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>LPV/RTV<sup>c</sup> (400&nbsp;mg/ 100&nbsp;mg twice
  daily)</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>n=123</span></b></p>
  </td>
  <td width=176 colspan=2 style='width:132.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Time-averaged difference ATV/RTV-LPV/RTV</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>[97.5% CI<sup>d</sup>]</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 style='width:72.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;48</span></b></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>Week&nbsp;96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=626 colspan=8 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  Mean Change from Baseline, log<sub>10</sub> copies/ml</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 style='width:72.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-1.93</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=90<sup> e</sup>)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-2.29 (n=64)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-1.87 (n=99)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>-2.08 (n=65)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>0.13</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>[-0.12, 0.39]</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>0.14</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>[-0.13, 0.41]</span></p>
  </td>
 </tr>
 <tr>
  <td width=626 colspan=8 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  &lt;50 copies/ml, %<sup>f </sup>(responder/evaluable)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 valign=top style='width:72.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All
  patients</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>36 (43/120)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>32 (38/120)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>42 (52/123)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>35 (41/118)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr style='height:5.6pt'>
  <td width=626 colspan=8 valign=bottom style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.6pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>HIV RNA
  &lt;50 copies/ml by select baseline PI substitutions,<sup>f, g</sup> %
  (responder/evaluable)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=16 valign=top style='width:12.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=81 valign=top style='width:60.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>0-2</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>44 (28/63)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>41 (26/63)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>56 (32/57)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>48 (26/54)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=16 valign=top style='width:12.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>3</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>18 (2/11)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>9 (1/11)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>38 (6/16)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>33 (5/15)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=16 valign=top style='width:12.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>&#8805; 4</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>27 (12/45)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>24 (11/45)</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>28 (14/50)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>20 (10/49)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 valign=bottom style='width:66.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=626 colspan=8 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>CD4
  Mean Change from Baseline, cells/mm<sup>3</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=97 colspan=2 valign=top style='width:72.9pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.5pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>All patients</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>110 (n=83)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>122 (n=60)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>121 (n=94)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>154 (n=60)</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
  <td width=88 style='width:66.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>NA</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>a</span></sup><span lang=BG style='font-size:9.0pt'>
The mean baseline CD4 cell count was 337&nbsp;cells/mm<sup>3</sup> (range: 14
to 1,543&nbsp;cells/mm<sup>3</sup>) and the mean baseline plasma HIV-1 RNA
level was 4.4&nbsp;log<sub>10</sub>&nbsp;copies/ml (range: 2.6 to 5.88&nbsp;log<sub>10</sub>&nbsp;copies/ml).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>b</span></sup><span lang=BG style='font-size:9.0pt'>
ATV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>c</span></sup><span lang=BG style='font-size:9.0pt'>
LPV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose
300&nbsp;mg/200&nbsp;mg tablets once daily).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>d</span></sup><span lang=BG style='font-size:9.0pt'>
Confidence interval.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>e</span></sup><span lang=BG style='font-size:9.0pt'>
Number of patients evaluable.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>f</span></sup><span lang=BG style='font-size:9.0pt'>
Intent-to-treat analysis, with missing values considered as failures.
Responders on LPV/RTV who completed treatment before Week 96 are excluded from
Week 96 analysis. The proportion of patients with HIV RNA
&lt;&nbsp;400&nbsp;copies/ml were 53% and 43% for ATV/RTV and 54% and 46% for
LPV/RTV at weeks&nbsp;48 and 96 respectively.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
style='font-size:9.0pt'>g</span></sup><span lang=BG style='font-size:9.0pt'>
Select substitutions include any change at positions L10, K20, L24, V32, L33,
M36, M46, G48, I50, I54, L63, A71, G73, V82, I84, and L90 (0-2, 3, 4 or more)
at baseline.</span></p>

<p class=EMEABodyText><span lang=BG style='font-size:9.0pt'>NA = not
applicable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Through 48&nbsp;weeks of treatment, the
mean changes from baseline in HIV RNA levels for REYATAZ + ritonavir and
lopinavir + ritonavir were similar (non-inferior). Consistent results were
obtained with the last observation carried forward method of analysis
(time-averaged difference of 0.11, 97.5% confidence interval [-0.15, 0.36]). By
as-treated analysis, excluding missing values, the proportions of patients with
HIV RNA &lt;&nbsp;400 copies/ml (&lt;&nbsp;50&nbsp;copies/ml) in the REYATAZ +
ritonavir arm and the lopinavir + ritonavir arm were 55% (40%) and 56% (46%),
respectively.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Through 96&nbsp;weeks of treatment, mean
HIV RNA changes from baseline for REYATAZ + ritonavir and lopinavir + ritonavir
met criteria for non-inferiority based on observed cases. Consistent results
were obtained with the last observation carried forward method of analysis. By
as-treated analysis, excluding missing values, the proportions of patients with
HIV RNA &lt;400 copies/ml (&lt;50 copies/ml) for REYATAZ + ritonavir were 84%
(72%) and for lopinavir + ritonavir were&nbsp;82% (72%). It is important to
note that at time of the 96-week analysis, 48 % of patients overall remained on
study.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ + saquinavir was shown to be
inferior to lopinavir + ritonavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><u><span lang=BG>Paediatric population</span></u></i></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric trials with REYATAZ capsules</span></i></p>

<p class=EMEABodyText><span lang=BG>Assessment of the pharmacokinetics, safety,
tolerability, and efficacy of REYATAZ is based on data from the open-label,
multicenter clinical trial AI424-020 conducted in patients from 3&nbsp;months
to 21&nbsp;years of age. Overall in this study, 182&nbsp;paediatric patients
(81&nbsp;antiretroviral-naive and 101&nbsp;antiretroviral-experienced) received
once daily REYATAZ (capsule or powder formulation), with or without ritonavir,
in combination with two NRTIs.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The clinical data derived from this study
are inadequate to support the use of atazanavir capsules (with or without
ritonavir) in children below 6&nbsp;years of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Efficacy data observed in the
41&nbsp;paediatric patients aged 6&nbsp;years to less than 18&nbsp;years that
received REYATAZ capsules with ritonavir are presented in Table&nbsp;7. For
treatment-naive paediatric patients, the mean baseline CD4&nbsp;cell count was
344&nbsp;cells/mm<sup>3</sup> (range: 2 to 800&nbsp;cells/ mm<sup>3</sup>) and
mean baseline plasma HIV-1 RNA was 4.67&nbsp;log<sub>10</sub>&nbsp;copies/ml
(range: 3.70 to 5.00&nbsp;log<sub>10</sub>&nbsp;copies/ml). For
treatment-experienced paediatric patients, the mean baseline CD4&nbsp;cell
count was 522&nbsp;cells/mm<sup>3</sup> (range: 100 to 1157&nbsp;cells/ mm<sup>3</sup>)
and mean baseline plasma HIV-1 RNA was 4.09&nbsp;log<sub>10</sub>&nbsp;copies/ml
(range: 3.28 to 5.00&nbsp;log<sub>10</sub>&nbsp;copies/ml).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-56.7pt'><b><span
lang=BG>Table 7: &nbsp;&nbsp;&nbsp;&nbsp; Efficacy Outcomes (paediatric
patients 6&nbsp;years to less than 18&nbsp;years of age) at Week 48
(Study&nbsp;AI424-020)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=568
 style='width:426.15pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=256 style='width:192.15pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>Parameter</span></b></p>
  </td>
  <td width=154 valign=bottom style='width:115.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Treatment-Naive<br>
  REYATAZ Capsules/ritonavir (300&nbsp;mg/100&nbsp;mg once daily) n=16</span></b></p>
  </td>
  <td width=158 valign=bottom style='width:118.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Treatment-Experienced REYATAZ Capsules/ritonavir
  (300&nbsp;mg/100&nbsp;mg once daily) n=25</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>HIV RNA &lt;50&nbsp;copies/ml, % <sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>All patients</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>81
  (13/16)</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>24
  (6/25)</span></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>HIV RNA &lt;400&nbsp;copies/ml, % <sup>a</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=BG>All patients</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>88
  (14/16)</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>32
  (8/25)</span></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>CD4 Mean Change from Baseline,
  cells/mm<sup>3</sup></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>All patients</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>293
  (n=14</span><sup><span lang=BG>b</span></sup><span lang=BG>)</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>229
  (n=14</span><sup><span lang=BG>b</span></sup><span lang=BG>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=BG>HIV RNA &lt;50 copies/ml by select
  baseline PI substitutions,<sup>c </sup>% (responder/evaluable</span></b><b><sup><span
  lang=BG>d</span></sup><span lang=BG>)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>0-2</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>NA</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>27
  (4/15)</span></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>3</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>NA</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>-</span></p>
  </td>
 </tr>
 <tr>
  <td width=256 valign=top style='width:192.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#8805; 4</span></p>
  </td>
  <td width=154 valign=top style='width:115.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=BG>NA</span></p>
  </td>
  <td width=158 valign=top style='width:118.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>0
  (0/3)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
lang=BG style='font-size:9.0pt'> Intent-to-treat analysis, with missing values
considered as failures.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
lang=BG style='font-size:9.0pt'> Number of patients evaluable.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>c </span></sup><span
lang=BG style='font-size:9.0pt'>PI major L24I, D30N, V32I, L33F, M46IL, I47AV,
G48V, I50LV, F53LY, I54ALMSTV, L76V, V82AFLST, I84V, N88DS, L90M; PI minor:
L10CFIRV, V11I, E35G, K43T, Q58E, A71ILTV, G73ACST, T74P, N83D, L89V.</span></p>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>d</span></sup><span
lang=BG style='font-size:9.0pt'> Includes patients with baseline resistance
data.</span></p>

<p class=EMEABodyText><span lang=BG style='font-size:9.0pt'>NA = not
applicable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Paediatric trials with REYATAZ oral
powder</span></i></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=BG style='font-size:11.0pt;color:windowtext'>Assessment of
the pharmacokinetics, safety, tolerability, and virologic response of REYATAZ
oral powder was based on data from two open-label, multicenter clinical trials.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>AI424-397 (PRINCE I): In paediatric patients from
3&nbsp;months to less than 6&nbsp;years of age</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>AI424-451 (PRINCE II): In paediatric patients from
3&nbsp;months to less than 11&nbsp;years of age</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=BG style='font-size:11.0pt;color:windowtext'>In these
studies, 155&nbsp;patients (59&nbsp;antiretroviral-naive and
96&nbsp;antiretroviral-experienced) received once daily REYATAZ oral powder and
ritonavir, in combination with two NRTIs.</span></p>

<p class=BMSBodyText style='margin:0in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=BG style='font-size:11.0pt;color:windowtext'>For inclusion
in both trials, treatment-naive patients had to have genotypic sensitivity to
REYATAZ and two NRTIs, and treatment-experienced patients had to have
documented genotypic and phenotypic sensitivity at screening to REYATAZ and at
least 2&nbsp;NRTIs.</span><span lang=BG style='font-size:11.0pt'> Patients
exposed only to antiretrovirals <i>in utero</i> or intrapartum were considered
treatment-naive. Patients who received REYATAZ or REYATAZ/ritonavir at any time
prior to study enrollment or who had a history of treatment failure on two or
more protease inhibitors, protease inhibitor resistance or evidence of
pre-existing cardiac abnormalities were excluded from the trials. Protease
inhibitor resistance was defined as genotypic resistance to atazanavir or
either component of the local NRTI backbone based on the criteria of 1) any
major mutations: I50L, I84V, N88S and 2) &#8805;&nbsp;2 of the following minor
or cross resistant mutations: M46I/L, G48V, I54L/V/M/T/A, V82A/T/FI, L90M,
V32I.</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=BG style='font-size:11.0pt'>At Week&nbsp;48 there were
134&nbsp;paediatric patients aged 3&nbsp;months to less than 11&nbsp;years that
received REYATAZ oral powder with ritonavir that were evaluated for efficacy.
These data are presented in Table&nbsp;8. For treatment-naive paediatric
patients, the mean baseline CD4&nbsp;cell count was 930&nbsp;cells/mm<sup>3</sup>
(range: 46 to 2291&nbsp;cells/mm<sup>3</sup>) and mean baseline plasma HIV-1
RNA was 4.81&nbsp;log<sub>10</sub>&nbsp;copies/ml (range: 3.4 to 5.9&nbsp;log<sub>10</sub>&nbsp;copies/ml).
For treatment-experienced paediatric patients, the mean baseline CD4&nbsp;cell
count was 1441&nbsp;cells/mm<sup>3</sup> (range: 84 to 5703&nbsp;cells/mm<sup>3</sup>)
and mean baseline plasma HIV-1 RNA was 4.67&nbsp;log<sub>10</sub>&nbsp;copies/ml
(range: 2.0 to 5.9&nbsp;log<sub>10</sub>&nbsp;copies/ml).</span></p>

<p class=BMSBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-bottom:3.0pt;page-break-after:avoid'><b><span
lang=BG>Table&nbsp;8: Efficacy Outcomes for oral powder (paediatric patients at
least 3&nbsp;months of age and weighing at least 5&nbsp;kg) at Week&nbsp;48
(Studies&nbsp;AI424-397 and AI424-451)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:38.95pt'>
  <td width=247 style='width:185.4pt;border:solid windowtext 1.0pt;border-bottom:
  solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt;height:38.95pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=BG style='color:black'>Parameter </span></b></p>
  </td>
  <td width=186 style='width:139.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.95pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span lang=BG>Treatment-Naive<br>
  REYATAZ Powder/ritonavir n=52</span></b></p>
  </td>
  <td width=198 style='width:148.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.95pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span lang=BG style='color:black'>Treatment-Experienced
  REYATAZ Powder/ritonavir n=82</span></b></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td width=631 colspan=3 valign=top style='width:473.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.75pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG
  style='color:black'>HIV RNA &lt;50&nbsp;copies/ml, %<sup>a</sup></span></b><b><span
  lang=BG style='font-size:7.0pt;color:black'> </span></b></p>
  </td>
 </tr>
 <tr style='height:7.25pt'>
  <td width=247 valign=top style='width:185.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.25pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 5&nbsp;to&nbsp;&lt;&nbsp;10&nbsp;kg (REYATAZ
  150&nbsp;and&nbsp;200&nbsp;mg) </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 10&nbsp;to&nbsp;&lt;&nbsp;15&nbsp;kg</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 15&nbsp;to&nbsp;&lt;&nbsp;25&nbsp;kg</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 25&nbsp;to&nbsp;&lt;&nbsp;35&nbsp;kg</span></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.25pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>33&nbsp;(4/12)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>59&nbsp;(13/22)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>61&nbsp;(11/18)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>-</span></p>
  </td>
  <td width=198 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.25pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>52&nbsp;(17/33)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>35&nbsp;(6/17)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>57&nbsp;(17/30)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>50.0&nbsp;(1/2)</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td width=631 colspan=3 valign=top style='width:473.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.75pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG
  style='color:black'>HIV RNA &lt;400 copies/ml, %<sup>a</sup></span></b><b><span
  lang=BG style='font-size:7.0pt;color:black'> </span></b></p>
  </td>
 </tr>
 <tr style='height:7.25pt'>
  <td width=247 valign=top style='width:185.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.5pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.25pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 5&nbsp;to&nbsp;&lt;&nbsp;10&nbsp;kg (REYATAZ
  150&nbsp;and&nbsp;200&nbsp;mg) </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 10&nbsp;to&nbsp;&lt;&nbsp;15&nbsp;kg</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 15&nbsp;to&nbsp;&lt;&nbsp;25&nbsp;kg</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 25&nbsp;to&nbsp;&lt;&nbsp;35&nbsp;kg</span></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.25pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>75&nbsp;(9/12)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>82&nbsp;(18/22)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>78&nbsp;(14/18)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>-</span></p>
  </td>
  <td width=198 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.25pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>61&nbsp;(20/33)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>59&nbsp;(10/17)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>67&nbsp;(20/30)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>50.0&nbsp;(1/2)</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td width=631 colspan=3 valign=top style='width:473.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.75pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG
  style='color:black'>CD4 Mean Change from Baseline, cells/mm<sup>3</sup></span></b><b><span
  lang=BG style='font-size:7.0pt;color:black'> </span></b></p>
  </td>
 </tr>
 <tr style='height:7.7pt'>
  <td width=247 valign=top style='width:185.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.5pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.7pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 5&nbsp;to&nbsp;&lt;&nbsp;10&nbsp;kg (REYATAZ
  150&nbsp;and&nbsp;200&nbsp;mg) </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 10&nbsp;to&nbsp;&lt;&nbsp;15&nbsp;kg</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 15&nbsp;to&nbsp;&lt;&nbsp;25&nbsp;kg</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='color:black'>at least 25&nbsp;to&nbsp;&lt;&nbsp;35&nbsp;kg</span></p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.7pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>293&nbsp;(n=7)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>293&nbsp;(n=11)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>305&nbsp;(n=9)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>-</span></p>
  </td>
  <td width=198 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.7pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>63&nbsp;(n=16)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>307&nbsp;(n=8)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>374&nbsp;(n=12)</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=BG style='color:black'>213&nbsp;(n=1)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
lang=BG style='font-size:9.0pt'> Intent-to-treat analysis, with missing values
considered as failures.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Absorption:</span></i><span lang=BG> in
HIV-infected patients (n=33, combined studies), multiple dosing of REYATAZ
300&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily with food produced
a geometric mean (CV%) for atazanavir, C<sub>max</sub> of 4466 (42%) ng/ml,
with time to C<sub>max</sub> of approximately 2.5 hours. The geometric mean
(CV%) for atazanavir C<sub>min</sub> and AUC was 654 (76%) ng/ml and 44185
(51%) ng&#8226;h/ml, respectively. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Food effect:</span></u><span lang=BG>
co-administration of REYATAZ and ritonavir with food optimises the
bioavailability of atazanavir. Co-administration of a single 300&nbsp;mg dose
of REYATAZ and 100&nbsp;mg dose of ritonavir with a light meal resulted in a
33% increase in the AUC and a 40% increase in both the C<sub>max</sub> and the
24&nbsp;hour concentration of atazanavir relative to the fasting state.
Co-administration with a high-fat meal did not affect the AUC of atazanavir
relative to fasting conditions and the C<sub>max</sub> was within 11% of
fasting values. The 24&nbsp;hour concentration following a high fat meal was
increased by approximately 33% due to delayed absorption; the median T<sub>max</sub>
increased from 2.0 to 5.0&nbsp;hours. Administration of REYATAZ with ritonavir
with either a light or a high-fat meal decreased the coefficient of variation
of AUC and C<sub>max</sub> by approximately 25% compared to the fasting state.
To enhance bioavailability and minimise variability, REYATAZ is to be taken
with food.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Distribution:</span></i><span lang=BG>
atazanavir was approximately 86% bound to human serum proteins over a concentration
range of 100 to 10,000&nbsp;ng/ml. Atazanavir binds to both alpha-1-acid
glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively,
at 1,000&nbsp;ng/ml). In a multiple-dose study in HIV-infected patients dosed
with 400&nbsp;mg of atazanavir once daily with a light meal for 12&nbsp;weeks,
atazanavir was detected in the cerebrospinal fluid and semen. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Metabolism:</span></i><b><span lang=BG> </span></b><span
lang=BG>studies in humans and <i>in vitro</i> studies using human liver
microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4
isozyme to oxygenated metabolites.<u> </u>Metabolites are then excreted in the
bile as either free or glucuronidated metabolites. Additional minor metabolic
pathways consist of N-dealkylation and hydrolysis. Two minor metabolites of
atazanavir in plasma have been characterised. Neither metabolite demonstrated <i>in
vitro</i> antiviral activity.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Elimination:</span></i><span lang=BG>
following a single 400&nbsp;mg dose of <sup>14</sup>C-atazanavir, 79% and 13%
of the total radioactivity was recovered in the faeces and urine, respectively.
Unchanged drug accounted for approximately 20% and 7% of the administered dose
in the faeces and urine, respectively. Mean urinary excretion of unchanged drug
was 7% following 2&nbsp;weeks of dosing at 800&nbsp;mg once daily. In
HIV-infected adult patients (n=33, combined studies) the mean half-life within
a dosing interval for atazanavir was 12 hours at steady state following a dose
of 300&nbsp;mg daily with ritonavir 100&nbsp;mg once daily with a light meal.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Linearity/non-linearity:</span></i><span
lang=BG> the pharmacokinetics of atazanavir were evaluated in healthy adult
volunteers and in HIV infected patients; significant differences were observed
between the two groups. The pharmacokinetics of atazanavir exhibit a non-linear
disposition.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=BG>Special
populations</span></u></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Renal impairment</span></i><span
lang=BG>: in healthy subjects, the renal elimination of unchanged atazanavir
was approximately 7% of the administered dose. There are no pharmacokinetic
data available for REYATAZ with ritonavir in patients with renal insufficiency.
REYATAZ (without ritonavir) has been studied in adult patients with severe
renal impairment (n=20), including those on haemodialysis, at multiple doses of
400&nbsp;mg once daily. Although this study presented some limitations (i.e.,
unbound drug concentrations not studied), results suggested that the atazanavir
pharmacokinetic parameters were decreased by 30% to 50% in patients undergoing
haemodialysis compared to patients with normal renal function. The mechanism of
this decrease is unknown (see sections&nbsp;4.2 and&nbsp;4.4.).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Hepatic impairment</span></i><span
lang=BG>: atazanavir is metabolised and eliminated primarily by the liver. The
effects of hepatic impairment on the pharmacokinetics of atazanavir after a
300&nbsp;mg dose with ritonavir have not been studied. Concentrations of
atazanavir with or without ritonavir are expected to be increased in patients
with moderately or severely impaired hepatic function
(see&nbsp;sections&nbsp;4.2,&nbsp;4.3, and&nbsp;4.4).</span></p>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><i><span lang=BG>Age/Gender:</span></i><span lang=BG> a
study of the pharmacokinetics of atazanavir was performed in 59&nbsp;healthy
male and female subjects (29&nbsp;young, 30&nbsp;elderly). There were no
clinically important pharmacokinetic differences based on age or gender.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Race:</span></i><span lang=BG> a
population pharmacokinetic analysis of samples from Phase II clinical trials
indicated no effect of race on the pharmacokinetics of atazanavir.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Pregnancy:</span></i></p>

<p class=EMEABodyText><span lang=BG>The pharmacokinetic data from HIV-infected
pregnant women receiving REYATAZ capsules with ritonavir are presented in
Table&nbsp;9.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Table&nbsp;9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steady-State
Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in
the Fed State</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=595
 style='width:446.55pt;margin-left:5.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:20.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:20.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=403 colspan=3 style='width:302.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:20.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>atazanavir 300&nbsp;mg with ritonavir 100&nbsp;mg</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=BG>Pharmacokinetic
  Parameter</span></b></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>2nd Trimester</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=9)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>3rd Trimester</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=20)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=BG>postpartum<sup>a</sup></span></b></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(n=36)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>C<sub>max</sub>
  ng/mL</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geometric
  mean (CV%)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>3729.09</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(39)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>3291.46</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(48)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>5649.10</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(31)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>AUC
  ng&#8226;h/mL</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geometric
  mean (CV%)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>34399.1</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(37)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>34251.5</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(43)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>60532.7</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(33)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:27.75pt'>
  <td width=192 style='width:2.0in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG>C<sub>min</sub>
  ng/mL</span><sup><span lang=BG style='font-size:14.0pt'>b</span></sup></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geometric
  mean (CV%)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>663.78</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(36)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>668.48</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(50)</span></p>
  </td>
  <td width=134 style='width:100.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>1420.64</span></p>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=BG>(47)</span></p>
  </td>
 </tr>
 <tr>
  <td width=595 colspan=4 valign=top style='width:446.55pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
  style='font-size:9.0pt'>a </span></sup><span lang=BG style='font-size:9.0pt'>Atazanavir
  peak concentrations and AUCs were found to be approximately 26-40% higher
  during the postpartum period (4-12&nbsp;weeks) than those observed
  historically in HIV infected, non-pregnant patients. Atazanavir plasma trough
  concentrations were approximately 2-fold higher during the postpartum period
  when compared to those observed historically in HIV infected non-pregnant
  patients.</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><sup><span lang=BG
  style='font-size:9.0pt'>b </span></sup><span lang=BG style='font-size:9.0pt'>C<sub>min</sub>
  is concentration 24&nbsp;hours post-dose.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=BG>Paediatric population</span></i></p>

<p class=MsoNormal><span lang=BG>There is a trend toward a higher clearance in
younger children when normalised for body weight. As a result, greater peak to
trough ratios are observed; however at recommended doses, geometric mean
atazanavir exposures (C<sub>min</sub>, C<sub>max</sub> and AUC) in paediatric
patients are expected to be similar to those observed in adults.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In repeat-dose toxicity studies, conducted
in mice, rats, and dogs, atazanavir-related findings were generally confined to
the liver and included generally minimal to mild increases in serum bilirubin
and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female
mice only, hepatic single-cell necrosis. Systemic exposures of atazanavir in
mice (males), rats, and dogs at doses associated with hepatic changes were at
least equal to that observed in humans given 400&nbsp;mg once daily. In female
mice, atazanavir exposure at a dose that produced single-cell necrosis was
12&nbsp;times the exposure in humans given 400&nbsp;mg once daily. Serum cholesterol
and glucose were minimally to mildly increased in rats but not in mice or dogs.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During <i>in vitro</i> studies, cloned
human cardiac potassium channel (hERG), was inhibited by 15% at a concentration
(30&nbsp;&#956;M) of atazanavir corresponding to 30&nbsp;fold the free drug
concentration at C<sub>max</sub> in humans. Similar concentrations of
atazanavir increased by 13% the action potential duration (APD<sub>90</sub>) in
rabbit Purkinje fibres study. Electrocardiographic changes (sinus bradycardia,
prolongation of PR interval, prolongation of QT interval, and prolongation of
QRS complex) were observed only in an initial 2&nbsp;week oral toxicity study
performed in dogs. Subsequent 9&nbsp;month oral toxicity studies in dogs showed
no drug-related electrocardiographic changes. The clinical relevance of these
non-clinical data is unknown. Potential cardiac effects of this product in
humans cannot be ruled out (see&nbsp;sections&nbsp;4.4 and&nbsp;4.8). The
potential for PR prolongation should be considered in cases of overdose
(see&nbsp;section&nbsp;4.9).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In a fertility and early embryonic
development study in rats, atazanavir altered oestrus cycling with no effects
on mating or fertility. No teratogenic effects were observed in rats or rabbits
at maternally toxic doses. In pregnant rabbits, gross lesions of the stomach
and intestines were observed in dead or moribund does at maternal doses 2 and
4&nbsp;times the highest dose administered in the definitive embryo-development
study. In the pre- and postnatal development assessment in rats, atazanavir
produced a transient reduction in body weight in the offspring at a maternally
toxic dose. Systemic exposure to atazanavir at doses that resulted in maternal
toxicity was at least equal to or slightly greater than that observed in humans
given 400&nbsp;mg once daily.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir was negative in an Ames
reverse-mutation assay but did induce chromosomal aberrations <i>in vitro</i>
in both the absence and presence of metabolic activation. In <i>in vivo</i>
studies in rats, atazanavir did not induce micronuclei in bone marrow, DNA
damage in duodenum (comet assay), or unscheduled DNA repair in liver at plasma
and tissue concentrations exceeding those that were clastogenic <i>in vitro</i>.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In long-term carcinogenicity studies of
atazanavir in mice and rats, an increased incidence of benign hepatic adenomas
was seen in female mice only. The increased incidence of benign hepatic
adenomas in female mice was likely secondary to cytotoxic liver changes
manifested by single-cell necrosis and is considered to have no relevance for
humans at intended therapeutic exposures. There were no tumorigenic findings in
male mice or in rats.</span></p>

<p class=EMEABodyText style='text-align:justify'>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Atazanavir increased opacity of bovine
corneas in an <i>in vitro</i> ocular irritation study, indicating it may be an
ocular irritant upon direct contact with the eye.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of
excipients</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Aspartame (E951)</span></p>

<p class=EMEABodyText><span lang=BG>Sucrose</span></p>

<p class=EMEABodyText><span lang=BG>Orange vanilla flavour</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not applicable.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>3&nbsp;years</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>After mixing with food or beverage, mixture
may be stored for up to 1&nbsp;hour at temperatures not above&nbsp;30&deg;C.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for storage</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>This medicinal product does not require any
special storage conditions. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ oral powder should be stored in the
original sachet and should not be opened until ready to use. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For storage conditions after mixing of the medicinal
product, see section&nbsp;6.3.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and
contents of container</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Polyester film/Aluminum/Polyethylene
sealant film sachet. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each carton contains 30&nbsp;sachets.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></p>

<p class=EMEAHeading2>&nbsp;</p>

<p class=EMEABodyText><i><span lang=BG>Instructions for use:</span></i></p>

<p class=EMEABodyText style='line-height:13.0pt'><span lang=BG>The dose and the
number of REYATAZ oral powder sachets needed is determined based on weight (see
section&nbsp;4.2.).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt;
line-height:13.0pt'><span lang=BG>1.&nbsp; Prior to mixing, the sachet is
tapped to settle the powder. A clean pair of scissors is used to cut each
sachet along the dotted line.</span></p>

<p class=EMEABodyText style='margin-top:0in;margin-right:0in;margin-bottom:
3.0pt;margin-left:28.35pt;text-indent:-14.15pt;line-height:13.0pt'><span
lang=BG>2.&nbsp; The appropriate option listed below is chosen for mixing and
administration with liquid infant formula, beverage or food. Larger volumes or
quantities of liquid infant formula, beverage or food may be used for dosing.
It should be ensured that the patient eats or drinks all the infant formula,
beverage or food that contains the powder.</span></p>

<p class=EMEABodyText style='margin-left:27.0pt;line-height:13.0pt'><span
lang=BG>A: To mix the recommended number of REYATAZ oral powder sachets with
liquid infant formula in a small medicine cup or small container and to
administer with an oral syringe, which can be obtained from a pharmacist:</span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in;line-height:
13.0pt'><span lang=BG style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=BG>A spoon
is used to mix the content of the appropriate number of sachets (4 or 5 sachets
depending on infant weight) with 10&nbsp;ml of prepared liquid infant formula
in the medicine cup or small container. The full amount of the mixture is drawn
up into an oral syringe and administered into either right or left inner cheek
of the infant. Another 10&nbsp;ml of formula is poured into the medicine cup or
small container to rinse off remaining REYATAZ oral powder in the cup or container.
The residual mixture is drawn up into the syringe and administered into either
the right or left inner cheek of the infant.</span></p>

<p class=EMEABodyText style='margin-left:27.0pt;line-height:13.0pt'><span
lang=BG>B: To mix the recommended number of REYATAZ oral powder sachets with a
beverage such as milk or water in a small drinking cup: </span></p>

<p class=EMEABodyTextIndent style='margin-left:1.0in'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>A spoon is used to mix the content of the sachets
with 30&nbsp;ml of the beverage. The child is to drink the mixture. An
additional 15&nbsp;ml of beverage is added to the drinking cup for thorough
rinsing of the cup and contents are mixed. The child is to drink the entire
residual mixture. </span></p>

<p class=EMEABodyText style='margin-left:1.0in;text-indent:-.25in;line-height:
13.0pt'><span lang=BG style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=BG>If
water is used, food should also be taken at the same time.</span></p>

<p class=EMEABodyText style='margin-left:27.0pt;line-height:13.0pt'><span
lang=BG>C: To mix the recommended number of REYATAZ oral powder sachets with
food such as applesauce or yogurt in a small container:</span></p>

<p class=EMEABodyText style='margin-top:0in;margin-right:0in;margin-bottom:
3.0pt;margin-left:1.0in;text-indent:-.25in;line-height:13.0pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>One tablespoon of food is used to mix the content
of the sachets. The mixture is fed to the infant or young child. An additional
tablespoon of food is added to the small container for thorough delivery of the
powder from the container and contents are mixed.The entire residual mixture is
fed to the child.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt;
line-height:13.0pt'><span lang=BG>3.&nbsp; The entire dosage of REYATAZ oral
powder (mixed in the liquid infant formula, beverage or food) is administered
within one hour of preparation (the mixture can be left at room stored at
temperatures not above 30&deg;C during this period).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt;
line-height:13.0pt'><span lang=BG>4.&nbsp; Additional infant formula, beverage
or food may be given after consumption of the entire mixture.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt;
line-height:13.0pt'><span lang=BG>5.&nbsp; Ritonavir is administered
immediately following REYATAZ powder administration.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For further details on the preparation and
administration of the REYATAZ oral powder, see the Patient Information Leaflet,
Instructions for Use section</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EU/1/03/267/012</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Date of first authorisation: 02 March 2004<br>
Date of latest renewal: 02 March 2009</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
REVISION OF THE TEXT</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>{MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEATitle><span lang=BG>ANNEX II</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1 style='margin-left:85.5pt;text-indent:-27.0pt'><span
lang=BG>a.&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1 style='margin-left:85.5pt;text-indent:-27.0pt'><span
lang=BG>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1 style='margin-left:85.5pt;text-indent:-27.0pt'><span
lang=BG>C.&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1 style='margin-left:85.5pt'><span lang=BG>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=BG>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><u><span lang=BG>Name and address of the manufacturers
responsible for batch release</span></u></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>CATALENT ANAGNI S.R.L.</span></p>

<p class=EMEABodyText><span lang=BG>Loc. Fontana del Ceraso</span><span
lang=EN-GB> snc</span></p>

<p class=MsoNormal><span lang=BG>Strada Provinciale 12 Casilina, 41</span></p>

<p class=EMEABodyText><span lang=BG>03012 Anagni (FR)</span></p>

<p class=EMEABodyText><span lang=BG>Italy</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>Swords Laboratories T/A Bristol-Myers
Squibb Pharmaceutical Operations, External Manufacturing</span></p>

<p class=EMEABodyText><span lang=BG>Plaza 254</span></p>

<p class=EMEABodyText><span lang=BG>Blanchardstown Corporate Park 2</span></p>

<p class=EMEABodyText><span lang=BG>Dublin 15, D15 T867</span></p>

<p class=EMEABodyText><span lang=BG>Ireland</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>Swords Laboratories T/A Lawrence
Laboratories</span></p>

<p class=EMEABodyText><span lang=BG>Unit 12</span><span lang=EN-GB> &amp; 15</span><span
lang=BG>, Distribution Centre</span></p>

<p class=EMEABodyText><span lang=BG>Shannon Industrial Estate </span></p>

<p class=EMEABodyText><span lang=BG>Shannon, Co. Clare, </span><span
lang=EN-GB>V14 DD39</span></p>

<p class=EMEABodyText><span lang=BG>Ireland</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Medicinal product subject to restricted
medical prescription (see Annex I: Summary of Product Characteristics,
section&nbsp;4.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1 style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=BG>C.&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent><span lang=BG style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=BG>Periodic
Safety Update Reports</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=BG>The requirements
for submission of periodic safety update reports for this medicinal product are
set out in the list of Union reference dates (EURD list) provided for under
Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on
the European medicines web-portal.</span></p>

<p class=EMEABodyText style='text-align:justify'><span style='font-size:12.0pt'>&nbsp;</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent><span lang=BG style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=BG>Risk
Management plan (RMP)</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=BG>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any
agreed subsequent updates of the RMP.</span></p>

<p class=EMEABodyText style='text-align:justify'>&nbsp;</p>

<p class=EMEABodyText style='text-align:justify'><span lang=BG>An updated RMP
should be submitted:</span></p>

<p class=EMEABodyTextIndent style='margin-left:.5in;text-align:justify'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>At the request of the European Medicines Agency;</span></p>

<p class=EMEABodyTextIndent style='margin-left:.5in;text-align:justify'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEATitle><span lang=BG>ANNEX III</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEATitle><span lang=BG>LABELLING AND PACKAGE LEAFLET</span></p>

<span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEATitle><span lang=BG>A. LABELLING</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING AND THE IMMEDIATE PACKAGING</span></p>

<p class=EMEATitlePAC>&nbsp;</p>

<p class=EMEATitlePAC><span lang=BG style='font-variant:small-caps'>OUTER
CARTON TEXT (BOTTLE AND BLISTER PRESENTATIONS) AND BOTTLE LABEL TEXT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 100&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipients: contains lactose (see leaflet
for further information).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Carton and
label bottle pack (1 bottle):</span><span lang=BG> 60 hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span><span
lang=BG> 60&nbsp;hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Oral use.</span></p>

<p class=EMEABodyText><span lang=BG>Capsules should be swallowed whole. Read
the package leaflet before use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText><span lang=BG>Store in the original package</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack </span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>60&nbsp;hard capsules:</span><span
lang=BG> EU/1/03/267/001</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack :</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>60&nbsp;hard
capsules:</span><span lang=BG> EU/1/03/267/002<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Medicinal product subject to medical
prescription.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Outer carton:</span><span
lang=BG> REYATAZ&nbsp;100&nbsp;mg</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG>PC: </span></p>

<p class=MsoNormal><span lang=BG>SN: </span></p>

<p class=MsoNormal><span lang=BG>&lt;NN&gt;: </span></p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>BRISTOL-MYERS&nbsp;SQUIBB&nbsp;PHARMA&nbsp;EEIG<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>PARTICULARS TO APPEAR ON THE OUTER PACKAGING
AND THE IMMEDIATE PACKAGING</span></p>

<p class=EMEATitlePAC>&nbsp;</p>

<p class=EMEATitlePAC><span lang=BG style='font-variant:small-caps'>OUTER
CARTON TEXT (BOTTLE AND BLISTER PRESENTATIONS) AND BOTTLE LABEL TEXT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 150&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipients: contains lactose (see leaflet
for further information).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Carton and
label bottle pack (1 bottle):</span><span lang=BG> 60 hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span><span
lang=BG> 60&nbsp;hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Oral use.</span></p>

<p class=EMEABodyText><span lang=BG>Capsules should be swallowed whole. Read
the package leaflet before use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText><span lang=BG>Store in the original package</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack </span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>60&nbsp;hard
capsules:</span><span lang=BG> EU/1/03/267/003</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack :</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>60&nbsp;hard
capsules:</span><span lang=BG> EU/1/03/267/004<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION
FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Medicinal product subject to medical
prescription.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Outer carton:</span><span
lang=BG> REYATAZ&nbsp;150&nbsp;mg</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG>PC: </span></p>

<p class=MsoNormal><span lang=BG>SN: </span></p>

<p class=MsoNormal><span lang=BG>&lt;NN&gt;: </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>BRISTOL-MYERS&nbsp;SQUIBB&nbsp;PHARMA&nbsp;EEIG<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING AND THE IMMEDIATE PACKAGING</span></p>

<p class=EMEATitlePAC>&nbsp;</p>

<p class=EMEATitlePAC><span lang=BG style='font-variant:small-caps'>OUTER
CARTON TEXT (BOTTLE AND BLISTER PRESENTATIONS) AND BOTTLE LABEL TEXT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 200&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipients: contains lactose (see leaflet
for further information).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Carton Bottle
pack (1 bottle):</span><span lang=BG> 60 hard capsules</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Carton Bottle
pack: (3&nbsp;bottles):</span><span lang=BG> 3&nbsp;x&nbsp;60&nbsp;hard
capsules (3&nbsp;bottles of 60&nbsp;hard capsules)</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Label Bottle
pack:</span><span lang=BG> 60&nbsp;hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span><span
lang=BG> 60&nbsp;hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Oral use.</span></p>

<p class=EMEABodyText><span lang=BG>Capsules should be swallowed whole. Read
the package leaflet before use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText><span lang=BG>Store in the original package</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack </span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>60&nbsp;hard
capsules:</span><span lang=BG> EU/1/03/267/005</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>3&nbsp;x&nbsp;60
hard capsules:</span><span lang=BG> EU/1/03/267/011</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack :</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>60&nbsp;hard capsules:</span><span
lang=BG> EU/1/03/267/006<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Medicinal product subject to medical
prescription.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Outer carton:</span><span
lang=BG> REYATAZ&nbsp;200&nbsp;mg</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG>PC: </span></p>

<p class=MsoNormal><span lang=BG>SN: </span></p>

<p class=MsoNormal><span lang=BG>&lt;NN&gt;: </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>BRISTOL-MYERS&nbsp;SQUIBB&nbsp;PHARMA&nbsp;EEIG<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING AND THE IMMEDIATE PACKAGING</span></p>

<p class=EMEATitlePAC>&nbsp;</p>

<p class=EMEATitlePAC><span lang=BG style='font-variant:small-caps'>OUTER
CARTON TEXT (BOTTLE AND BLISTER PRESENTATIONS) AND BOTTLE LABEL TEXT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each capsule contains 300&nbsp;mg of atazanavir
(as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Excipients: contains lactose (see leaflet
for further information).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Carton Bottle
pack (1 bottle):</span><span lang=BG> 30 hard capsules</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Carton Bottle
pack: (3 bottles): </span><span lang=BG>3 x 30 hard capsules (3 bottles of 30
hard capsules)<br>
<span style='background:lightgrey'>Label Bottle pack: </span>30 hard capsules <br>
<br>
</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span><span
lang=BG> 30&nbsp;hard capsules</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Oral use.</span></p>

<p class=EMEABodyText><span lang=BG>Capsules should be swallowed whole. Read
the package leaflet before use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack:</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText><span lang=BG>Store in the original package</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Bottle pack </span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>30&nbsp;hard
capsules:</span><span lang=BG> EU/1/03/267/008</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>3 x 30 hard capsules:</span><span
lang=BG> EU/1/03/267/010<br>
<br>
</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Blister pack :</span></p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>30&nbsp;hard
capsules:</span><span lang=BG> EU/1/03/267/009<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Medicinal product subject to medical
prescription.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Outer carton:</span><span
lang=BG> REYATAZ&nbsp;300&nbsp;mg</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG>PC: </span></p>

<p class=MsoNormal><span lang=BG>SN: </span></p>

<p class=MsoNormal><span lang=BG>&lt;NN&gt;: </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>BRISTOL-MYERS&nbsp;SQUIBB&nbsp;PHARMA&nbsp;EEIG<br>
<br>
</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING <br>
<br>
</span></p>

<p class=EMEATitlePAC><span lang=BG style='font-variant:small-caps'>OUTER
CARTON TEXT </span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;50&nbsp;mg oral powder</span></p>

<p class=EMEABodyText><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Each sachet contains 50&nbsp;mg of
atazanavir (as sulphate).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Contains aspartame and sucrose. See leaflet
for further information</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Oral Powder</span></p>

<p class=EMEABodyText><span lang=BG>30 sachets</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=BG>Oral use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><i>&nbsp;</i></p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Does not require any special storage
conditions. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EU/1/03/267/012</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Medicinal product subject to medical
prescription.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG style='background:lightgrey'>Outer carton:</span><span
lang=BG> REYATAZ&nbsp;50&nbsp;mg</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=BG>PC: </span></p>

<p class=MsoNormal><span lang=BG>SN: </span></p>

<p class=MsoNormal><span lang=BG>&lt;NN&gt;: </span></p>

<p class=EMEABodyText>&nbsp;</p>

<span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>&nbsp;</b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=BG>REYATAZ
50&nbsp;mg ORAL POWDER - FOIL SACHET</span></b></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;50&nbsp;mg oral powder</span></p>

<p class=EMEABodyText><span lang=BG>Atazanavir</span></p>

<p class=EMEABodyText><span lang=BG>Oral use</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Read the package leaflet before use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>EXP {MM/YYYY}</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Lot</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>50&nbsp;mg </span></p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEATitle><span lang=BG>B. PACKAGE LEAFLET</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=BG>Package leaflet: Information for the user</span></p>

<p class=EMEATitle>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center'><b><span lang=BG>REYATAZ&nbsp;100&nbsp;mg
hard capsules</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you have any further questions, ask your doctor
or pharmacist.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>This medicine has been prescribed for you only. Do
not pass it on to others.<br>
It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you get any side effects talk to your doctor, or
pharmacist. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4.</span></p>

<p class=EMEABodyText><b><span lang=BG>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=BG>What is in this leaflet</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and what it is used for</span></p>

<p class=EMEABodyText><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></p>

<p class=EMEABodyText><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and What it is used for</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is an antiviral (or
antiretroviral) medicine. </span></b><span lang=BG>It is one of a group called <i>protease
inhibitors</i>. These medicines control Human Immunodeficiency Virus (HIV)
infection by stopping a protein that the HIV needs for its multiplication. They
work by reducing the amount of HIV in your body and this in turn, strengthens
your immune system. In this way REYATAZ reduces the risk of developing
illnesses linked to HIV&nbsp;infection.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ capsules may be used by adults and
children 6&nbsp;years of age and older. Your doctor has prescribed REYATAZ for
you because you are infected by the HIV that causes Acquired Immunodeficiency
Syndrome (AIDS). It is normally used in combination with other anti-HIV
medicines. Your doctor will discuss with you which combination of these
medicines with REYATAZ is best for you.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Do not take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are allergic </span></b><span lang=BG>to
atazanavir or any of the other ingredients of this medicine (listed in
section&nbsp;6)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you have moderate to severe liver problems. </span></b><span
lang=BG>Your doctor will evaluate how severe your liver disease is before
deciding whether you can take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are taking any of these medicines:</span></b><span
lang=BG> see also <i>Other medicines and REYATAZ</i></span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>rifampicin (an antibiotic used to treat
tuberculosis)<span style='color:green'> </span></span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>astemizole or terfenadine (commonly used to treat
allergy symptoms, these medicines may be available without prescription);
cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide
(used to treat schizophrenia); quinidine or bepridil (used to correct heart
rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to
treat headaches); and alfuzosin (used to treat enlarged prostatic gland)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder); lurasidone (used to treat
schizophrenia)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>medicines containing
St.&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum</i>, a herbal
preparation)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>triazolam and oral (taken by mouth) midazolam (used
to help you sleep and/or to relieve anxiety)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>simvastatin and lovastatin (used to lower blood
cholesterol).</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>grazoprevir-containing products, including
elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed
dose combination (used to treat chronic hepatitis&nbsp; C infection)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not take sildenafil with REYATAZ when
sildenafil is used for the treatment of pulmonary arterial hypertension.
Sildenafil is also used for the treatment of erectile dysfunction. Tell your
doctor if you are using sildenafil for the treatment of erectile dysfunction.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor at once if any of these
apply to you.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Warnings and precautions</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is not a cure for
HIV&nbsp;infection. </span></b><span lang=BG>You may continue to develop
infections or other illnesses linked to HIV&nbsp;infection. You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy. Discuss with your doctor the precautions needed to avoid
infecting other people.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some people will need special care before
or while taking REYATAZ. Talk to your doctor or pharmacist before taking
REYATAZ and make sure your doctor knows:</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you have hepatitis&nbsp;B or&nbsp;C</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you develop signs or symptoms of gall stones (pain
at the right side of your stomach)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you have type&nbsp;A or B&nbsp;haemophilia</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you require haemodialysis</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in'><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ may affect how well your kidneys
work.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Kidney stones have been reported in
patients taking REYATAZ. If you develop signs or symptoms of kidney stones
(pain in your side, blood in your urine, pain when you urinate), please inform
your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In some patients with advanced HIV
infection (AIDS) and a history of opportunistic infection, signs and symptoms
of inflammation from previous infections may occur soon after anti-HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms. If you notice
any symptoms of infection, please inform your doctor immediately. In addition
to the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any
symptoms of infection or other symptoms such as muscle weakness, weakness
beginning in hands and feet and moving up towards the trunk of the body,
palpitations, tremor or hyperactivity, please inform your doctor immediately to
seek necessary treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some patients taking combination
antiretroviral therapy may develop a bone disease called osteonecrosis (death
of bone tissue caused by loss of blood supply to the bone). The length of
combination antiretroviral therapy, corticosteroid use, alcohol consumption,
severe immunosuppression, higher body mass index, among others, may be some of
the many risk factors for developing this disease. Signs of osteonecrosis are
joint stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty in movement. If you notice any of these symptoms please inform your
doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hyperbilirubinaemia (an increase in the
level of bilirubin in the blood) has occurred in patients receiving REYATAZ.
The signs may be a mild yellowing of the skin or eyes. If you notice any of
these symptoms please inform your doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Serious skin rash, including Stevens-Johnson
syndrome, has been reported in patients taking REYATAZ. If you develop a rash
inform your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>If you notice a change in the way your
heart beats (heart rhythm changes), please inform your doctor. Children
receiving REYATAZ may require their heart to be monitored. Your child's doctor
will decide this.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Children </span></b></p>

<p class=EMEABodyText><b><span lang=BG>Do not give this medicine to children</span></b><span
lang=BG> younger than 3&nbsp;months of age and weighing less than 5&nbsp;kg.
The use of REYATAZ in children less than 3&nbsp;months of age and weighing less
than 5&nbsp;kg has not been studied due to the risk of serious complications.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Other medicines and REYATAZ</span></p>

<p class=EMEABodyText><b><span lang=BG>You must not take REYATAZ with certain
medicines.</span></b><span lang=BG> These are listed under Do not take REYATAZ,
at the start of Section&nbsp;2. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are other medicines that may not mix
with REYATAZ. Tell your doctor if you are taking, have recently taken, or might
take any other medicines. It is especially important to mention these:</span></p>

<p class=EMEABodyTextIndent><span lang=BG style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=BG>other
medicines to treat HIV&nbsp;infection (e.g. indinavir, nevirapine and
efavirenz)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>boceprevir and sofosbuvir/velpatasvir/voxilaprevir
(used to treat hepatitis&nbsp;C)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sildenafil, vardenafil, or tadalafil (used by men
to treat impotence (erectile dysfunction)) </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you are taking an oral contraceptive (<b>&quot;the
Pill&quot;</b>) with REYATAZ to prevent pregnancy, be sure to take it exactly
as instructed by your doctor and not miss any doses</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>any medicines used to treat diseases related to the
acid in the stomach (e.g. antacids to be taken 1&nbsp;hour before taking
REYATAZ or 2&nbsp;hours after taking REYATAZ, H<sub>2</sub>-blockers like
famotidine and proton pump inhibitors like omeprazole)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>medicines to lower blood pressure, to slow heart
rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine,
verapamil)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>atorvastatin, pravastatin, and fluvastatin (used to
lower blood cholesterol)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>salmeterol (used to treat asthma)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>cyclosporin, tacrolimus, and sirolimus (medicines
to decrease the effects of body's immune system)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>certain antibiotics (rifabutin, clarithromycin)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>ketoconazole, itraconazole, and voriconazole (antifungals)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>warfarin (anticoagulant, used to reduce the blood
clots)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>carbamazepine, phenytoin, phenobarbital,
lamotrigine (antiepileptics)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>irinotecan (used to treat cancer)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sedative agents (e.g. midazolam administered by
injection)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>buprenorphine (used to treat opioid addiction and
pain).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some medicines may interact with ritonavir,
a medicine that is taken with REYATAZ. It is important to tell your doctor if
you are taking fluticasone or budesonide (given by nose or inhaled to treat
allergic symptoms or asthma).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ with food and drink</span></p>

<p class=EMEABodyText><span lang=BG>It is important that you take REYATAZ with
food (a meal or a substantial snack) as this helps the body absorb the
medicine.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Pregnancy and breast-feeding</span></p>

<p class=EMEABodyText><span lang=BG>If you are pregnant or breast-feeding,
think that you may be pregnant or are planning to have a baby, ask your doctor
for advice before taking this medicine. Atazanavir, the active substance of
REYATAZ, is excreted in human milk. Patients should not breast-feed while
taking REYATAZ. It is recommended that women infected with HIV do not
breast-feed because the virus might be transmitted through the breast milk.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=BG>If you feel dizzy or lightheaded, do not
drive or use machines and contact your doctor immediately.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ contains lactose.</span></p>

<p class=EMEABodyText><span lang=BG>If you have been told by your doctor that
you have an intolerance to some sugars (e.g. lactose), contact your doctor
before taking this medicinal product.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>How to take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Always take this medicine exactly as your
doctor has told you. Check with your doctor if you are not sure. This way, you
can be sure your medicine is fully effective and you reduce the risk of the
virus developing resistance to the treatment. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>The recommended adult dose of REYATAZ
capsules is 300&nbsp;mg once daily with 100&nbsp;mg ritonavir once daily and
with food, </span></b><span lang=BG>in combination with other anti-HIV
medicines. Your doctor may adjust the dose of REYATAZ according to your
anti-HIV therapy.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText style='margin-bottom:3.0pt'><b><span lang=BG>For children
(6 to less than 18&nbsp;years of age), your child's doctor will decide the
right dose based on your child's weight. </span></b><span lang=BG>The dose of
REYATAZ capsules for children is calculated by body weight and is taken once
daily with food and 100&nbsp;mg ritonavir as shown below:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Body Weight</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(kg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>REYATAZ Dose once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Ritonavir Dose* once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>15
  to less than 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>200</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>at
  least 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>300</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:9.0pt'>*Ritonavir capsules, tablets or oral solution may be
  used.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ is also available as an oral powder
for use in children at least 3&nbsp;months old and weighing at least 5&nbsp;kg.
Switching to REYATAZ capsules from REYATAZ oral powder is encouraged as soon as
patients are able to consistently swallow capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>A change in dose may occur when switching
between oral powder and capsules. Your doctor will decide the right dose based
on your child&#8217;s weight.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are no dosing recommendations for
REYATAZ in paediatric patients less than 3&nbsp;months of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Take REYATAZ capsules with food </span></b><span
lang=BG>(a meal or a substantial snack). Swallow the capsules whole. <b>Do not
open the capsules.</b></span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you take more REYATAZ than you should</span></p>

<p class=EMEABodyText><span lang=BG>Yellowing of the skin and/or eyes
(jaundice) and irregular heart beat (QTc prolongation) may occur if you or your
child take too much REYATAZ.</span></p>

<p class=EMEABodyText><span lang=BG>If you accidentally take more REYATAZ
capsules than your doctor recommended, contact your HIV doctor at once or contact
the nearest hospital for advice.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you forget to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>If you miss a dose, take the missed dose as
soon as possible with food and then take your next scheduled dose at its
regular time. If it is almost time for your next dose, do not take the missed
dose. Wait and take the next dose at its regular time. <b>Do not take a double
dose to make up for a forgotten dose.</b></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>If you stop taking REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>Do not stop taking REYATAZ before talking
to your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>If you have any further questions on the
use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>Possible side effects</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Like all medicines, this medicine can cause
side effects, although not everybody gets them. When treating
HIV&nbsp;infection, it is not always easy to identify what side effects are
caused by REYATAZ, by the other medicines you are taking, or by the
HIV&nbsp;infection itself. Tell your doctor if you notice anything unusual
about your health.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor immediately if you develop
any of the following serious side effects:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Skin rash, itching that may occasionally be severe
has been reported. The rash usually disappears within 2&nbsp;weeks without any
change to your REYATAZ treatment. Severe rash may be developed in association
with other symptoms which could be serious. Stop taking REYATAZ and talk to
your doctor immediately if you develop a severe rash or a rash with flu-like
illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling
in the face, inflammation of the eye which causes redness (conjunctivitis),
painful, warm, or red lumps (nodules). </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Yellowing of your skin or the white part of your
eyes caused by high levels of bilirubin in your blood has been commonly
reported. This side effect is usually not dangerous in adults and infants older
than 3&nbsp;months of age; but it might be a symptom of a serious problem. If
your skin or the white part of your eyes turns yellow, talk to your doctor
immediately.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Changes in the way your heart beats (heart rhythm
change) may occasionally happen. Talk to your doctor immediately if you get
dizzy, lightheaded or if you suddenly faint. These could be symptoms of a
serious heart problem. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Liver problems may uncommonly happen. Your doctor
should do blood tests prior you start REYATAZ and during treatment. If you have
liver problems, including hepatitis B or C infection, you may experience a
worsening of your liver problems. Talk to your doctor immediately if you get
dark (tea-colored) urine, itching, yellowing of your skin or the white part of
your eyes, pain around the stomach, pale colored stools or nausea.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Gallbladder problems uncommonly happen in people
taking REYATAZ. Symptoms of gallbladder problems may include pain in the right
or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or
the white part of your eyes.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>REYATAZ may affect how well your kidneys work.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Kidney stones uncommonly happen in people taking
REYATAZ. Talk to your doctor immediately if you get symptoms of kidney stones
which may include, pain in your low back or low stomach-area, blood in your
urine or pain when you urinate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other side effects reported for patients
treated with REYATAZ are the following:</span></p>

<p class=EMEABodyText><span lang=BG>Common (may affect up to 1 in 10 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>headache</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>vomiting, diarrhoea, abdominal pain (stomach pain
of discomfort), nausea, dyspepsia (indigestion)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>fatigue (extreme tiredness)</span></p>

<p class=EMEABodyText><span lang=BG>Uncommon (may affect up to 1 in 100
people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>peripheral neuropathy (numbness, weakness, tingling
or pain in the arms and legs)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hypersensitivity (allergic reaction)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>asthenia (unusual tiredness or weakness)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>weight decreased, weight gain, anorexia (loss of
appetite), appetite increased</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>depression, anxiety, sleep disorder</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>disorientation, amnesia (loss of memory),
dizziness, somnolence (sleepiness), abnormal dream</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>syncope (fainting), hypertension (high blood
pressure)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>dyspnoea (shortness of breath)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>pancreatitis (inflammation of the pancreas),
gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and
cold sores), dysgeusia (impairment of the sense of taste), flatulence (wind),
dry mouth, abdominal distension</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>angioedema (severe swelling of the skin and other
tissues most often the lips or the eyes)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>alopecia (unusual hair loss or thinning), pruritus
(itching)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>muscle atrophy (muscle shrinkage), arthralgia
(joint pain), myalgia (aching muscles)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>interstitial nephritis (kidney inflammation),
haematuria (blood in the urine), proteinuria (excess protein in the urine),
pollakiuria (increased frequency of urination)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gynaecomastia (breast enlargement in men)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>chest pain, malaise (generally feeling unwell),
fever</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>insomnia (difficulty sleeping)</span></p>

<p class=EMEABodyText><span lang=BG>Rare (may affect up to 1 in 1,000 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gait disturbance (abnormal manner of walking)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>oedema (swelling)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hepatosplenomegaly (enlargement of the liver and
spleen)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>myopathy (aching muscles, muscle tenderness of
weakness, not caused by exercise)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>kidney pain</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=BG>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=BG>If you get any side effects, talk to your doctor or nurse.</span><span
lang=BG style='color:red'> </span><span lang=BG>This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via </span><span lang=BG style='background:lightgrey'>the national reporting
system listed in </span><span lang=BG><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not use this medicine after the expiry
date which is stated on the label, carton or blister. The expiry date refers to
the last day of that month.</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>Contents of the pack and other information</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ contains</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The active substance is atazanavir. Each capsule
contains 100&nbsp;mg of atazanavir (as sulphate). </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The other ingredients are crospovidone, lactose
monohydrate, and magnesium stearate. The capsule shell and printing ink contain
gelatine, shellac, ammonium hydroxide, simethicone, propylene glycol,
indigocarmin (E132) and titanium dioxide (E171).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ looks like and contents of the
pack</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>Each capsule of REYATAZ&nbsp;100 mg
contains 100&nbsp;mg atazanavir. </span></p>

<p class=EMEABodyText><span lang=BG>Opaque blue and white capsule printed with
white and blue inks, with &quot;BMS&nbsp;100&nbsp;mg&quot; on one half and with
&quot;3623&quot; on the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules are
supplied in bottles of 60&nbsp;capsules. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;100&nbsp;mg hard capsules are
also supplied in blister strips in packs of 60&nbsp;capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not all pack sizes may be marketed in all
countries. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Marketing Authorisation Holder</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Manufacturer</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=FR-BE>CATALENT ANAGNI S.R.L.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Loc. Fontana del Ceraso snc</span></p>

<p class=EMEABodyText><span lang=EN-GB>Strada Provinciale 12 Casilina, 41</span></p>

<p class=EMEABodyText><span lang=EN-GB>03012 Anagni (FR)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Swords
Laboratories T/A Bristol-Myers Squibb Pharmaceutical Operations, External
Manufacturing</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Plaza 254</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Blanchardstown
Corporate Park 2</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Dublin 15,
D15 T867</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>For any further information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Belgique/Belgi&euml;/Belgien</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 370
  52 369140</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Te&#1083;.:
  + 359 800 12 400</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-family:TimesNewRoman'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#268;esk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 420
  221 016 111</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Magyarorsz&aacute;g</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 36
  1 9206 550</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 45
  45 93 05 06</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Malta</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GmbH &amp; Co. KGaA</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 49
  89 121 42-0</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb B.V.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 31
  (0)30 300 2222</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 372
  640 1030</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Norge</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Norway Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 47
  67 55 53 50</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Ouml;sterreich</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GesmbH</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 43
  1 60 14 30</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Espa&ntilde;a</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 34
  91 456 53 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Polska</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 48
  22 5796666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>France</span></b></p>
  <p class=MsoNormal><span lang=BG>Bristol-Myers Squibb SARL</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l:
  + 33 (0) 1 58 83 84 96</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Farmac&ecirc;utica
  Portuguesa, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 351
  21 440 70 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Tel: +
  385 1 2078 508</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Rom&acirc;nia</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 40
  (0)21 272 16 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals uc</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 353
  (0)1 483 3625</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 386
  1 2355 100</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Iacute;sland</span></b></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Bristol-Myers
  Squibb AB hj&aacute; Vistor hf.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovensk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 421
  2 59298411</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Italia</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Oy Bristol-Myers Squibb (Finland) Ab</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Puh/Tel: +
  358 9 251 21 230</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb AB</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 46
  8 704 71 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Latvija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 371
  67708347</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>United
  Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 44
  (0800) 731 1736</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><b><span lang=BG>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Other sources of information</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicine is available
on the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=BG>Package leaflet: Information for the user</span></p>

<p class=EMEATitle>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center'><b><span lang=BG>REYATAZ&nbsp;150&nbsp;mg
hard capsules</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you have any further questions, ask your doctor
or pharmacist.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>This medicine has been prescribed for you only. Do
not pass it on to others.<br>
It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you get any side effects talk to your doctor, or
pharmacist. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4.</span></p>

<p class=EMEABodyText><b><span lang=BG>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=BG>What is in this leaflet</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and what it is used for</span></p>

<p class=EMEABodyText><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></p>

<p class=EMEABodyText><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>What REYATAZ is and What it is used for</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is an antiviral (or
antiretroviral) medicine. </span></b><span lang=BG>It is one of a group called <i>protease
inhibitors</i>. These medicines control Human Immunodeficiency Virus (HIV)
infection by stopping a protein that the HIV needs for its multiplication. They
work by reducing the amount of HIV in your body and this in turn, strengthens
your immune system. In this way REYATAZ reduces the risk of developing
illnesses linked to HIV&nbsp;infection.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ capsules may be used by adults and
children 6&nbsp;years of age and older. Your doctor has prescribed REYATAZ for
you because you are infected by the HIV that causes Acquired Immunodeficiency
Syndrome (AIDS). It is normally used in combination with other anti-HIV
medicines. Your doctor will discuss with you which combination of these
medicines with REYATAZ is best for you.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Do not take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are allergic </span></b><span lang=BG>to
atazanavir or any of the other ingredients of this medicine (listed in
section&nbsp;6)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you have moderate to severe liver problems. </span></b><span
lang=BG>Your doctor will evaluate how severe your liver disease is before
deciding whether you can take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are taking any of these medicines: </span></b><span
lang=BG>see also <i>Other medicines and REYATAZ</i></span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>rifampicin (an antibiotic used to treat
tuberculosis)<span style='color:green'> </span></span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>astemizole or terfenadine (commonly used to treat
allergy symptoms, these medicines may be available without prescription);
cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide
(used to treat schizophrenia); quinidine or bepridil (used to correct heart
rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to
treat headaches); and alfuzosin (used to treat enlarged prostatic gland)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder); lurasidone (used to treat
schizophrenia)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>medicines containing
St.&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum</i>, a herbal
preparation)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>triazolam and oral (taken by mouth) midazolam (used
to help you sleep and/or to relieve anxiety)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>simvastatin and lovastatin (used to lower blood
cholesterol).</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>grazoprevir-containing products, including
elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed
dose combination (used to treat chronic hepatitis&nbsp;C infection)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not take sildenafil with REYATAZ when
sildenafil is used for the treatment of pulmonary arterial hypertension.
Sildenafil is also used for the treatment of erectile dysfunction. Tell your
doctor if you are using sildenafil for the treatment of erectile dysfunction.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor at once if any of these
apply to you.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Warnings and precautions</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is not a cure for
HIV&nbsp;infection. </span></b><span lang=BG>You may continue to develop
infections or other illnesses linked to HIV&nbsp;infection. You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy. Discuss with your doctor the precautions needed to
avoid infecting other people.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some people will need special care before
or while taking REYATAZ. Talk to your doctor or pharmacist before taking
REYATAZ and make sure your doctor knows:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you have hepatitis&nbsp;B or&nbsp;C</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you develop signs or symptoms of gall stones
(pain at the right side of your stomach)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you have type&nbsp;A or B&nbsp;haemophilia</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you require haemodialysis</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ may affect how well your kidneys
work.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Kidney stones have been reported in
patients taking REYATAZ. If you develop signs or symptoms of kidney stones
(pain in your side, blood in your urine, pain when you urinate), please inform
your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In some patients with advanced HIV
infection (AIDS) and a history of opportunistic infection, signs and symptoms
of inflammation from previous infections may occur soon after anti-HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms. If you notice
any symptoms of infection, please inform your doctor immediately. In addition
to the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any
symptoms of infection or other symptoms such as muscle weakness, weakness
beginning in hands and feet and moving up towards the trunk of the body,
palpitations, tremor or hyperactivity, please inform your doctor immediately to
seek necessary treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some patients taking combination
antiretroviral therapy may develop a bone disease called osteonecrosis (death
of bone tissue caused by loss of blood supply to the bone). The length of
combination antiretroviral therapy, corticosteroid use, alcohol consumption,
severe immunosuppression, higher body mass index, among others, may be some of
the many risk factors for developing this disease. Signs of osteonecrosis are
joint stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty in movement. If you notice any of these symptoms please inform your
doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hyperbilirubinaemia (an increase in the
level of bilirubin in the blood) has occurred in patients receiving REYATAZ.
The signs may be a mild yellowing of the skin or eyes. If you notice any of
these symptoms please inform your doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Serious skin rash, including
Stevens-Johnson syndrome, has been reported in patients taking REYATAZ. If you
develop a rash inform your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>If you notice a change in the way your
heart beats (heart rhythm changes), please inform your doctor. Children
receiving REYATAZ may require their heart to be monitored. Your child's doctor
will decide this.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Children</span></b></p>

<p class=EMEABodyText><b><span lang=BG>Do not give this medicine to children</span></b><span
lang=BG> younger than 3&nbsp;months of age and weighing less than 5&nbsp;kg.
The use of REYATAZ in children less than 3&nbsp;months of age and weighing less
than 5&nbsp;kg has not been studied due to the risk of serious complications.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Other medicines and REYATAZ</span></p>

<p class=EMEABodyText><b><span lang=BG>You must not take REYATAZ with certain
medicines.</span></b><span lang=BG> These are listed under Do not take REYATAZ,
at the start of Section&nbsp;2. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are other medicines that may not mix
with REYATAZ. Tell your doctor if you are taking, have recently taken, or might
take any other medicines. It is especially important to mention these:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>other medicines to treat HIV&nbsp;infection (e.g.
indinavir, nevirapine and efavirenz)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>boceprevir and sofosbuvir/velpatasvir/voxilaprevir
(used to treat hepatitis&nbsp;C)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sildenafil, vardenafil, or tadalafil (used by men
to treat impotence (erectile dysfunction)) </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you are taking an oral contraceptive (<b>&quot;the
Pill&quot;</b>) with REYATAZ to prevent pregnancy, be sure to take it exactly
as instructed by your doctor and not miss any doses</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>any medicines used to treat diseases related to the
acid in the stomach (e.g. antacids to be taken 1&nbsp;hour before taking
REYATAZ or 2&nbsp;hours after taking REYATAZ, H<sub>2</sub>-blockers like
famotidine and proton pump inhibitors like omeprazole)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>medicines to lower blood pressure, to slow heart
rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine,
verapamil)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>atorvastatin, pravastatin, and fluvastatin (used to
lower blood cholesterol)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>salmeterol (used to treat asthma)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>cyclosporin, tacrolimus, and sirolimus (medicines
to decrease the effects of body's immune system)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>certain antibiotics (rifabutin, clarithromycin)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>ketoconazole, itraconazole, and voriconazole
(antifungals)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>warfarin (anticoagulant, used to reduce the blood
clots)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>carbamazepine, phenytoin, phenobarbital,
lamotrigine (antiepileptics)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>irinotecan (used to treat cancer)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sedative agents (e.g. midazolam administered by
injection)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>buprenorphine (used to treat opioid addiction and
pain).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some medicines may interact with ritonavir,
a medicine that is taken with REYATAZ. It is important to tell your doctor if
you are taking fluticasone or budesonide (given by nose or inhaled to treat
allergic symptoms or asthma).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ with food and drink</span></p>

<p class=EMEABodyText><span lang=BG>It is important that you take REYATAZ with
food (a meal or a substantial snack) as this helps the body absorb the
medicine.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Pregnancy and breast-feeding</span></p>

<p class=EMEABodyText><span lang=BG>If you are pregnant or breast-feeding,
think that you may be pregnant or are planning to have a baby, ask your doctor
for advice before taking this medicine. Atazanavir, the active substance of
REYATAZ, is excreted in human milk. Patients should not breast-feed while
taking REYATAZ. It is recommended that women infected with HIV do not
breast-feed because the virus might be transmitted through the breast milk.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=BG>If you feel dizzy or lightheaded, do not
drive or use machines and contact your doctor immediately.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ contains lactose.</span></p>

<p class=EMEABodyText><span lang=BG>If you have been told by your doctor that
you have an intolerance to some sugars (e.g. lactose), contact your doctor
before taking this medicinal product.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>How to take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Always take this medicine exactly as your
doctor has told you. Check with your doctor if you are not sure. This way, you
can be sure your medicine is fully effective and you reduce the risk of the
virus developing resistance to the treatment. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>The recommended adult dose of REYATAZ
capsules is 300&nbsp;mg once daily with 100&nbsp;mg ritonavir once daily and
with food, </span></b><span lang=BG>in combination with other anti-HIV
medicines. Your doctor may adjust the dose of REYATAZ according to your
anti-HIV therapy.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText style='margin-bottom:3.0pt'><b><span lang=BG>For children
(6 to less than 18&nbsp;years of age), your child's doctor will decide the
right dose based on your child's weight. </span></b><span lang=BG>The dose of
REYATAZ capsules for children is calculated by body weight and is taken once
daily with food and 100&nbsp;mg ritonavir as shown below:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Body Weight</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(kg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>REYATAZ Dose once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Ritonavir Dose* once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>15
  to less than 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>200</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>at
  least 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>300</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:9.0pt'>*Ritonavir capsules, tablets or oral solution may be
  used.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ is also available as an oral powder
for use in children at least 3&nbsp;months old and weighing at least 5&nbsp;kg.
Switching to REYATAZ capsules from REYATAZ oral powder is encouraged as soon as
patients are able to consistently swallow capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>A change in dose may occur when switching
between oral powder and capsules. Your doctor will decide the right dose based
on your child&#8217;s weight.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are no dosing recommendations for
REYATAZ in paediatric patients less than 3&nbsp;months of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Take REYATAZ capsules with food </span></b><span
lang=BG>(a meal or a substantial snack). Swallow the capsules whole. <b>Do not
open the capsules.</b></span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you take more REYATAZ than you should</span></p>

<p class=EMEABodyText><span lang=BG>Yellowing of the skin and/or eyes
(jaundice) and irregular heart beat (QTc prolongation) may occur if you or your
child take too much REYATAZ.</span></p>

<p class=EMEABodyText><span lang=BG>If you accidentally take more REYATAZ
capsules than your doctor recommended, contact your HIV doctor at once or
contact the nearest hospital for advice.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you forget to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>If you miss a dose, take the missed dose as
soon as possible with food and then take your next scheduled dose at its regular
time. If it is almost time for your next dose, do not take the missed dose.
Wait and take the next dose at its regular time. <b>Do not take a double dose
to make up for a forgotten dose.</b></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>If you stop taking REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>Do not stop taking REYATAZ before talking
to your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>If you have any further questions on the
use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>Possible side effects</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Like all medicines, this medicine can cause
side effects, although not everybody gets them. When treating HIV&nbsp;infection,
it is not always easy to identify what side effects are caused by REYATAZ, by
the other medicines you are taking, or by the HIV&nbsp;infection itself. Tell
your doctor if you notice anything unusual about your health.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor immediately if you develop
any of the following serious side effects:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Skin rash, itching that may occasionally be severe
has been reported. The rash usually disappears within 2&nbsp;weeks without any
change to your REYATAZ treatment. Severe rash may be developed in association
with other symptoms which could be serious. Stop taking REYATAZ and talk to
your doctor immediately if you develop a severe rash or a rash with flu-like
illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling
in the face, inflammation of the eye which causes redness (conjunctivitis),
painful, warm, or red lumps (nodules). </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Yellowing of your skin or the white part of your
eyes caused by high levels of bilirubin in your blood has been commonly
reported. This side effect is usually not dangerous in adults and infants older
than 3&nbsp;months of age; but it might be a symptom of a serious problem. If
your skin or the white part of your eyes turns yellow, talk to your doctor
immediately.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Changes in the way your heart beats (heart rhythm
change) may occasionally happen. Talk to your doctor immediately if you get
dizzy, lightheaded or if you suddenly faint. These could be symptoms of a
serious heart problem. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Liver problems may uncommonly happen. Your doctor
should do blood tests prior you start REYATAZ and during treatment. If you have
liver problems, including hepatitis B or C infection, you may experience a
worsening of your liver problems. Talk to your doctor immediately if you get
dark (tea-colored) urine, itching, yellowing of your skin or the white part of
your eyes, pain around the stomach, pale colored stools or nausea.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Gallbladder problems uncommonly happen in people
taking REYATAZ. Symptoms of gallbladder problems may include pain in the right
or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or
the white part of your eyes.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>REYATAZ may affect how well your kidneys work.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Kidney stones uncommonly happen in people taking
REYATAZ. Talk to your doctor immediately if you get symptoms of kidney stones
which may include, pain in your low back or low stomach-area, blood in your
urine or pain when you urinate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other side effects reported for patients
treated with REYATAZ are the following:</span></p>

<p class=EMEABodyText><span lang=BG>Common (may affect up to 1 in 10 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>headache</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>vomiting, diarrhoea, abdominal pain (stomach pain
of discomfort), nausea, dyspepsia (indigestion)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>fatigue (extreme tiredness)</span></p>

<p class=EMEABodyText><span lang=BG>Uncommon (may affect up to 1 in 100
people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>peripheral neuropathy (numbness, weakness, tingling
or pain in the arms and legs)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hypersensitivity (allergic reaction)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>asthenia (unusual tiredness or weakness)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>weight decreased, weight gain, anorexia (loss of
appetite), appetite increased</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>depression, anxiety, sleep disorder</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>disorientation, amnesia (loss of memory),
dizziness, somnolence (sleepiness), abnormal dream</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>syncope (fainting), hypertension (high blood
pressure)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>dyspnoea (shortness of breath)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>pancreatitis (inflammation of the pancreas),
gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and
cold sores), dysgeusia (impairment of the sense of taste), flatulence (wind),
dry mouth, abdominal distension</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>angioedema (severe swelling of the skin and other
tissues most often the lips or the eyes)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>alopecia (unusual hair loss or thinning), pruritus
(itching)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>muscle atrophy (muscle shrinkage), arthralgia
(joint pain), myalgia (aching muscles)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>, interstitial nephritis (kidney inflammation),
haematuria (blood in the urine), proteinuria (excess protein in the urine),
pollakiuria (increased frequency of urination)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gynaecomastia (breast enlargement in men)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>chest pain, malaise (generally feeling unwell),
fever</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>insomnia (difficulty sleeping)</span></p>

<p class=EMEABodyText><span lang=BG>Rare (may affect up to 1 in 1,000 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gait disturbance (abnormal manner of walking)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>oedema (swelling)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hepatosplenomegaly (enlargement of the liver and
spleen)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>myopathy (aching muscles, muscle tenderness of
weakness, not caused by exercise)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>kidney pain</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=BG>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=BG>If you get any side effects, talk to your doctor or nurse.</span><span
lang=BG style='color:red'> </span><span lang=BG>This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via </span><span lang=BG style='background:lightgrey'>the national reporting
system listed in </span><span lang=BG><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not use this medicine after the expiry
date which is stated on the label, carton or blister. The expiry date refers to
the last day of that month.</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ contains</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The active substance is atazanavir. Each capsule
contains 150&nbsp;mg of atazanavir (as sulphate). </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The other ingredients are crospovidone, lactose
monohydrate, and magnesium stearate. The capsule shell and printing ink contain
gelatine, shellac, ammonium hydroxide, simethicone, propylene glycol,
indigocarmin (E132) and titanium dioxide (E171).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ looks like and contents of the
pack</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>Each capsule of REYATAZ&nbsp;150 mg
contains 150&nbsp;mg atazanavir. </span></p>

<p class=EMEABodyText><span lang=BG>Opaque blue and powder blue capsule printed
with white and blue inks, with &quot;BMS&nbsp;150&nbsp;mg&quot; on one half and
with &quot;3624&quot; on the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules are
supplied in bottles of 60&nbsp;capsules. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;150&nbsp;mg hard capsules are
also supplied in blister strips in packs of 60&nbsp;capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not all pack sizes may be marketed in all
countries. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Marketing Authorisation Holder</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=MsoNormal><span lang=BG>&nbsp;</span></p>

<p class=EMEAAddress><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Manufacturer</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=FR-BE>CATALENT ANAGNI S.R.L.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Loc. Fontana del Ceraso snc</span></p>

<p class=EMEABodyText><span lang=EN-GB>Strada Provinciale 12 Casilina, 41</span></p>

<p class=EMEABodyText><span lang=EN-GB>03012 Anagni (FR)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Swords
Laboratories T/A Bristol-Myers Squibb Pharmaceutical Operations, External
Manufacturing</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Plaza 254</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Blanchardstown
Corporate Park 2</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Dublin 15,
D15 T867</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>For any further information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Belgique/Belgi&euml;/Belgien</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 370
  52 369140</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Te&#1083;.:
  + 359 800 12 400</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-family:TimesNewRoman'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#268;esk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 420
  221 016 111</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Magyarorsz&aacute;g</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 36
  1 9206 550</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 45
  45 93 05 06</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Malta</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GmbH &amp; Co. KGaA</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 49
  89 121 42-0</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb B.V.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 31
  (0)30 300 2222</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 372
  640 1030</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Norge</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Norway Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 47
  67 55 53 50</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Ouml;sterreich</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GesmbH</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 43
  1 60 14 30</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Espa&ntilde;a</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 34
  91 456 53 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Polska</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 48
  22 5796666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>France</span></b></p>
  <p class=MsoNormal><span lang=BG>Bristol-Myers Squibb SARL</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l:
  + 33 (0) 1 58 83 84 96</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Farmac&ecirc;utica
  Portuguesa, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 351
  21 440 70 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Tel: +
  385 1 2078 508</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Rom&acirc;nia</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 40
  (0)21 272 16 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals uc</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 353
  (0)1 483 3625</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 386
  1 2355 100</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Iacute;sland</span></b></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Bristol-Myers
  Squibb AB hj&aacute; Vistor hf.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovensk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 421
  2 59298411</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Italia</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Oy Bristol-Myers Squibb (Finland) Ab</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Puh/Tel: +
  358 9 251 21 230</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb AB</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 46
  8 704 71 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Latvija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 371
  67708347</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>United
  Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 44
  (0800) 731 1736</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><b><span lang=BG>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Other sources of information</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=BG>Package leaflet: Information for the user</span></p>

<p class=EMEATitle>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center'><b><span lang=BG>REYATAZ&nbsp;200&nbsp;mg
hard capsules</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you have any further questions, ask your doctor
or pharmacist.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>This medicine has been prescribed for you only. Do
not pass it on to others.<br>
It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you get any side effects talk to your doctor, or
pharmacist. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4.</span></p>

<p class=EMEABodyText><b><span lang=BG>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=BG>What is in this leaflet</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and what it is used for</span></p>

<p class=EMEABodyText><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></p>

<p class=EMEABodyText><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>What REYATAZ is and What it is used for</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is an antiviral (or
antiretroviral) medicine. </span></b><span lang=BG>It is one of a group called <i>protease
inhibitors</i>. These medicines control Human Immunodeficiency Virus (HIV)
infection by stopping a protein that the HIV needs for its multiplication. They
work by reducing the amount of HIV in your body and this in turn, strengthens
your immune system. In this way REYATAZ reduces the risk of developing
illnesses linked to HIV&nbsp;infection.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ capsules may be used by adults and
children 6&nbsp;years of age and older. Your doctor has prescribed REYATAZ for
you because you are infected by the HIV that causes Acquired Immunodeficiency
Syndrome (AIDS). It is normally used in combination with other anti-HIV
medicines. Your doctor will discuss with you which combination of these
medicines with REYATAZ is best for you.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Do not take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are allergic </span></b><span lang=BG>to
atazanavir or any of the other ingredients of this medicine (listed in section&nbsp;6)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you have moderate to severe liver problems. </span></b><span
lang=BG>Your doctor will evaluate how severe your liver disease is before
deciding whether you can take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are taking any of these medicines: </span></b><span
lang=BG>see also <i>Other medicines and REYATAZ</i></span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>rifampicin (an antibiotic used to treat
tuberculosis)<span style='color:green'> </span></span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>astemizole or terfenadine (commonly used to treat
allergy symptoms, these medicines may be available without prescription);
cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide
(used to treat schizophrenia); quinidine or bepridil (used to correct heart
rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to
treat headaches); and alfuzosin (used to treat enlarged prostatic gland)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder); lurasidone (used to treat
schizophrenia)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>medicines containing
St.&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum</i>, a herbal
preparation)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>triazolam and oral (taken by mouth) midazolam (used
to help you sleep and/or to relieve anxiety)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>simvastatin and lovastatin (used to lower blood
cholesterol).</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>grazoprevir-containing products, including
elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed
dose combination (used to treat chronic hepatitis&nbsp;C infection)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not take sildenafil with REYATAZ when
sildenafil is used for the treatment of pulmonary arterial hypertension.
Sildenafil is also used for the treatment of erectile dysfunction. Tell your
doctor if you are using sildenafil for the treatment of erectile dysfunction.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor at once if any of these
apply to you.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Warnings and precautions</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is not a cure for
HIV&nbsp;infection. </span></b><span lang=BG>You may continue to develop
infections or other illnesses linked to HIV&nbsp;infection. You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy. Discuss with your doctor the precautions needed to
avoid infecting other people.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some people will need special care before
or while taking REYATAZ. Talk to your doctor or pharmacist before taking
REYATAZ and make sure your doctor knows:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you have hepatitis&nbsp;B or&nbsp;C</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you develop signs or symptoms of gall stones
(pain at the right side of your stomach)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you have type&nbsp;A or B&nbsp;haemophilia</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you require haemodialysis</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ may affect how well your kidneys
work.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Kidney stones have been reported in
patients taking REYATAZ. If you develop signs or symptoms of kidney stones
(pain in your side, blood in your urine, pain when you urinate), please inform
your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In some patients with advanced HIV
infection (AIDS) and a history of opportunistic infection, signs and symptoms
of inflammation from previous infections may occur soon after anti-HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms. If you notice
any symptoms of infection, please inform your doctor immediately. In addition to
the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any
symptoms of infection or other symptoms such as muscle weakness, weakness
beginning in hands and feet and moving up towards the trunk of the body,
palpitations, tremor or hyperactivity, please inform your doctor immediately to
seek necessary treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some patients taking combination
antiretroviral therapy may develop a bone disease called osteonecrosis (death
of bone tissue caused by loss of blood supply to the bone). The length of
combination antiretroviral therapy, corticosteroid use, alcohol consumption,
severe immunosuppression, higher body mass index, among others, may be some of
the many risk factors for developing this disease. Signs of osteonecrosis are
joint stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty in movement. If you notice any of these symptoms please inform your
doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hyperbilirubinaemia (an increase in the
level of bilirubin in the blood) has occurred in patients receiving REYATAZ.
The signs may be a mild yellowing of the skin or eyes. If you notice any of
these symptoms please inform your doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Serious skin rash, including
Stevens-Johnson syndrome, has been reported in patients taking REYATAZ. If you
develop a rash inform your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>If you notice a change in the way your
heart beats (heart rhythm changes), please inform your doctor. Children
receiving REYATAZ may require their heart to be monitored. Your child's doctor
will decide this.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Children</span></b></p>

<p class=EMEABodyText><b><span lang=BG>Do not give this medicine to children</span></b><span
lang=BG> younger than 3&nbsp;months of age and weighing less than 5&nbsp;kg.
The use of REYATAZ in children less than 3&nbsp;months of age and weighing less
than 5&nbsp;kg has not been studied due to the risk of serious complications.</span></p>

<p class=EMEABodyText><s><span style='text-decoration:none'>&nbsp;</span></s></p>

<p class=EMEAHeading2><span lang=BG>Other medicines and REYATAZ</span></p>

<p class=EMEABodyText><b><span lang=BG>You must not take REYATAZ with certain
medicines.</span></b><span lang=BG> These are listed under Do not take REYATAZ,
at the start of Section&nbsp;2. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are other medicines that may not mix
with REYATAZ. Tell your doctor if you are taking, have recently taken, or might
take any other medicines. It is especially important to mention these:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>other medicines to treat HIV&nbsp;infection (e.g.
indinavir, nevirapine and efavirenz)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>boceprevir and sofosbuvir/velpatasvir/voxilaprevir
(used to treat hepatitis&nbsp;C)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sildenafil, vardenafil, or tadalafil (used by men
to treat impotence (erectile dysfunction)) </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you are taking an oral contraceptive (<b>&quot;the
Pill&quot;</b>) with REYATAZ to prevent pregnancy, be sure to take it exactly
as instructed by your doctor and not miss any doses</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>any medicines used to treat diseases related to the
acid in the stomach (e.g. antacids to be taken 1&nbsp;hour before taking
REYATAZ or 2&nbsp;hours after taking REYATAZ, H<sub>2</sub>-blockers like
famotidine and proton pump inhibitors like omeprazole)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>medicines to lower blood pressure, to slow heart
rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine,
verapamil)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>atorvastatin, pravastatin, and fluvastatin (used to
lower blood cholesterol)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>salmeterol (used to treat asthma)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>cyclosporin, tacrolimus, and sirolimus (medicines
to decrease the effects of body's immune system)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>certain antibiotics (rifabutin, clarithromycin)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>ketoconazole, itraconazole, and voriconazole
(antifungals)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>warfarin (anticoagulant, used to reduce the blood
clots)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>carbamazepine, phenytoin, phenobarbital,
lamotrigine (antiepileptics)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>irinotecan (used to treat cancer)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sedative agents (e.g. midazolam administered by
injection)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>buprenorphine (used to treat opioid addiction and
pain).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some medicines may interact with ritonavir,
a medicine that is taken with REYATAZ. It is important to tell your doctor if
you are taking fluticasone or budesonide (given by nose or inhaled to treat
allergic symptoms or asthma).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ with food and drink</span></p>

<p class=EMEABodyText><span lang=BG>It is important that you take REYATAZ with
food (a meal or a substantial snack) as this helps the body absorb the
medicine.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Pregnancy and breast-feeding</span></p>

<p class=EMEABodyText><span lang=BG>If you are pregnant or breast-feeding,
think that you may be pregnant or are planning to have a baby, ask your doctor
for advice before taking this medicine. Atazanavir, the active substance of REYATAZ,
is excreted in human milk. Patients should not breast-feed while taking
REYATAZ. It is recommended that women infected with HIV do not breast-feed
because the virus might be transmitted through the breast milk.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=BG>If you feel dizzy or lightheaded, do not
drive or use machines and contact your doctor immediately.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ contains lactose.</span></p>

<p class=EMEABodyText><span lang=BG>If you have been told by your doctor that
you have an intolerance to some sugars (e.g. lactose), contact your doctor
before taking this medicinal product.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Always take this medicine exactly as your
doctor has told you. Check with your doctor if you are not sure. This way, you
can be sure your medicine is fully effective and you reduce the risk of the
virus developing resistance to the treatment. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>The recommended adult dose of REYATAZ
capsules is 300&nbsp;mg once daily with 100&nbsp;mg ritonavir once daily and
with food, </span></b><span lang=BG>in combination with other anti-HIV
medicines. Your doctor may adjust the dose of REYATAZ according to your
anti-HIV therapy.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText style='margin-bottom:3.0pt'><b><span lang=BG>For children
(6 to less than 18&nbsp;years of age), your child's doctor will decide the
right dose based on your child's weight. </span></b><span lang=BG>The dose of
REYATAZ capsules for children is calculated by body weight and is taken once
daily with food and 100&nbsp;mg ritonavir as shown below:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Body Weight</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(kg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>REYATAZ Dose once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Ritonavir Dose* once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>15
  to less than 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>200</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>at
  least 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>300</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:9.0pt'>*Ritonavir capsules, tablets or oral solution may be
  used.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ is also available as an oral powder
for use in children at least 3&nbsp;months old and weighing at least 5&nbsp;kg.
Switching to REYATAZ capsules from REYATAZ oral powder is encouraged as soon as
patients are able to consistently swallow capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>A change in dose may occur when switching
between oral powder and capsules. Your doctor will decide the right dose based
on your child&#8217;s weight.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are no dosing recommendations for
REYATAZ in paediatric patients less than 3&nbsp;months of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Take REYATAZ capsules with food </span></b><span
lang=BG>(a meal or a substantial snack). Swallow the capsules whole. <b>Do not
open the capsules.</b></span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you take more REYATAZ than you should</span></p>

<p class=EMEABodyText><span lang=BG>Yellowing of the skin and/or eyes
(jaundice) and irregular heart beat (QTc prolongation) may occur if you or your
child take too much REYATAZ.</span></p>

<p class=EMEABodyText><span lang=BG>If you accidentally take more REYATAZ
capsules than your doctor recommended, contact your HIV doctor at once or
contact the nearest hospital for advice.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you forget to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>If you miss a dose, take the missed dose as
soon as possible with food and then take your next scheduled dose at its
regular time. If it is almost time for your next dose, do not take the missed
dose. Wait and take the next dose at its regular time. <b>Do not take a double
dose to make up for a forgotten dose.</b></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>If you stop taking REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>Do not stop taking REYATAZ before talking
to your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>If you have any further questions on the
use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>Possible side effects</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Like all medicines, this medicine can cause
side effects, although not everybody gets them. When treating
HIV&nbsp;infection, it is not always easy to identify what side effects are
caused by REYATAZ, by the other medicines you are taking, or by the
HIV&nbsp;infection itself. Tell your doctor if you notice anything unusual
about your health.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor immediately if you develop
any of the following serious side effects:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Skin rash, itching that may occasionally be severe
has been reported. The rash usually disappears within 2&nbsp;weeks without any
change to your REYATAZ treatment. Severe rash may be developed in association
with other symptoms which could be serious. Stop taking REYATAZ and talk to
your doctor immediately if you develop a severe rash or a rash with flu-like
illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling
in the face, inflammation of the eye which causes redness (conjunctivitis),
painful, warm, or red lumps (nodules). </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Yellowing of your skin or the white part of your
eyes caused by high levels of bilirubin in your blood has been commonly
reported. This side effect is usually not dangerous in adults and infants older
than 3&nbsp;months of age; but it might be a symptom of a serious problem. If
your skin or the white part of your eyes turns yellow, talk to your doctor immediately.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Changes in the way your heart beats (heart rhythm
change) may occasionally happen. Talk to your doctor immediately if you get
dizzy, lightheaded or if you suddenly faint. These could be symptoms of a
serious heart problem. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Liver problems may uncommonly happen. Your doctor
should do blood tests prior you start REYATAZ and during treatment. If you have
liver problems, including hepatitis B or C infection, you may experience a
worsening of your liver problems. Talk to your doctor immediately if you get
dark (tea-colored) urine, itching, yellowing of your skin or the white part of
your eyes, pain around the stomach, pale colored stools or nausea.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Gallbladder problems uncommonly happen in people
taking REYATAZ. Symptoms of gallbladder problems may include pain in the right
or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or
the white part of your eyes.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>REYATAZ may affect how well your kidneys work.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Kidney stones uncommonly happen in people taking
REYATAZ. Talk to your doctor immediately if you get symptoms of kidney stones
which may include, pain in your low back or low stomach-area, blood in your
urine or pain when you urinate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other side effects reported for patients
treated with REYATAZ are the following:</span></p>

<p class=EMEABodyText><span lang=BG>Common (may affect up to 1 in 10 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>headache</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>vomiting, diarrhoea, abdominal pain (stomach pain
of discomfort), nausea, dyspepsia (indigestion)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>fatigue (extreme tiredness)</span></p>

<p class=EMEABodyText><span lang=BG>Uncommon (may affect up to 1 in 100
people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>peripheral neuropathy (numbness, weakness, tingling
or pain in the arms and legs)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hypersensitivity (allergic reaction)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>asthenia (unusual tiredness or weakness)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>weight decreased, weight gain, anorexia (loss of
appetite), appetite increased</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>depression, anxiety, sleep disorder</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>disorientation, amnesia (loss of memory),
dizziness, somnolence (sleepiness), abnormal dream</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>syncope (fainting), hypertension (high blood
pressure)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>dyspnoea (shortness of breath)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>pancreatitis (inflammation of the pancreas),
gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and
cold sores), dysgeusia (impairment of the sense of taste), flatulence (wind),
dry mouth, abdominal distension</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>angioedema (severe swelling of the skin and other
tissues most often the lips or the eyes)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>alopecia (unusual hair loss or thinning), pruritus
(itching)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>muscle atrophy (muscle shrinkage), arthralgia
(joint pain), myalgia (aching muscles)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>interstitial nephritis (kidney inflammation),
haematuria (blood in the urine), proteinuria (excess protein in the urine),
pollakiuria (increased frequency of urination)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gynaecomastia (breast enlargement in men)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>chest pain, malaise (generally feeling unwell),
fever</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>insomnia (difficulty sleeping)</span></p>

<p class=EMEABodyText><span lang=BG>Rare (may affect up to 1 in 1,000 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gait disturbance (abnormal manner of walking)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>oedema (swelling)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hepatosplenomegaly (enlargement of the liver and
spleen)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>myopathy (aching muscles, muscle tenderness of
weakness, not caused by exercise)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>kidney pain</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=BG>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=BG>If you get any side effects, talk to your doctor or nurse.</span><span
lang=BG style='color:red'> </span><span lang=BG>This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via </span><span lang=BG style='background:lightgrey'>the national reporting
system listed in </span><span lang=BG><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not use this medicine after the expiry
date which is stated on the label, carton or blister. The expiry date refers to
the last day of that month.</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines you
no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ contains</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The active substance is atazanavir. Each capsule
contains 200&nbsp;mg of atazanavir (as sulphate). </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The other ingredients are crospovidone, lactose
monohydrate, and magnesium stearate. The capsule shell and printing ink contain
gelatine, shellac, ammonium hydroxide, simethicone, propylene glycol,
indigocarmin (E132) and titanium dioxide (E171).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ looks like and contents of the
pack</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>Each capsule of REYATAZ&nbsp;200 mg
contains 200&nbsp;mg atazanavir. </span></p>

<p class=EMEABodyText><span lang=BG>Opaque blue capsule printed with white ink,
with &quot;BMS&nbsp;200&nbsp;mg&quot; on one half and with &quot;3631&quot; on
the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules are
supplied in bottles of 60&nbsp;capsules. Either one or three bottles of
60&nbsp;hard capsules are provided in one carton.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;200&nbsp;mg hard capsules are
also supplied in blister strips in packs of 60&nbsp;capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not all pack sizes may be marketed in all
countries. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Marketing Authorisation Holder</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=EMEAAddress style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Manufacturer</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=EN-GB>CATALENT ANAGNI S.R.L.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Loc. Fontana del Ceraso snc</span></p>

<p class=EMEABodyText><span lang=EN-GB>Strada Provinciale 12 Casilina, 41</span></p>

<p class=EMEABodyText><span lang=EN-GB>03012 Anagni (FR)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Swords
Laboratories T/A Bristol-Myers Squibb Pharmaceutical Operations, External
Manufacturing</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Plaza 254</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Blanchardstown
Corporate Park 2</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Dublin 15,
D15 T867</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>For any further information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Belgique/Belgi&euml;/Belgien</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 370
  52 369140</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Te&#1083;.:
  + 359 800 12 400</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-family:TimesNewRoman'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#268;esk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 420
  221 016 111</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Magyarorsz&aacute;g</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 36
  1 9206 550</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 45
  45 93 05 06</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Malta</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GmbH &amp; Co. KGaA</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 49
  89 121 42-0</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb B.V.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 31
  (0)30 300 2222</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 372
  640 1030</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Norge</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Norway Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 47
  67 55 53 50</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Ouml;sterreich</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GesmbH</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 43
  1 60 14 30</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Espa&ntilde;a</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 34
  91 456 53 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Polska</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 48
  22 5796666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>France</span></b></p>
  <p class=MsoNormal><span lang=BG>Bristol-Myers Squibb SARL</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l:
  + 33 (0) 1 58 83 84 96</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Farmac&ecirc;utica
  Portuguesa, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 351
  21 440 70 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Tel: +
  385 1 2078 508</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Rom&acirc;nia</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 40
  (0)21 272 16 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals uc</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 353
  (0)1 483 3625</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 386
  1 2355 100</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Iacute;sland</span></b></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Bristol-Myers
  Squibb AB hj&aacute; Vistor hf.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovensk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 421
  2 59298411</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Italia</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Oy Bristol-Myers Squibb (Finland) Ab</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Puh/Tel: +
  358 9 251 21 230</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb AB</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 46
  8 704 71 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Latvija&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 371
  67708347</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>United
  Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 44
  (0800) 731 1736</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><b><span lang=BG>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Other sources of information</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=BG>Package leaflet: Information for the user</span></p>

<p class=EMEATitle>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center'><b><span lang=BG>REYATAZ&nbsp;300&nbsp;mg
hard capsules</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you have any further questions, ask your doctor
or pharmacist.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>This medicine has been prescribed for you only. Do
not pass it on to others.<br>
It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you get any side effects talk to your doctor, or
pharmacist. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4.</span></p>

<p class=EMEABodyText><b><span lang=BG>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=BG>What is in this leaflet</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and what it is used for</span></p>

<p class=EMEABodyText><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></p>

<p class=EMEABodyText><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>What REYATAZ is and What it is used for</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is an antiviral (or
antiretroviral) medicine. </span></b><span lang=BG>It is one of a group called <i>protease
inhibitors</i>. These medicines control Human Immunodeficiency Virus (HIV)
infection by stopping a protein that the HIV needs for its multiplication. They
work by reducing the amount of HIV in your body and this in turn, strengthens
your immune system. In this way REYATAZ reduces the risk of developing
illnesses linked to HIV&nbsp;infection.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ capsules may be used by adults and
children 6&nbsp;years of age and older. Your doctor has prescribed REYATAZ for
you because you are infected by the HIV that causes Acquired Immunodeficiency
Syndrome (AIDS). It is normally used in combination with other anti-HIV
medicines. Your doctor will discuss with you which combination of these medicines
with REYATAZ is best for you.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Do not take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are allergic </span></b><span lang=BG>to
atazanavir or any of the other ingredients of this medicine (listed in
section&nbsp;6)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you have moderate to severe liver problems. </span></b><span
lang=BG>Your doctor will evaluate how severe your liver disease is before
deciding whether you can take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are taking any of these medicines: </span></b><span
lang=BG>see also <i>Other medicines and REYATAZ</i></span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>rifampicin (an antibiotic used to treat
tuberculosis)<span style='color:green'> </span></span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>astemizole or terfenadine (commonly used to treat
allergy symptoms, these medicines may be available without prescription);
cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide
(used to treat schizophrenia); quinidine or bepridil (used to correct heart
rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to
treat headaches); and alfuzosin (used to treat enlarged prostatic gland)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder); lurasidone (used to treat
schizophrenia)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>medicines containing
St.&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum</i>, a herbal
preparation)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>triazolam and oral (taken by mouth) midazolam (used
to help you sleep and/or to relieve anxiety)</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>simvastatin and lovastatin (used to lower blood
cholesterol).</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.25pt;text-indent:-26.9pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>grazoprevir-containing products, including
elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed
dose combination (used to treat chronic hepatitis&nbsp;C infection)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not take sildenafil with REYATAZ when
sildenafil is used for the treatment of pulmonary arterial hypertension.
Sildenafil is also used for the treatment of erectile dysfunction. Tell your
doctor if you are using sildenafil for the treatment of erectile dysfunction.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor at once if any of these
apply to you.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Warnings and precautions</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is not a cure for
HIV&nbsp;infection. </span></b><span lang=BG>You may continue to develop
infections or other illnesses linked to HIV&nbsp;infection. You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy. Discuss with your doctor the precautions needed to
avoid infecting other people.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some people will need special care before
or while taking REYATAZ. Talk to your doctor or pharmacist before taking
REYATAZ and make sure your doctor knows:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you have hepatitis&nbsp;B or&nbsp;C</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you develop signs or symptoms of gall stones
(pain at the right side of your stomach)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you have type&nbsp;A or B&nbsp;haemophilia</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you require haemodialysis</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ may affect how well your kidneys
work.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Kidney stones have been reported in
patients taking REYATAZ. If you develop signs or symptoms of kidney stones
(pain in your side, blood in your urine, pain when you urinate), please inform
your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In some patients with advanced HIV
infection (AIDS) and a history of opportunistic infection, signs and symptoms
of inflammation from previous infections may occur soon after anti-HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms. If you notice
any symptoms of infection, please inform your doctor immediately. In addition
to the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any
symptoms of infection or other symptoms such as muscle weakness, weakness
beginning in hands and feet and moving up towards the trunk of the body,
palpitations, tremor or hyperactivity, please inform your doctor immediately to
seek necessary treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some patients taking combination
antiretroviral therapy may develop a bone disease called osteonecrosis (death
of bone tissue caused by loss of blood supply to the bone). The length of
combination antiretroviral therapy, corticosteroid use, alcohol consumption,
severe immunosuppression, higher body mass index, among others, may be some of
the many risk factors for developing this disease. Signs of osteonecrosis are
joint stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty in movement. If you notice any of these symptoms please inform your
doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hyperbilirubinaemia (an increase in the
level of bilirubin in the blood) has occurred in patients receiving REYATAZ.
The signs may be a mild yellowing of the skin or eyes. If you notice any of
these symptoms please inform your doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Serious skin rash, including
Stevens-Johnson syndrome, has been reported in patients taking REYATAZ. If you
develop a rash inform your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>If you notice a change in the way your
heart beats (heart rhythm changes), please inform your doctor. Children
receiving REYATAZ may require their heart to be monitored. Your child's doctor
will decide this.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Children </span></b></p>

<p class=EMEABodyText><b><span lang=BG>Do not give this medicine to children</span></b><span
lang=BG> younger than 3&nbsp;months of age and weighing less than 5&nbsp;kg.
The use of REYATAZ in children less than 3&nbsp;months of age and weighing less
than 5&nbsp;kg has not been studied due to the risk of serious complications.</span></p>

<p class=EMEABodyText><s><span style='text-decoration:none'>&nbsp;</span></s></p>

<p class=EMEAHeading2><span lang=BG>Other medicines and REYATAZ</span></p>

<p class=EMEABodyText><b><span lang=BG>You must not take REYATAZ with certain
medicines.</span></b><span lang=BG> These are listed under Do not take REYATAZ,
at the start of Section&nbsp;2. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are other medicines that may not mix
with REYATAZ. Tell your doctor if you are taking, have recently taken, or might
take any other medicines. It is especially important to mention these:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>other medicines to treat HIV&nbsp;infection (e.g.
indinavir, nevirapine and efavirenz)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>boceprevir and sofosbuvir/velpatasvir/voxilaprevir
(used to treat hepatitis&nbsp;C)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sildenafil, vardenafil, or tadalafil (used by men
to treat impotence (erectile dysfunction)) </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you are taking an oral contraceptive (<b>&quot;the
Pill&quot;</b>) with REYATAZ to prevent pregancy, be sure to take it exactly as
instructed by your doctor and not miss any doses</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>any medicines used to treat diseases related to the
acid in the stomach (e.g. antacids to be taken 1&nbsp;hour before taking
REYATAZ or 2&nbsp;hours after taking REYATAZ, H<sub>2</sub>-blockers like
famotidine and proton pump inhibitors like omeprazole)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>medicines to lower blood pressure, to slow heart
rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine,
verapamil)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>atorvastatin, pravastatin, and fluvastatin (used to
lower blood cholesterol)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>salmeterol (used to treat asthma)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>cyclosporin, tacrolimus, and sirolimus (medicines
to decrease the effects of body's immune system)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>certain antibiotics (rifabutin, clarithromycin)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>ketoconazole, itraconazole, and voriconazole
(antifungals)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>warfarin (anticoagulant, used to reduce the blood
clots)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>carbamazepine, phenytoin, phenobarbital,
lamotrigine (antiepileptics)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>irinotecan (used to treat cancer)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sedative agents (e.g. midazolam administered by
injection)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>buprenorphine (used to treat opioid addiction and
pain).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some medicines may interact with ritonavir,
a medicine that is taken with REYATAZ. It is important to tell your doctor if
you are taking fluticasone or budesonide (given by nose or inhaled to treat
allergic symptoms or asthma).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ with food and drink</span></p>

<p class=EMEABodyText><span lang=BG>It is important that you take REYATAZ with
food (a meal or a substantial snack) as this helps the body absorb the medicine.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Pregnancy and breast-feeding</span></p>

<p class=EMEABodyText><span lang=BG>If you are pregnant or breast-feeding,
think that you may be pregnant or are planning to have a baby, ask your doctor
for advice before taking this medicine. Atazanavir, the active substance of
REYATAZ, is excreted in human milk. Patients should not breast-feed while
taking REYATAZ. It is recommended that women infected with HIV do not
breast-feed because the virus might be transmitted through the breast milk.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=BG>If you feel dizzy or lightheaded, do not
drive or use machines and contact your doctor immediately.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ contains lactose.</span></p>

<p class=EMEABodyText><span lang=BG>If you have been told by your doctor that
you have an intolerance to some sugars (e.g. lactose), contact your doctor
before taking this medicinal product.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>How to take REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Always take this medicine exactly as your
doctor has told you. Check with your doctor if you are not sure. This way, you
can be sure your medicine is fully effective and you reduce the risk of the
virus developing resistance to the treatment. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>The recommended adult dose of REYATAZ
capsules is 300&nbsp;mg once daily with 100&nbsp;mg ritonavir once daily and
with food, </span></b><span lang=BG>in combination with other anti-HIV
medicines. Your doctor may adjust the dose of REYATAZ according to your
anti-HIV therapy.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText style='margin-bottom:3.0pt'><b><span lang=BG>For children
(6 to less than 18&nbsp;years of age), your child's doctor will decide the
right dose based on your child's weight. </span></b><span lang=BG>The dose of
REYATAZ capsules for children is calculated by body weight and is taken once
daily with food and 100&nbsp;mg ritonavir as shown below:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Body Weight</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(kg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>REYATAZ Dose once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Ritonavir Dose* once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>15
  to less than 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>200</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>at
  least 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>300</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=BG
  style='font-size:9.0pt'>*Ritonavir capsules, tablets or oral solution may be
  used.</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ is also available as an oral powder
for use in children at least 3&nbsp;months old and weighing at least 5&nbsp;kg.
Switching to REYATAZ capsules from REYATAZ oral powder is encouraged as soon as
patients are able to consistently swallow capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>A change in dose may occur when switching
between oral powder and capsules. Your doctor will decide the right dose based
on your child&#8217;s weight.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are no dosing recommendations for
REYATAZ in paediatric patients less than 3&nbsp;months of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Take REYATAZ capsules with food </span></b><span
lang=BG>(a meal or a substantial snack). Swallow the capsules whole. <b>Do not
open the capsules.</b></span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you take more REYATAZ than you should</span></p>

<p class=EMEABodyText><span lang=BG>Yellowing of the skin and/or eyes
(jaundice) and irregular heart beat (QTc prolongation) may occur if you or your
child take too much REYATAZ.</span></p>

<p class=EMEABodyText><span lang=BG>If you accidentally take more REYATAZ
capsules than your doctor recommended, contact your HIV doctor at once or
contact the nearest hospital for advice.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you forget to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>If you miss a dose, take the missed dose as
soon as possible with food and then take your next scheduled dose at its
regular time. If it is almost time for your next dose, do not take the missed
dose. Wait and take the next dose at its regular time. <b>Do not take a double
dose to make up for a forgotten dose.</b></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>If you stop taking REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>Do not stop taking REYATAZ before talking
to your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>If you have any further questions on the
use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>Possible side effects</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Like all medicines, this medicine can cause
side effects, although not everybody gets them. When treating
HIV&nbsp;infection, it is not always easy to identify what side effects are
caused by REYATAZ, by the other medicines you are taking, or by the
HIV&nbsp;infection itself. Tell your doctor if you notice anything unusual about
your health.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor immediately if you develop
any of the following serious side effects:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Skin rash, itching that may occasionally be severe
has been reported. The rash usually disappears within 2&nbsp;weeks without any
change to your REYATAZ treatment. Severe rash may be developed in association
with other symptoms which could be serious. Stop taking REYATAZ and talk to
your doctor immediately if you develop a severe rash or a rash with flu-like
illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling
in the face, inflammation of the eye which causes redness (conjunctivitis),
painful, warm, or red lumps (nodules). </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Yellowing of your skin or the white part of your
eyes caused by high levels of bilirubin in your blood has been commonly
reported. This side effect is usually not dangerous in adults and infants older
than 3&nbsp;months of age; but it might be a symptom of a serious problem. If
your skin or the white part of your eyes turns yellow, talk to your doctor immediately.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Changes in the way your heart beats (heart rhythm
change) may occasionally happen. Talk to your doctor immediately if you get
dizzy, lightheaded or if you suddenly faint. These could be symptoms of a
serious heart problem. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Liver problems may uncommonly happen. Your doctor
should do blood tests prior you start REYATAZ and during treatment. If you have
liver problems, including hepatitis B or C infection, you may experience a
worsening of your liver problems. Talk to your doctor immediately if you get
dark (tea-colored) urine, itching, yellowing of your skin or the white part of
your eyes, pain around the stomach, pale colored stools or nausea.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Gallbladder problems uncommonly happen in people
taking REYATAZ. Symptoms of gallbladder problems may include pain in the right
or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or
the white part of your eyes.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>REYATAZ may affect how well your kidneys work.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Kidney stones uncommonly happen in people taking
REYATAZ. Talk to your doctor immediately if you get symptoms of kidney stones
which may include, pain in your low back or low stomach-area, blood in your
urine or pain when you urinate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other side effects reported for patients
treated with REYATAZ are the following:</span></p>

<p class=EMEABodyText><span lang=BG>Common (may affect up to 1 in 10 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>headache</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>vomiting, diarrhoea, abdominal pain (stomach pain
of discomfort), nausea, dyspepsia (indigestion)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>fatigue (extreme tiredness)</span></p>

<p class=EMEABodyText><span lang=BG>Uncommon (may affect up to 1 in 100
people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>peripheral neuropathy (numbness, weakness, tingling
or pain in the arms and legs)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hypersensitivity (allergic reaction)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>asthenia (unusual tiredness or weakness)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>weight decreased, weight gain, anorexia (loss of
appetite), appetite increased</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>depression, anxiety, sleep disorder</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>disorientation, amnesia (loss of memory),
dizziness, somnolence (sleepiness), abnormal dream</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>syncope (fainting), hypertension (high blood
pressure)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>dyspnoea (shortness of breath)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>pancreatitis (inflammation of the pancreas),
gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and
cold sores), dysgeusia (impairment of the sense of taste), flatulence (wind),
dry mouth, abdominal distension</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>angioedema (severe swelling of the skin and other
tissues most often the lips or the eyes)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>alopecia (unusual hair loss or thinning), pruritus
(itching)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>muscle atrophy (muscle shrinkage), arthralgia
(joint pain), myalgia (aching muscles)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>interstitial nephritis (kidney inflammation),
haematuria (blood in the urine), proteinuria (excess protein in the urine),
pollakiuria (increased frequency of urination)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gynaecomastia (breast enlargement in men)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>chest pain, malaise (generally feeling unwell),
fever</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>insomnia (difficulty sleeping)</span></p>

<p class=EMEABodyText><span lang=BG>Rare (may affect up to 1 in 1,000 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gait disturbance (abnormal manner of walking)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>oedema (swelling)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hepatosplenomegaly (enlargement of the liver and
spleen)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>myopathy (aching muscles, muscle tenderness of
weakness, not caused by exercise)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>kidney pain</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=BG>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=BG>If you get any side effects, talk to your doctor or nurse.</span><span
lang=BG style='color:red'> </span><span lang=BG>This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via </span><span lang=BG style='background:lightgrey'>the national reporting
system listed in </span><span lang=BG><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not use this medicine after the expiry
date which is stated on the label, carton or blister. The expiry date refers to
the last day of that month.</span></p>

<p class=EMEABodyText><span lang=BG>Do not store above 25&deg;C.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines you
no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=BG style='text-transform:none'>Contents of the pack and other information</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ contains</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The active substance is atazanavir. Each capsule
contains 300&nbsp;mg of atazanavir (as sulphate). </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The other ingredients are crospovidone, lactose
monohydrate, and magnesium stearate. The capsule shell and printing ink contain
gelatine, shellac, ammonium hydroxide, simethicone, red iron oxide, black iron
oxide, yellow iron oxide, propylene glycol, indigocarmin (E132) and titanium
dioxide (E171).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ looks like and contents of the
pack</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>Each capsule of REYATAZ&nbsp;300 mg
contains 300&nbsp;mg atazanavir. </span></p>

<p class=EMEABodyText><span lang=BG>Opaque red and blue capsule printed with
white ink, with &quot;BMS&nbsp;300&nbsp;mg&quot; on one half and with
&quot;3622&quot; on the other half.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules are
supplied in bottles of 30&nbsp;capsules. Either one or three bottles of 30 hard
capsules are provided in one carton.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ&nbsp;300&nbsp;mg hard capsules are
also supplied in blister strips in packs of 30&nbsp;capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Not all pack sizes may be marketed in all
countries. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Marketing Authorisation Holder</span></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Manufacturer</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=EN-GB>CATALENT ANAGNI S.R.L.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Loc. Fontana del Ceraso snc</span></p>

<p class=EMEABodyText><span lang=EN-GB>Strada Provinciale 12 Casilina, 41</span></p>

<p class=EMEABodyText><span lang=EN-GB>03012 Anagni (FR)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Swords
Laboratories T/A Bristol-Myers Squibb Pharmaceutical Operations, External
Manufacturing</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Plaza 254</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Blanchardstown
Corporate Park 2</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Dublin 15,
D15 T867</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>For any further information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Belgique/Belgi&euml;/Belgien</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 370
  52 369140</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Te&#1083;.:
  + 359 800 12 400</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-family:TimesNewRoman'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#268;esk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 420
  221 016 111</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Magyarorsz&aacute;g</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 36
  1 9206 550</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 45
  45 93 05 06</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Malta</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GmbH &amp; Co. KGaA</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 49
  89 121 42-0</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb B.V.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 31
  (0)30 300 2222</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 372
  640 1030</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Norge</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Norway Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 47
  67 55 53 50</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Ouml;sterreich</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GesmbH</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 43
  1 60 14 30</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Espa&ntilde;a</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 34
  91 456 53 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Polska</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 48
  22 5796666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>France</span></b></p>
  <p class=MsoNormal><span lang=BG>Bristol-Myers Squibb SARL</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l:
  + 33 (0) 1 58 83 84 96</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Farmac&ecirc;utica
  Portuguesa, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 351
  21 440 70 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Tel: +
  385 1 2078 508</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Rom&acirc;nia</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 40
  (0)21 272 16 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals uc</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 353
  (0)1 483 3625</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 386
  1 2355 100</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Iacute;sland</span></b></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Bristol-Myers
  Squibb AB hj&aacute; Vistor hf.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovensk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 421
  2 59298411</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Italia</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Oy Bristol-Myers Squibb (Finland) Ab</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Puh/Tel: +
  358 9 251 21 230</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb AB</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 46
  8 704 71 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Latvija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 371
  67708347</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>United
  Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 44
  (0800) 731 1736</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><b><span lang=BG>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Other sources of information</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicine is available
on the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=BG>Package leaflet: Information for the user</span></p>

<p class=EMEATitle>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center'><b><span lang=BG>REYATAZ&nbsp;50&nbsp;mg
oral powder</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=BG>atazanavir</span></p>

<p class=EMEABodyText align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>Keep this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you have any further questions, ask your doctor
or pharmacist.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>This medicine has been prescribed for you only. Do
not pass it on to others.<br>
It may harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>If you get any side effects talk to your doctor, or
pharmacist. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4</span></p>

<p class=EMEABodyText><b><span lang=BG>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=BG>What is in this leaflet</span></b></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and what it is used for</span></p>

<p class=EMEABodyText><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects </span></p>

<p class=EMEABodyText><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
REYATAZ is and What it is used for</span></b></p>

<p class=EMEAHeading1><span style='font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is an antiviral (or
antiretroviral) medicine. </span></b><span lang=BG>It is one of a group called <i>protease
inhibitors</i>. These medicines control Human Immunodeficiency Virus (HIV)
infection by stopping a protein that the HIV needs for its multiplication. They
work by reducing the amount of HIV in your body and this in turn, strengthens
your immune system. In this way REYATAZ reduces the risk of developing
illnesses linked to HIV&nbsp;infection.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>REYATAZ oral powder may be used by children
at least 3&nbsp;months of age and weighing at least 5&nbsp;kg (see section 3
How to take REYATAZ). Your doctor has prescribed REYATAZ for you because you
are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS).
It should always be used with a low dose of ritonavir and in combination with
other anti-HIV medicines. Your doctor will discuss with you which combination
of these medicines with REYATAZ is best for you.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take REYATAZ</span></b></p>

<p class=EMEAHeading1><span style='font-weight:normal'>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=BG>Do not take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are allergic </span></b><span lang=BG>to
atazanavir or any of the other ingredients of this medicine (listed in
section&nbsp;6)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you have moderate to severe liver problems. </span></b><span
lang=BG>Your doctor will evaluate how severe your liver disease is before
deciding whether you can take REYATAZ</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=BG>if you are taking any of these medicines: </span></b><span
lang=BG>see also <i>Other medicines and REYATAZ</i></span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>rifampicin (an antibiotic used to treat
tuberculosis)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>astemizole or terfenadine (commonly used to treat
allergy symptoms, these medicines may be available without prescription);
cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide
(used to treat schizophrenia); quinidine or bepridil (used to correct heart
rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to
treat headaches); and alfuzosin (used to treat enlarged prostatic gland)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder); lurasidone (used to treat
schizophrenia)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>medicines containing
St.&nbsp;John&#8217;s&nbsp;wort<i> (Hypericum perforatum</i>, a herbal preparation)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>triazolam and oral (taken by mouth) midazolam (used
to help you sleep and/or to relieve anxiety)</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>simvastatin and lovastatin (used to lower blood
cholesterol).</span></p>

<p class=EMEABodyTextIndent style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>grazoprevir-containing products, including
elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed
dose combination (used to treat chronic hepatitis&nbsp;C infection)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not take sildenafil with REYATAZ when
sildenafil is used for the treatment of pulmonary arterial hypertension.
Sildenafil is also used for the treatment of erectile dysfunction. Tell your
doctor if you are using sildenafil for the treatment of erectile dysfunction.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor at once if any of these
apply to you.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Warnings and precautions</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>REYATAZ is not a cure for
HIV&nbsp;infection. </span></b><span lang=BG>You may continue to develop
infections or other illnesses linked to HIV&nbsp;infection. You can still pass
on HIV when taking this medicine, although the risk is lowered by effective
antiretroviral therapy. Discuss with your doctor the precautions needed to
avoid infecting other people.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some people will need special care before
or while taking REYATAZ. Talk to your doctor or pharmacist before taking
REYATAZ and make sure your doctor knows:</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you have hepatitis B or C</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you develop signs or symptoms of gall stones
(pain at the right side of your stomach)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you have type A or B haemophilia</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>if you require haemodialysis</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ may affect how well your kidneys
work.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Kidney stones have been reported in
patients taking REYATAZ. If you develop signs or symptoms of kidney stones
(pain in your side, blood in your urine, pain when you urinate), please inform
your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>In some patients with advanced HIV
infection (AIDS) and a history of opportunistic infection, signs and symptoms
of inflammation from previous infections may occur soon after anti-HIV
treatment is started. It is believed that these symptoms are due to an
improvement in the body&#8217;s immune response, enabling the body to fight
infections that may have been present with no obvious symptoms. If you notice
any symptoms of infection, please inform your doctor immediately. In addition
to the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any
symptoms of infection or other symptoms such as muscle weakness, weakness
beginning in hands and feet and moving up towards the trunk of the body,
palpitations, tremor or hyperactivity, please inform your doctor immediately to
seek necessary treatment.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some patients taking combination
antiretroviral therapy may develop a bone disease called osteonecrosis (death
of bone tissue caused by loss of blood supply to the bone). The length of
combination antiretroviral therapy, corticosteroid use, alcohol consumption,
severe immunosuppression, higher body mass index, among others, may be some of
the many risk factors for developing this disease. Signs of osteonecrosis are
joint stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty in movement. If you notice any of these symptoms please inform your
doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Hyperbilirubinaemia (an increase in the
level of bilirubin in the blood) has occurred in patients receiving REYATAZ.
The signs may be a mild yellowing of the skin or eyes. If you notice any of
these symptoms please inform your doctor.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Serious skin rash, including
Stevens-Johnson syndrome, has been reported in patients taking REYATAZ. If you
develop a rash inform your doctor immediately.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>If you notice a change in the way your
heart beats (heart rhythm changes), please inform your doctor. Children receiving
REYATAZ may require their heart to be monitored. Your child's doctor will
decide this.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Children</span></b></p>

<p class=EMEABodyText><b><span lang=BG>Do not give this medicine to children</span></b><span
lang=BG> younger than 3&nbsp;months of age and weighing less than 5&nbsp;kg.
The use of REYATAZ in children less than 3&nbsp;months of age and weighing less
than 5&nbsp;kg has not been studied due to the risk of serious complications.</span></p>

<p class=EMEABodyText><s><span style='text-decoration:none'>&nbsp;</span></s></p>

<p class=EMEAHeading2><span lang=BG>Other medicines and REYATAZ</span></p>

<p class=EMEABodyText><b><span lang=BG>You must not take REYATAZ with certain
medicines.</span></b><span lang=BG> These are listed under Do not take REYATAZ,
at the start of Section 2. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are other medicines that may not mix
with REYATAZ. Tell your doctor if you are taking, have recently taken, or might
take any other medicines. It is especially important to mention these:</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>other medicines to treat HIV&nbsp;infection (e.g.
indinavir, nevirapine and efavirenz)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>boceprevir and sofosbuvir/velpatasvir/voxilaprevir
(used to treat hepatitis C)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sildenafil, vardenafil, or tadalafil (used by men
to treat impotence (erectile dysfunction)) </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>if you are taking an oral contraceptive (<b>&quot;the
Pill&quot;</b>) with REYATAZ to prevent pregancy, be sure to take it exactly as
instructed by your doctor and not miss any doses</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>any medicines used to treat diseases related to the
acid in the stomach (e.g. antacids to be taken 1&nbsp;hour before taking
REYATAZ or 2&nbsp;hours after taking REYATAZ, H<sub>2</sub>-blockers like
famotidine and proton pump inhibitors like omeprazole)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>medicines to lower blood pressure, to slow heart
rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine,
verapamil)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>atorvastatin, pravastatin, and fluvastatin (used to
lower blood cholesterol)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>salmeterol (used to treat asthma)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>cyclosporin, tacrolimus, and sirolimus (medicines
to decrease the effects of body's immune system)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>certain antibiotics (rifabutin, clarithromycin)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>ketoconazole, itraconazole, and voriconazole
(antifungals)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>warfarin (anticoagulant, used to reduce the blood
clots)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>carbamazepine, phenytoin, phenobarbital,
lamotrigine (antiepileptics)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>irinotecan (used to treat cancer)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>sedative agents (e.g. midazolam administered by
injection)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>buprenorphine (used to treat opioid addiction and
pain).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Some medicines may interact with ritonavir,
a medicine that is taken with REYATAZ. It is important to tell your doctor if
you are taking fluticasone or budesonide (given by nose or inhaled to treat
allergic symptoms or asthma).</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ with food and drink</span></p>

<p class=EMEABodyText><span lang=BG>See section&nbsp;3 How to take REYATAZ.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Pregnancy and breast-feeding</span></p>

<p class=EMEABodyText><span lang=BG>If you are pregnant or breast-feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine. Atazanavir, the active substance of
REYATAZ, is excreted in human milk. Patients should not breast-feed while
taking REYATAZ. It is recommended that women infected with HIV do not
breast-feed because the virus might be transmitted through the breast milk.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Driving and using machines</span></p>

<p class=EMEABodyText><span lang=BG>If you feel dizzy or lightheaded, do not
drive or use machines, and contact your doctor immediately.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>REYATAZ oral powder contains :</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>63 mg of aspartame per sachet. Aspartame is a
source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a
rare genetic disorder in which phenylalanine builds up because the body cannot
remove it properly.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>1.3&nbsp;g of sucrose per sachet. If you have been
told by your doctor that your child has an intolerance to some sugars, contact
your doctor before giving this medicinal product to your child.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading1><span lang=BG style='text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take REYATAZ</span></p>

<p class=EMEAHeading1><span style='font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>Always take this medicine exactly as your
doctor has told you. Check with your doctor if you are not sure. This way, you
can be sure your medicine is fully effective and you reduce the risk of the
virus developing resistance to the treatment. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='margin-bottom:3.0pt'><b><span lang=BG>For children
(at least 3&nbsp;months of age and weighing at least 5&nbsp;kg), your child's
doctor will decide the right dose based on your child's weight. </span></b><span
lang=BG>The dose of REYATAZ oral powder for children is calculated by body
weight and is taken once daily with food and ritonavir as shown below:</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Body Weight</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(kg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>REYATAZ Dose once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>Ritonavir Dose once daily</span></b></p>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=BG>(mg)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>At
  least 5 to less than 15</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>200&nbsp;mg
  (4&nbsp;sachets<sup>a</sup>)</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>80&nbsp;mg<sup>b</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>At
  least 15 to less than 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>250&nbsp;mg
  (5&nbsp;sachets<sup>a</sup>)</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>80&nbsp;mg<sup>b</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>at
  least 35</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>300&nbsp;mg
  (6&nbsp;sachets<sup>a</sup>)</span></p>
  </td>
  <td width=206 valign=top style='width:154.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span lang=BG>100&nbsp;mg<sup>c</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>a</span></sup><span
  lang=BG style='font-size:9.0pt'>Each sachet contains 50&nbsp;mg of REYATAZ</span></p>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>b</span></sup><span
  lang=BG style='font-size:9.0pt'>Ritonavir oral solution</span></p>
  <p class=EMEABodyText><sup><span lang=BG style='font-size:9.0pt'>c</span></sup><span
  lang=BG style='font-size:9.0pt'>Ritonavir oral solution or capsule/tablet</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>REYATAZ is also available in capsules for
use in adults and children at least 6&nbsp;years of age who weigh at least
15&nbsp;kg and who are able to swallow the capsules. Switching from REYATAZ
oral powder to REYATAZ capsules is encouraged as soon as patients are able to
consistently swallow capsules.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>A change in dose may occur when switching
between oral powder and capsules. Your doctor will decide the right dose based
on your child&#8217;s weight.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>There are no dosing recommendations for
REYATAZ in paediatric patients less than 3&nbsp;months of age.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Instructions for REYATAZ oral powder: </span></b></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>For children who are able to drink from a cup,
REYATAZ oral powder must be taken with food or drinks. If REYATAZ oral powder
is mixed with water, food should also be taken at the same time.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>For children who cannot eat solid food or drink
from a cup, REYATAZ oral powder must be mixed with infant formula and should be
given using an oral syringe. Ask your pharmacist for an oral syringe. Do not
use an infant bottle to give REYATAZ mixed with infant formula. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>See the &quot;Instructions for use&quot; at the end
of the package leaflet for how to prepare and give a dose of REYATAZ oral
powder.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>REYATAZ oral powder should be given within
60&nbsp;minutes of mixing.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>If you take more REYATAZ than you should</span></p>

<p class=EMEABodyText><span lang=BG>Yellowing of the skin and/or eyes
(jaundice) and irregular heart beat (QTc prolongation) may occur if you or your
child take too much REYATAZ.</span></p>

<p class=EMEABodyText><span lang=BG>If you accidentally take or give more
REYATAZ oral powder than your doctor recommended, contact your HIV doctor at
once or contact the nearest hospital for advice.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>If you forget to take REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>If you miss a dose or if you forget to give
your child a dose, take or give the missed dose as soon as possible with food
and then take or give the next scheduled dose at its regular time. If it is
almost time for your or your child's next dose, do not take or give the missed
dose. Wait and take or give the next dose at its regular time. <b>Do not take
or give a double dose to make up for a forgotten dose. </b></span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>If you stop taking REYATAZ</span></p>

<p class=EMEABodyText><span lang=BG>Do not stop taking REYATAZ before talking
to your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>If you have any further questions on the
use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=EMEAHeading1>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Like all medicines, this medicine can cause
side effects, although not everybody gets them. When treating
HIV&nbsp;infection, it is not always easy to identify what side effects are
caused by REYATAZ, by the other medicines you are taking, or by the HIV&nbsp;infection
itself. Tell your doctor if you notice anything unusual about your health.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Tell your doctor immediately if you develop
any of the following serious side effects:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Skin rash, itching that may occasionally be severe
has been reported. The rash usually disappears within 2&nbsp;weeks without any
change to your REYATAZ treatment. Severe rash may be developed in association
with other symptoms which could be serious. Stop taking REYATAZ and talk to
your doctor immediately if you develop a severe rash or a rash with flu-like
illness symptoms, blisters, fever, mouth sores, muscle or joint pain, swelling
in the face, inflammation of the eye which causes redness (conjunctivitis),
painful, warm, or red lumps (nodules). </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Yellowing of your skin or the white part of your
eyes caused by high levels of bilirubin in your blood has been commonly
reported. This side effect is usually not dangerous in adults and infants older
than 3&nbsp;months of age; but it might be a symptom of a serious problem. If
your skin or the white part of your eyes turns yellow, talk to your doctor
immediately.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Changes in the way your heart beats (heart rhythm
change) may occasionally happen. Talk to your doctor immediately if you get
dizzy, lightheaded or if you suddenly faint. These could be symptoms of a
serious heart problem. </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Liver problems may uncommonly happen. Your doctor
should do blood tests prior you start REYATAZ and during treatment. If you have
liver problems, including hepatitis B or C infection, you may experience a worsening
of your liver problems. Talk to your doctor immediately if you get dark
(tea-colored) urine, itching, yellowing of your skin or the white part of your
eyes, pain around the stomach, pale colored stools or nausea.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Gallbladder problems uncommonly happen in people
taking REYATAZ. Symptoms of gallbladder problems may include pain in the right
or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or
the white part of your eyes.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>REYATAZ may affect how well your kidneys work.</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>Kidney stones uncommonly happen in people taking
REYATAZ. Talk to your doctor immediately if you get symptoms of kidney stones
which may include, pain in your low back or low stomach-area, blood in your
urine or pain when you urinate.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Other side effects reported for patients
treated with REYATAZ are the following:</span></p>

<p class=EMEABodyText><span lang=BG>Common (may affect up to 1 in 10 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>headache</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>vomiting, diarrhoea, abdominal pain (stomach pain
of discomfort), nausea, dyspepsia (indigestion)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>fatigue (extreme tiredness)</span></p>

<p class=EMEABodyText><span lang=BG>Uncommon (may affect up to 1 in 100
people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>peripheral neuropathy (numbness, weakness, tingling
or pain in the arms and legs)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hypersensitivity (allergic reaction)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>asthenia (unusual tiredness or weakness)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>weight decreased, weight gain, anorexia (loss of
appetite), appetite increased</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>depression, anxiety, sleep disorder</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>disorientation, amnesia (loss of memory),
dizziness, somnolence (sleepiness), abnormal dream</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>syncope (fainting), hypertension (high blood
pressure)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>dyspnoea (shortness of breath)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>pancreatitis (inflammation of the pancreas),
gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and
cold sores), dysgeusia (impairment of the sense of taste), flatulence (wind),
dry mouth, abdominal distension</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>angioedema (severe swelling of the skin and other
tissues most often the lips or the eyes)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>alopecia (unusual hair loss or thinning), pruritus
(itching)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>muscle atrophy (muscle shrinkage), arthralgia
(joint pain), myalgia (aching muscles)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>interstitial nephritis (kidney inflammation),
haematuria (blood in the urine), proteinuria (excess protein in the urine),
pollakiuria (increased frequency of urination)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>gynaecomastia (breast enlargement in men)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>chest pain, malaise (generally feeling unwell),
fever</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt'><span lang=BG
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=BG>insomnia (difficulty sleeping)</span></p>

<p class=EMEABodyText><span lang=BG>Rare (may affect up to 1 in 1,000 people): </span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>gait disturbance (abnormal manner of walking)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>oedema (swelling)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>hepatosplenomegaly (enlargement of the liver and
spleen)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>myopathy (aching muscles, muscle tenderness of
weakness, not caused by exercise)</span></p>

<p class=EMEABodyTextIndent style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=BG style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=BG>kidney pain</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=BG>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=BG>If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via </span><span lang=BG style='background:lightgrey'>the
national reporting system listed in </span><span lang=BG><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store REYATAZ</span></b></p>

<p class=EMEAHeading1><span style='font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=BG>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not use this medicine after the expiry
date which is stated on the carton or sachet. The expiry date refers to the
last day of that month.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>This medicinal product does not require any
special storage conditions. Do not open the sachet until ready to use.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>After mixing the oral powder with food or
drinks, it may be stored at room temperature (not above 30<sup>o</sup>C) for up
to 1&nbsp;hour.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=EMEAHeading1><span style='font-weight:normal'>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ contains</span></p>

<p class=EMEABodyText><span lang=BG>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The active substance is atazanavir. Each sachet
contains 50&nbsp;mg of atazanavir (as sulphate). </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=BG>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=BG>The other ingredients are aspartame (E951), sucrose
and orange vanilla flavour.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>What REYATAZ looks like and contents of the
pack</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><span lang=BG>Each sachet of REYATAZ&nbsp;50 mg oral
powder contains 50&nbsp;mg atazanavir. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>One pack size is available: 1&nbsp;carton
with 30&nbsp;sachets.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEAHeading2><span lang=BG>Marketing Authorisation Holder </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=MsoNormal><span lang=BG>Bristol-Myers Squibb Pharma EEIG<br>
Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=MsoNormal><span lang=BG>Ireland </span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=EMEAHeading2><span lang=BG>Manufacturer</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Swords Laboratories T/A Lawrence
Laboratories</span></p>

<p class=EMEABodyText><span lang=BG>Unit 12</span><span lang=EN-GB> &amp; 15</span><span
lang=BG>, Distribution Centre</span></p>

<p class=EMEABodyText><span lang=BG>Shannon Industrial Estate </span></p>

<p class=EMEABodyText><span lang=BG>Shannon, Co. Clare, </span><span
lang=EN-GB>V14 DD39</span></p>

<p class=EMEABodyText><span lang=BG>Ireland</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>For any further information about this
medicine, please contact the local representative of the Marketing Authorisation
Holder:</span></p>

<p class=EMEABodyText>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Belgique/Belgi&euml;/Belgien</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 370
  52 369140</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Te&#1083;.:
  + 359 800 12 400</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-family:TimesNewRoman'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=BG>N.V. Bristol-Myers Squibb Belgium S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#268;esk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 420
  221 016 111</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Magyarorsz&aacute;g</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 36
  1 9206 550</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 45
  45 93 05 06</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Malta</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GmbH &amp; Co. KGaA</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 49
  89 121 42-0</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb B.V.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 31
  (0)30 300 2222</span></p>
  <p class=MsoNormal><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 372
  640 1030</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Norge</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Norway Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tlf: + 47
  67 55 53 50</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Ouml;sterreich</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb GesmbH</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 43
  1 60 14 30</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Espa&ntilde;a</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 34
  91 456 53 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Polska</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel.: + 48
  22 5796666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>France</span></b></p>
  <p class=MsoNormal><span lang=BG>Bristol-Myers Squibb SARL</span></p>
  <p class=EMEABodyText><span lang=BG>T&eacute;l: + 33 (0)1 58 83 84 96</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Farmac&ecirc;utica
  Portuguesa, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 351
  21 440 70 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Tel: +385
  1 2078 508</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Rom&acirc;nia</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 40
  (0)21 272 16 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals uc</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 353
  (0)1 483 3625</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 386
  1 2355 100</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&Iacute;sland</span></b></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Bristol-Myers
  Squibb AB hj&aacute; Vistor hf.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>S&iacute;mi:
  + 354 535 7000</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Slovensk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb spol. s r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 421
  2 59298411</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Italia</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 39
  06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=BG>Oy Bristol-Myers Squibb (Finland) Ab</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Puh/Tel: +
  358 9 251 21 230</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=BG style='font-variant:small-caps'>Bristol-Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb AB</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 46
  8 704 71 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>Latvija</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 371
  67708347</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=BG>United
  Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=BG>Bristol-Myers Squibb Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>Tel: + 44
  (0800) 731 1736</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><b><span lang=BG>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><b><span lang=BG>Other sources of information</span></b></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu/.</span></p>

<b><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle align=left style='text-align:left'><span lang=BG>Instructions
for use</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>These instructions show you how to prepare
and give a dose of REYATAZ oral powder. Make sure that you read and understand
these instructions before giving this medicine to your child.</span></p>

<p class=EMEABodyText><span lang=BG>Your child's doctor will decide the right
dose based on your child's age and weight. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>Always give your child the medicine within
60&nbsp;minutes of mixing.</span></p>

<p class=EMEABodyText><b>&nbsp;</b></p>

<p class=EMEABodyText><b><span lang=BG>Before giving the medicine</span></b></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine
the dose and the number of REYATAZ oral powder sachets needed
(see&nbsp;section&nbsp;3 How to take REYATAZ).</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp; Before use, tap
the sachet. Cut each sachet along the dotted line.</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp; Choose the
appropriate option listed below for giving REYATAZ oral powder to your child.
Larger volumes or quantities of liquid infant formula, beverage or food may be
used. Ensure that all the infant formula, beverage or food that contains the
medicine is taken.</span></p>

<p class=EMEABodyText style='margin-top:6.0pt;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in'><b><span lang=BG>Preparing and giving the medicine with
liquid infant formula using a medicine cup or small container and oral syringe
(</span></b><span lang=BG>ask your pharmacist for an oral syringe<b>):</b></span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp; Take a medicine
cup or small container and put the sachets&#8217; content in the cup or small
container.</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp; Add 10&nbsp;ml of
prepared liquid infant formula and mix using a spoon.</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp; Put the oral
syringe tip into the mixture and pull back the plunger until the full amount of
infant formula is taken up.</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp; Place the syringe
in your child's mouth towards the cheek and push the plunger down to release
the medicine.</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp; Put another
10&nbsp;ml of prepared infant formula in the cup or container and rinse the
remaining oral powder from the cup or container. </span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>6.&nbsp;&nbsp;&nbsp;&nbsp; Put the syringe
tip into the mixture and pull back the plunger until the full amount of infant
formula is taken up.</span></p>

<p class=EMEABodyText style='margin-left:44.8pt;text-indent:-26.95pt;
line-height:13.0pt'><span lang=BG>7.&nbsp;&nbsp;&nbsp;&nbsp; Place the syringe
in your child's mouth towards the cheek and push the plunger down to release
the medicine.</span></p>

<p class=EMEABodyText style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:44.8pt;text-indent:-26.95pt;line-height:13.0pt'><span
lang=BG>8.&nbsp;&nbsp;&nbsp;&nbsp; Give to your child the recommended dose of
ritonavir immediately after giving REYATAZ oral powder.</span></p>

<p class=EMEABodyText style='margin-bottom:6.0pt'><b><span lang=BG>Preparing
and giving the medicine with drinks</span></b></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-28.35pt;
line-height:13.0pt'><span lang=BG>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put
the sachets&#8217; content in a small drinking cup.</span></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-28.35pt;
line-height:13.0pt'><span lang=BG>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add
30&nbsp;ml of the drink and mix with a spoon. </span></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-28.35pt;
line-height:13.0pt'><span lang=BG>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have
the child drink the mixture.</span></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-28.35pt;
line-height:13.0pt'><span lang=BG>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add
another 15&nbsp;ml of the drink, mix and have the child drink the mixture.</span></p>

<p class=EMEABodyText style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:42.55pt;text-indent:-28.35pt;line-height:13.0pt'><span
lang=BG>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If water is used, food should
also be taken at the same time.</span></p>

<p class=EMEABodyText style='margin-bottom:6.0pt'><b><span lang=BG>Preparing
and giving the medicine with food</span></b></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-21.25pt;
line-height:13.0pt'><span lang=BG>1.&nbsp;&nbsp;&nbsp; Fill a small container
with the sachets' content. </span></p>

<p class=EMEABodyText style='margin-left:42.55pt;text-indent:-21.25pt;
line-height:13.0pt'><span lang=BG>2.&nbsp;&nbsp;&nbsp; Add a minimum of one
tablespoon of food and mix.</span></p>

<p class=EMEABodyText style='margin-left:21.3pt;line-height:13.0pt'><span
lang=BG>3.&nbsp;&nbsp;&nbsp; Feed your child with the mixture.</span></p>

<p class=EMEABodyText style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:21.3pt;line-height:13.0pt'><span lang=BG>4.&nbsp;&nbsp;&nbsp; Add
an additional tablespoon in the container, mix and feed to your child again.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=BG>If you have any questions on how to prepare
or give a dose of REYATAZ oral powder, talk to your doctor, pharmacist or
nurse. </span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

</div>

</body>

</html>
